19. Literaturverzeichnis – Endometrial Cancer
1. ICD-10-GM 2018 Systematisches Verzeichnis : Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 2017.
2. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), AWMF-Regelwerk „Leitlinien“, 2017.
3. Atkins, D., Best, D., Briss, P. A., Eccles, M., Falck-Ytter, Y., Flottorp, S., et.al. Grading quality of evidence and strength of recommendations, BMJ, 2004. 328: p. 1490., https://www.ncbi.nlm.nih.gov/pubmed/15205295
4. Robert, Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e, V., Krebs in Deutschland 2015/2016, 2019.
5. Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V., Petitti, D., Hormone replacement therapy and endometrial cancer risk: a meta-analysis (Structured abstract), Obstetrics and Gynecology, 1995. 85: p. 304-313., https://www.ncbi.nlm.nih.gov/pubmed/7824251
6. Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., Allan, J. D., Postmenopausal hormone replacement therapy: scientific review, JAMA, 2002. 288: p. 872-81., https://www.ncbi.nlm.nih.gov/pubmed/12186605
7. Allen, N. E., Tsilidis, K. K., Key, T. J., Dossus, L., Kaaks, R., Lund, E., et.al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition, Am J Epidemiol, 2010. 172: p. 1394-403., https://www.ncbi.nlm.nih.gov/pubmed/20961969
8. Lacey, J. V., Jr., Brinton, L. A., Lubin, J. H., Sherman, M. E., Schatzkin, A., Schairer, C., Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women, Cancer Epidemiol Biomarkers Prev, 2005. 14: p. 1724-31., https://www.ncbi.nlm.nih.gov/pubmed/16030108
9. Razavi, P., Pike, M. C., Horn-Ross, P. L., Templeman, C., Bernstein, L., Ursin, G., Long-term postmenopausal hormone therapy and endometrial cancer, Cancer Epidemiol Biomarkers Prev, 2010. 19: p. 475-83., https://www.ncbi.nlm.nih.gov/pubmed/20086105
10. Beral, V., Bull, D., Reeves, G., Endometrial cancer and hormone-replacement therapy in the Million Women Study, Lancet, 2005. 365: p. 1543-51., https://www.ncbi.nlm.nih.gov/pubmed/15866308
11. Tempfer, CB, Hilal, Z, Kern, P, Juhasz-Boess, I, Rezniczek, GA, Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review., Cancers (Basel), 2020. 12 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/32781573/
12. Marjoribanks, J., Farquhar, C., Roberts, H., Lethaby, A., Lee, J., Long-term hormone therapy for perimenopausal and postmenopausal women, Cochrane Database Syst Rev, 2017. 1(1): p. Cd004143.
13. Beral, V., Bull, D., Reeves, G., Endometrial cancer and hormone-replacement therapy in the Million Women Study, Lancet, 2005. 365: p. 1543-51., https://www.ncbi.nlm.nih.gov/pubmed/15866308
14. Lacey, J. V., Jr., Brinton, L. A., Lubin, J. H., Sherman, M. E., Schatzkin, A., Schairer, C., Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women, Cancer Epidemiol Biomarkers Prev, 2005. 14: p. 1724-31., https://www.ncbi.nlm.nih.gov/pubmed/16030108
15. Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., Allan, J. D., Postmenopausal hormone replacement therapy: scientific review, JAMA, 2002. 288: p. 872-81., https://www.ncbi.nlm.nih.gov/pubmed/12186605
16. Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V., Petitti, D., Hormone replacement therapy and endometrial cancer risk: a meta-analysis (Structured abstract), Obstetrics and Gynecology, 1995. 85: p. 304-313., https://www.ncbi.nlm.nih.gov/pubmed/7824251
17. Allen, N. E., Tsilidis, K. K., Key, T. J., Dossus, L., Kaaks, R., Lund, E., et.al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition, Am J Epidemiol, 2010. 172: p. 1394-403., https://www.ncbi.nlm.nih.gov/pubmed/20961969
18. Chlebowski, R. T., Anderson, G. L., Sarto, G. E., Haque, R., Runowicz, C. D., Aragaki, A. K., et.al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial, J Natl Cancer Inst, 2015. 108:, https://www.ncbi.nlm.nih.gov/pubmed/26668177
19. Fournier, A., Dossus, L., Mesrine, S., Vilier, A., Boutron-Ruault, M. C., Clavel-Chapelon, F., et.al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008, Am J Epidemiol, 2014. 180: p. 508-17., https://www.ncbi.nlm.nih.gov/pubmed/25008104
20. Mørch, LS, Kjaer, SK, Keiding, N, Løkkegaard, E, Lidegaard, Ø, The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study., Int J Cancer, 2016. 138 (6)(6): p. 1506-15., https://pubmed.ncbi.nlm.nih.gov/26421912/
21. Doherty, J. A., Cushing-Haugen, K. L., Saltzman, B. S., Voigt, L. F., Hill, D. A., Beresford, S. A., et.al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer, Am J Obstet Gynecol, 2007. 197: p. 139 e1-7., https://www.ncbi.nlm.nih.gov/pubmed/17689625
22. Sjögren, L. L., Mørch, L. S., Løkkegaard, E., Hormone replacement therapy and the risk of endometrial cancer: A systematic review, Maturitas, 2016. 91: p. 25-35.
23. Chlebowski, R. T., Anderson, G. L., Sarto, G. E., Haque, R., Runowicz, C. D., Aragaki, A. K., et.al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial, J Natl Cancer Inst, 2015. 108:, https://www.ncbi.nlm.nih.gov/pubmed/26668177
24. Phipps, A. I., Doherty, J. A., Voigt, L. F., Hill, D. A., Beresford, S. A., Rossing, M. A., et.al. Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer, Cancer Causes Control, 2011. 22: p. 1639-46., https://link.springer.com/article/10.1007%2Fs10552-011-9840-6
25. Razavi, P., Pike, M. C., Horn-Ross, P. L., Templeman, C., Bernstein, L., Ursin, G., Long-term postmenopausal hormone therapy and endometrial cancer, Cancer Epidemiol Biomarkers Prev, 2010. 19: p. 475-83., https://www.ncbi.nlm.nih.gov/pubmed/20086105
26. Fournier, A., Dossus, L., Mesrine, S., Vilier, A., Boutron-Ruault, M. C., Clavel-Chapelon, F., et.al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008, Am J Epidemiol, 2014. 180: p. 508-17., https://www.ncbi.nlm.nih.gov/pubmed/25008104
27. T, h, e, , W, r, et.al. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, JAMA, 1996. 275: p. 370-5., https://www.ncbi.nlm.nih.gov/pubmed/8569016
28. Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M., Renehan, A. G., Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis, Cancer Epidemiol Biomarkers Prev, 2010. 19: p. 3119-30., https://www.ncbi.nlm.nih.gov/pubmed/21030602
29. Nelson, H. D., Smith, M. E., Griffin, J. C., Fu, R., Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force, Ann Intern Med, 2013. 158: p. 604-14., https://www.ncbi.nlm.nih.gov/pubmed/23588749
30. Al-Mubarak, M., Tibau, A., Templeton, A. J., Cescon, D. W., Ocana, A., Seruga, B., et.al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis, PLoS One, 2014. 9: p. e88238., https://www.ncbi.nlm.nih.gov/pubmed/24586311
31. Braithwaite, R. S., Chlebowski, R. T., Lau, J., George, S., Hess, R., Col, N. F., Meta-analysis of vascular and neoplastic events associated with tamoxifen, J Gen Intern Med, 2003. 18: p. 937-47., https://www.ncbi.nlm.nih.gov/pubmed/14687281
32. DeMichele, A., Troxel, A. B., Berlin, J. A., Weber, A. L., Bunin, G. R., Turzo, E., et.al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study, J Clin Oncol, 2008. 26: p. 4151-9., https://www.ncbi.nlm.nih.gov/pubmed/18757329
33. Emons, G, Mustea, A, Tempfer, C, Tamoxifen and Endometrial Cancer: A Janus-Headed Drug., Cancers (Basel), 2020. 12 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/32906618/
34. Braithwaite, R. S., Chlebowski, R. T., Lau, J., George, S., Hess, R., Col, N. F., Meta-analysis of vascular and neoplastic events associated with tamoxifen, J Gen Intern Med, 2003. 18: p. 937-47., https://www.ncbi.nlm.nih.gov/pubmed/14687281
35. Nelson, H. D., Smith, M. E., Griffin, J. C., Fu, R., Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force, Ann Intern Med, 2013. 158: p. 604-14., https://www.ncbi.nlm.nih.gov/pubmed/23588749
36. C, l, a, r, k, e, et.al. WITHDRAWN: Tamoxifen for early breast cancer, Cochrane Database Syst Rev, 2008. p. Cd000486., https://www.ncbi.nlm.nih.gov/pubmed/18843611
37. Al-Mubarak, M., Tibau, A., Templeton, A. J., Cescon, D. W., Ocana, A., Seruga, B., et.al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis, PLoS One, 2014. 9: p. e88238., https://www.ncbi.nlm.nih.gov/pubmed/24586311
38. Emons, G., Mustea, A., Tempfer, C., Tamoxifen and Endometrial Cancer: A Janus-Headed Drug, Cancers (Basel), 2020. 12(9):, https://pubmed.ncbi.nlm.nih.gov/32906618/
39. DeMichele, A., Troxel, A. B., Berlin, J. A., Weber, A. L., Bunin, G. R., Turzo, E., et.al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study, J Clin Oncol, 2008. 26: p. 4151-9., https://www.ncbi.nlm.nih.gov/pubmed/18757329
40. C, o, l, l, a, b, et.al. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies, Lancet Oncol, 2015. 16: p. 1061-1070., https://www.ncbi.nlm.nih.gov/pubmed/26254030
41. Gierisch, J. M., Coeytaux, R. R., Urrutia, R. P., Havrilesky, L. J., Moorman, P. G., Lowery, W. J., et.al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review, Cancer Epidemiol Biomarkers Prev, 2013. 22: p. 1931-43., https://www.ncbi.nlm.nih.gov/pubmed/24014598
42. Ignatov, A, Ortmann, O, Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen., Cancers (Basel), 2020. 12 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/32630728/
43. S, c, h, l, e, s, et.al. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis, Hum Reprod, 1997. 12: p. 1851-63., https://www.ncbi.nlm.nih.gov/pubmed/9363696
44. Gorenoi, V., Schonermark, M. P., Hagen, A., Benefits and risks of hormonal contraception for women, GMS Health Technol Assess, 2007. 3: p. Doc06., https://www.ncbi.nlm.nih.gov/pubmed/21289940
45. Gierisch, J. M., Coeytaux, R. R., Urrutia, R. P., Havrilesky, L. J., Moorman, P. G., Lowery, W. J., et.al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review, Cancer Epidemiol Biomarkers Prev, 2013. 22: p. 1931-43., https://www.ncbi.nlm.nih.gov/pubmed/24014598
46. Dossus, L., Allen, N., Kaaks, R., Bakken, K., Lund, E., Tjonneland, A., et.al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition, Int J Cancer, 2009. 127: p. 442-51., https://www.ncbi.nlm.nih.gov/pubmed/19924816
47. C, o, l, l, a, b, et.al. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies, Lancet Oncol, 2015. 16: p. 1061-1070., https://www.ncbi.nlm.nih.gov/pubmed/26254030
48. Parazzini, F., Pelucchi, C., Talamini, R., Montella, M., La Vecchia, C., Use of fertility drugs and risk of endometrial cancer in an Italian case-control study, Eur J Cancer Prev, 2010. 19: p. 428-30., https://www.ncbi.nlm.nih.gov/pubmed/20634699
49. Siristatidis, C., Sergentanis, T. N., Kanavidis, P., Trivella, M., Sotiraki, M., Mavromatis, I., et.al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis, Human Reproduction Update, 2013. 19: p. 105-123., https://www.ncbi.nlm.nih.gov/pubmed/23255514
50. Skalkidou, A., Sergentanis, T. N., Gialamas, S. P., Georgakis, M. K., Psaltopoulou, T., Trivella, M., et.al. Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility, Cochrane Database Syst Rev, 2017. 3(3): p. Cd010931.
51. Parazzini, F., Pelucchi, C., Talamini, R., Montella, M., La Vecchia, C., Use of fertility drugs and risk of endometrial cancer in an Italian case-control study, Eur J Cancer Prev, 2010. 19: p. 428-30., https://www.ncbi.nlm.nih.gov/pubmed/20634699
52. Siristatidis, C., Sergentanis, T. N., Kanavidis, P., Trivella, M., Sotiraki, M., Mavromatis, I., et.al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis, Human Reproduction Update, 2013. 19: p. 105-123., https://www.ncbi.nlm.nih.gov/pubmed/23255514
53. Ettinger, B., Kenemans, P., Johnson, S. R., Mol-Arts, M., Van Os, S., Seifert, W., et.al. Endometrial effects of tibolone in elderly, osteoporotic women, Obstet Gynecol, 2008. 112: p. 653-9., https://www.ncbi.nlm.nih.gov/pubmed/18757665
54. Ettinger, B., Kenemans, P., Johnson, S. R., Mol-Arts, M., Van Os, S., Seifert, W., et.al. Endometrial effects of tibolone in elderly, osteoporotic women, Obstet Gynecol, 2008. 112: p. 653-9., https://www.ncbi.nlm.nih.gov/pubmed/18757665
55. Formoso, G., Perrone, E., Maltoni, S., Balduzzi, S., D'Amico, R., Bassi, C., et.al. Short and long term effects of tibolone in postmenopausal women, Cochrane Database Syst Rev, 2012. 2: p. Cd008536.
56. Dossus, L., Allen, N., Kaaks, R., Bakken, K., Lund, E., Tjonneland, A., et.al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition, Int J Cancer, 2009. 127: p. 442-51., https://www.ncbi.nlm.nih.gov/pubmed/19924816
57. Karageorgi, S., Hankinson, S. E., Kraft, P., De Vivo, I., Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004, Int J Cancer, 2009. 126: p. 208-16., https://www.ncbi.nlm.nih.gov/pubmed/19551854
58. Setiawan, V. W., Pike, M. C., Karageorgi, S., Deming, S. L., Anderson, K., Bernstein, L., et.al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium, Am J Epidemiol, 2012. 176: p. 269-78., https://www.ncbi.nlm.nih.gov/pubmed/22831825
59. Friberg, E., Orsini, N., Mantzoros, C. S., Wolk, A., Diabetes mellitus and risk of endometrial cancer: a meta-analysis, Diabetologia, 2007. 50: p. 1365-74., https://www.ncbi.nlm.nih.gov/pubmed/17476474
60. Haoula, Z., Salman, M., Atiomo, W., Evaluating the association between endometrial cancer and polycystic ovary syndrome, Hum Reprod, 2012. 27: p. 1327-31., https://www.ncbi.nlm.nih.gov/pubmed/22367984
61. Choi, Y., Giovannucci, E., Lee, J. E., Glycaemic index and glycaemic load in relation to risk of diabetes-related cancers: a meta-analysis, Br J Nutr, 2012. 108: p. 1934-47., https://www.ncbi.nlm.nih.gov/pubmed/23167978
62. Gnagnarella, P., Gandini, S., La Vecchia, C., Maisonneuve, P., Glycemic index, glycemic load, and cancer risk: a meta-analysis, Am J Clin Nutr, 2008. 87: p. 1793-801., https://www.ncbi.nlm.nih.gov/pubmed/18541570
63. Liao, C., Zhang, D., Mungo, C., Andrew Tompkins, D., Zeidan, A. M., Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies, Gynecol Oncol, 2014. 135: p. 163-171., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404750/
64. Barone, B. B., Yeh, H. C., Snyder, C. F., Peairs, K. S., Stein, K. B., Derr, R. L., et.al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis, Jama, 2008. 300: p. 2754-64., https://www.ncbi.nlm.nih.gov/pubmed/19088353
65. Chittenden, B. G., Fullerton, G., Maheshwari, A., Bhattacharya, S., Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review, Reprod Biomed Online, 2009. 19: p. 398-405., https://www.ncbi.nlm.nih.gov/pubmed/19778486
66. Huang, Y., Cai, X., Qiu, M., Chen, P., Tang, H., Hu, Y., et.al. Prediabetes and the risk of cancer: a meta-analysis, Diabetologia, 2014. 57: p. 2261-9., https://www.ncbi.nlm.nih.gov/pubmed/25208757
67. Barry, J. A., Azizia, M. M., Hardiman, P. J., Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update, 2014. 20: p. 748-58., https://www.ncbi.nlm.nih.gov/pubmed/24688118
68. Fearnley, E. J., Marquart, L., Spurdle, A. B., Weinstein, P., Webb, P. M., Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study, Cancer Causes Control, 2010. 21: p. 2303-8., https://www.ncbi.nlm.nih.gov/pubmed/20953904
69. Gottschau, M., Kjaer, S. K., Jensen, A., Munk, C., Mellemkjaer, L., Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study, Gynecol Oncol, 2014. 136: p. 99-103., https://www.ncbi.nlm.nih.gov/pubmed/25451694
70. Luo, J., Beresford, S., Chen, C., Chlebowski, R., Garcia, L., Kuller, L., et.al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer, Br J Cancer, 2014. 111: p. 1432-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183842/
71. Mulholland, H. G., Murray, L. J., Cardwell, C. R., Cantwell, M. M., Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis, Br J Cancer, 2008. 99: p. 434-41., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527795/
72. Nagle, C. M., Olsen, C. M., Ibiebele, T. I., Spurdle, A. B., Webb, P. M., Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis, Eur J Nutr, 2012. 52: p. 705-15., https://www.ncbi.nlm.nih.gov/pubmed/22648201
73. Zhang, Z. H., Su, P. Y., Hao, J. H., Sun, Y. H., The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies, Int J Gynecol Cancer, 2013. 23: p. 294-303., https://www.ncbi.nlm.nih.gov/pubmed/23287960
74. Dobbins, M., Decorby, K., Choi, B. C., The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011, ISRN Prev Med, 2013. 2013: p. 680536., https://www.ncbi.nlm.nih.gov/pubmed/24977095
75. Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M., Renehan, A. G., Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis, Cancer Epidemiol Biomarkers Prev, 2010. 19: p. 3119-30., https://www.ncbi.nlm.nih.gov/pubmed/21030602
76. Bergstrom, A., Pisani, P., Tenet, V., Wolk, A., Adami, H. O., Overweight as an avoidable cause of cancer in Europe, Int J Cancer, 2001. 91: p. 421-30., https://www.ncbi.nlm.nih.gov/pubmed/11169969
77. Reeves, K. W., Carter, G. C., Rodabough, R. J., Lane, D., McNeeley, S. G., Stefanick, M. L., et.al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative, Gynecol Oncol, 2011. 121: p. 376-82., https://www.ncbi.nlm.nih.gov/pubmed/21324514
78. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, 2008. 371: p. 569-78., https://www.ncbi.nlm.nih.gov/pubmed/18280327
79. Ward, K. K., Roncancio, A. M., Shah, N. R., Davis, M. A., Saenz, C. C., McHale, M. T., et.al. The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women, Am J Obstet Gynecol, 2013. 209: p. 579 e1-5., https://www.ncbi.nlm.nih.gov/pubmed/23938608
80. Dörk, T, Hillemanns, P, Tempfer, C, Breu, J, Fleisch, MC, Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management., Cancers (Basel), 2020. 12 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/32854222/
81. Ma, X, Zhao, LG, Sun, JW, Yang, Y, Zheng, JL, Gao, J, et.al. Association between breastfeeding and risk of endometrial cancer: a meta-analysis of epidemiological studies., Eur J Cancer Prev, 2018. 27 (2)(2): p. 144-151., https://pubmed.ncbi.nlm.nih.gov/26258808/
82. Setiawan, V. W., Pike, M. C., Karageorgi, S., Deming, S. L., Anderson, K., Bernstein, L., et.al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium, Am J Epidemiol, 2012. 176: p. 269-78., https://www.ncbi.nlm.nih.gov/pubmed/22831825
83. Karageorgi, S., Hankinson, S. E., Kraft, P., De Vivo, I., Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004, Int J Cancer, 2009. 126: p. 208-16., https://www.ncbi.nlm.nih.gov/pubmed/19551854
84. Friberg, E., Orsini, N., Mantzoros, C. S., Wolk, A., Diabetes mellitus and risk of endometrial cancer: a meta-analysis, Diabetologia, 2007. 50: p. 1365-74., https://www.ncbi.nlm.nih.gov/pubmed/17476474
85. Barone, B. B., Yeh, H. C., Snyder, C. F., Peairs, K. S., Stein, K. B., Derr, R. L., et.al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis, Jama, 2008. 300: p. 2754-64., https://www.ncbi.nlm.nih.gov/pubmed/19088353
86. Huang, Y., Cai, X., Qiu, M., Chen, P., Tang, H., Hu, Y., et.al. Prediabetes and the risk of cancer: a meta-analysis, Diabetologia, 2014. 57: p. 2261-9., https://www.ncbi.nlm.nih.gov/pubmed/25208757
87. Zhang, Z. H., Su, P. Y., Hao, J. H., Sun, Y. H., The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies, Int J Gynecol Cancer, 2013. 23: p. 294-303., https://www.ncbi.nlm.nih.gov/pubmed/23287960
88. Liao, C., Zhang, D., Mungo, C., Andrew Tompkins, D., Zeidan, A. M., Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies, Gynecol Oncol, 2014. 135: p. 163-171., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404750/
89. Luo, J., Beresford, S., Chen, C., Chlebowski, R., Garcia, L., Kuller, L., et.al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer, Br J Cancer, 2014. 111: p. 1432-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183842/
90. Gnagnarella, P., Gandini, S., La Vecchia, C., Maisonneuve, P., Glycemic index, glycemic load, and cancer risk: a meta-analysis, Am J Clin Nutr, 2008. 87: p. 1793-801., https://www.ncbi.nlm.nih.gov/pubmed/18541570
91. Mulholland, H. G., Murray, L. J., Cardwell, C. R., Cantwell, M. M., Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis, Br J Cancer, 2008. 99: p. 434-41., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527795/
92. Choi, Y., Giovannucci, E., Lee, J. E., Glycaemic index and glycaemic load in relation to risk of diabetes-related cancers: a meta-analysis, Br J Nutr, 2012. 108: p. 1934-47., https://www.ncbi.nlm.nih.gov/pubmed/23167978
93. Nagle, C. M., Olsen, C. M., Ibiebele, T. I., Spurdle, A. B., Webb, P. M., Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis, Eur J Nutr, 2012. 52: p. 705-15., https://www.ncbi.nlm.nih.gov/pubmed/22648201
94. Bjorge, T., Stocks, T., Lukanova, A., Tretli, S., Selmer, R., Manjer, J., et.al. Metabolic syndrome and endometrial carcinoma, Am J Epidemiol, 2010. 171: p. 892-902., https://www.ncbi.nlm.nih.gov/pubmed/20219764
95. Esposito, K., Chiodini, P., Colao, A., Lenzi, A., Giugliano, D., Metabolic syndrome and risk of cancer: a systematic review and meta-analysis, Diabetes Care, 2012. 35: p. 2402-11., https://www.ncbi.nlm.nih.gov/pubmed/23093685
96. Baptiste, C. G., Battista, M. C., Trottier, A., Baillargeon, J. P., Insulin and hyperandrogenism in women with polycystic ovary syndrome, J Steroid Biochem Mol Biol, 2009. 122: p. 42-52., https://www.ncbi.nlm.nih.gov/pubmed/20036327
97. Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P., La Sala, G. B., Fauser, B. C., Pregnancy complications in women with polycystic ovary syndrome, Hum Reprod Update, 2015. 21: p. 575-92., https://www.ncbi.nlm.nih.gov/pubmed/26117684
98. Fearnley, E. J., Marquart, L., Spurdle, A. B., Weinstein, P., Webb, P. M., Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study, Cancer Causes Control, 2010. 21: p. 2303-8., https://www.ncbi.nlm.nih.gov/pubmed/20953904
99. Gottschau, M., Kjaer, S. K., Jensen, A., Munk, C., Mellemkjaer, L., Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study, Gynecol Oncol, 2014. 136: p. 99-103., https://www.ncbi.nlm.nih.gov/pubmed/25451694
100. Chittenden, B. G., Fullerton, G., Maheshwari, A., Bhattacharya, S., Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review, Reprod Biomed Online, 2009. 19: p. 398-405., https://www.ncbi.nlm.nih.gov/pubmed/19778486
101. Haoula, Z., Salman, M., Atiomo, W., Evaluating the association between endometrial cancer and polycystic ovary syndrome, Hum Reprod, 2012. 27: p. 1327-31., https://www.ncbi.nlm.nih.gov/pubmed/22367984
102. Barry, J. A., Azizia, M. M., Hardiman, P. J., Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update, 2014. 20: p. 748-58., https://www.ncbi.nlm.nih.gov/pubmed/24688118
103. Ward, K. K., Roncancio, A. M., Shah, N. R., Davis, M. A., Saenz, C. C., McHale, M. T., et.al. The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women, Am J Obstet Gynecol, 2013. 209: p. 579 e1-5., https://www.ncbi.nlm.nih.gov/pubmed/23938608
104. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, 2008. 371: p. 569-78., https://www.ncbi.nlm.nih.gov/pubmed/18280327
105. Dobbins, M., Decorby, K., Choi, B. C., The Association between Obesity and Cancer Risk: A Meta-Analysis of Observational Studies from 1985 to 2011, ISRN Prev Med, 2013. 2013: p. 680536., https://www.ncbi.nlm.nih.gov/pubmed/24977095
106. Bergstrom, A., Pisani, P., Tenet, V., Wolk, A., Adami, H. O., Overweight as an avoidable cause of cancer in Europe, Int J Cancer, 2001. 91: p. 421-30., https://www.ncbi.nlm.nih.gov/pubmed/11169969
107. Reeves, K. W., Carter, G. C., Rodabough, R. J., Lane, D., McNeeley, S. G., Stefanick, M. L., et.al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative, Gynecol Oncol, 2011. 121: p. 376-82., https://www.ncbi.nlm.nih.gov/pubmed/21324514
108. Cote, M. L., Alhajj, T., Ruterbusch, J. J., Bernstein, L., Brinton, L. A., Blot, W. J., et.al. Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2), Cancer Causes Control, 2014. 26: p. 287-96., https://www.ncbi.nlm.nih.gov/pubmed/25534916
109. Win, A. K., Reece, J. C., Ryan, S., Family history and risk of endometrial cancer: a systematic review and meta-analysis, Obstet Gynecol, 2015. 125: p. 89-98., https://www.ncbi.nlm.nih.gov/pubmed/25560109
110. Liu, J., Jiang, W., Mao, K., An, Y., Su, F., Kim, B. Y., et.al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis, Breast Cancer Res Treat, 2015. 150: p. 439-45., https://www.ncbi.nlm.nih.gov/pubmed/25764167
111. Bandera, E. V., Kushi, L. H., Moore, D. F., Gifkins, D. M., McCullough, M. L., Association between dietary fiber and endometrial cancer: a dose-response meta-analysis, Am J Clin Nutr, 2007. 86: p. 1730-7., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2214669/
112. Myung, S. K., Ju, W., Choi, H. J., Kim, S. C., Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis, BJOG, 2009. 116: p. 1697-705., https://www.ncbi.nlm.nih.gov/pubmed/19775307
113. Ollberding, N. J., Lim, U., Wilkens, L. R., Setiawan, V. W., Shvetsov, Y. B., Henderson, B. E., et.al. Legume, soy, tofu, and isoflavone intake and endometrial cancer risk in postmenopausal women in the multiethnic cohort study, J Natl Cancer Inst, 2011. 104: p. 67-76., https://www.ncbi.nlm.nih.gov/pubmed/22158125
114. Bandera, E. V., Gifkins, D. M., Moore, D. F., McCullough, M. L., Kushi, L. H., Antioxidant vitamins and the risk of endometrial cancer: a dose-response meta-analysis, Cancer Causes Control, 2009. 20: p. 699-711., https://www.ncbi.nlm.nih.gov/pubmed/19083131
115. Inoue-Choi, M., Robien, K., Mariani, A., Cerhan, J. R., Anderson, K. E., Sugar-sweetened beverage intake and the risk of type I and type II endometrial cancer among postmenopausal women, Cancer Epidemiol Biomarkers Prev, 2013. 22: p. 2384-94., https://www.ncbi.nlm.nih.gov/pubmed/24273064
116. Yu, X., Bao, Z., Zou, J., Dong, J., Coffee consumption and risk of cancers: a meta-analysis of cohort studies, BMC Cancer, 2011. 11: p. 96., https://www.ncbi.nlm.nih.gov/pubmed/21406107
117. Je, Y., Hankinson, S. E., Tworoger, S. S., De Vivo, I., Giovannucci, E., A prospective cohort study of coffee consumption and risk of endometrial cancer over a 26-year follow-up, Cancer Epidemiol Biomarkers Prev, 2011. 20: p. 2487-95., https://www.ncbi.nlm.nih.gov/pubmed/22109346
118. Bravi, F., Scotti, L., Bosetti, C., Gallus, S., Negri, E., La Vecchia, C., et.al. Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies, Am J Obstet Gynecol, 2009. 200: p. 130-5., https://www.ncbi.nlm.nih.gov/pubmed/19110217
119. Uccella, S., Mariani, A., Wang, A. H., Vierkant, R. A., Cliby, W. A., Robien, K., et.al. Intake of coffee, caffeine and other methylxanthines and risk of Type I vs Type II endometrial cancer, Br J Cancer, 2013. 109: p. 1908-13., https://www.ncbi.nlm.nih.gov/pubmed/24022184
120. Tang, N. P., Li, H., Qiu, Y. L., Zhou, G. M., Ma, J., Tea consumption and risk of endometrial cancer: a metaanalysis, Am J Obstet Gynecol, 2009. 201: p. 605.e1-8., https://www.ncbi.nlm.nih.gov/pubmed/19766982
121. Ma, X, Zhao, LG, Sun, JW, Yang, Y, Zheng, JL, Gao, J, et.al. Association between breastfeeding and risk of endometrial cancer: a meta-analysis of epidemiological studies., Eur J Cancer Prev, 2018. 27 (2)(2): p. 144-151., https://pubmed.ncbi.nlm.nih.gov/26258808/
122. McCullough, M. L., Bandera, E. V., Moore, D. F., Kushi, L. H., Vitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature, Prev Med, 2007. 46: p. 298-302., https://www.ncbi.nlm.nih.gov/pubmed/18155758
123. Neill, A. S., Nagle, C. M., Protani, M. M., Obermair, A., Spurdle, A. B., Webb, P. M., Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis, Int J Cancer, 2012. 132: p. 1146-55., https://www.ncbi.nlm.nih.gov/pubmed/22777678
124. Zhou, B., Yang, L., Sun, Q., Cong, R., Gu, H., Tang, N., et.al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis, Am J Med, 2008. 121: p. 501-508.e3., https://www.ncbi.nlm.nih.gov/pubmed/18501231
125. Viswanathan, A. N., Hankinson, S. E., Schernhammer, E. S., Night shift work and the risk of endometrial cancer, Cancer Res, 2007. 67: p. 10618-22., https://www.ncbi.nlm.nih.gov/pubmed/17975006
126. Raglan, Olivia, Kalliala, Ilkka, Markozannes, Georgios, Cividini, Sofia, Gunter, Marc J., Nautiyal, Jaya, et.al. Risk factors for endometrial cancer: An umbrella review of the literature, International journal of cancer, 2019. 145(7): p. 1719-1730., http://europepmc.org/abstract/MED/30387875, https://doi.org/10.1002/ijc.31961
127. Keum, N., Ju, W., Lee, D. H., Ding, E. L., Hsieh, C. C., Goodman, J. E., et.al. Leisure-time physical activity and endometrial cancer risk: dose-response meta-analysis of epidemiological studies, Int J Cancer, 2014. 135: p. 682-94., https://www.ncbi.nlm.nih.gov/pubmed/24375149
128. Gierach, G. L., Chang, S. C., Brinton, L. A., Lacey, J. V., Jr., Hollenbeck, A. R., Schatzkin, A., et.al. Physical activity, sedentary behavior, and endometrial cancer risk in the NIH-AARP Diet and Health Study, Int J Cancer, 2009. 124: p. 2139-47., https://www.ncbi.nlm.nih.gov/pubmed/19123463
129. Moore, S. C., Gierach, G. L., Schatzkin, A., Matthews, C. E., Physical activity, sedentary behaviours, and the prevention of endometrial cancer, Br J Cancer, 2010. 103: p. 933-8., https://www.ncbi.nlm.nih.gov/pubmed/20877336
130. Schmid, D., Leitzmann, M. F., Television viewing and time spent sedentary in relation to cancer risk: a meta-analysis, J Natl Cancer Inst, 2014. 106:, https://www.ncbi.nlm.nih.gov/pubmed/24935969
131. Voskuil, D. W., Monninkhof, E. M., Elias, S. G., Vlems, F. A., van Leeuwen, F. E., Physical activity and endometrial cancer risk, a systematic review of current evidence, Cancer Epidemiol Biomarkers Prev, 2007. 16: p. 639-48., https://www.ncbi.nlm.nih.gov/pubmed/17416752
132. Kohler, LN, Garcia, DO, Harris, RB, Oren, E, Roe, DJ, Jacobs, ET, Adherence to Diet and Physical Activity Cancer Prevention Guidelines and Cancer Outcomes: A Systematic Review., Cancer Epidemiol Biomarkers Prev, 2016. 25 (7)(7): p. 1018-28., https://pubmed.ncbi.nlm.nih.gov/27340121/
133. Zhang, X, Rhoades, J, Caan, BJ, Cohn, DE, Salani, R, Noria, S, et.al. Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis., Int J Gynecol Cancer, 2019. 29 (9)(9): p. 1361-1371., https://pubmed.ncbi.nlm.nih.gov/31451560/
134. Felix, A. S., Gaudet, M. M., La Vecchia, C., Nagle, C. M., Shu, X. O., Weiderpass, E., et.al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium, Int J Cancer, 2014. 136: p. E410-22., https://www.ncbi.nlm.nih.gov/pubmed/25242594
135. Soini, T., Hurskainen, R., Grenman, S., Maenpaa, J., Paavonen, J., Pukkala, E., Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland, Obstet Gynecol, 2014. 124: p. 292-9., https://www.ncbi.nlm.nih.gov/pubmed/25004338
136. Keum, N., Ju, W., Lee, D. H., Ding, E. L., Hsieh, C. C., Goodman, J. E., et.al. Leisure-time physical activity and endometrial cancer risk: dose-response meta-analysis of epidemiological studies, Int J Cancer, 2014. 135: p. 682-94., https://www.ncbi.nlm.nih.gov/pubmed/24375149
137. Gierach, G. L., Chang, S. C., Brinton, L. A., Lacey, J. V., Jr., Hollenbeck, A. R., Schatzkin, A., et.al. Physical activity, sedentary behavior, and endometrial cancer risk in the NIH-AARP Diet and Health Study, Int J Cancer, 2009. 124: p. 2139-47., https://www.ncbi.nlm.nih.gov/pubmed/19123463
138. Moore, S. C., Gierach, G. L., Schatzkin, A., Matthews, C. E., Physical activity, sedentary behaviours, and the prevention of endometrial cancer, Br J Cancer, 2010. 103: p. 933-8., https://www.ncbi.nlm.nih.gov/pubmed/20877336
139. Voskuil, D. W., Monninkhof, E. M., Elias, S. G., Vlems, F. A., van Leeuwen, F. E., Physical activity and endometrial cancer risk, a systematic review of current evidence, Cancer Epidemiol Biomarkers Prev, 2007. 16: p. 639-48., https://www.ncbi.nlm.nih.gov/pubmed/17416752
140. Schmid, D., Leitzmann, M. F., Television viewing and time spent sedentary in relation to cancer risk: a meta-analysis, J Natl Cancer Inst, 2014. 106:, https://www.ncbi.nlm.nih.gov/pubmed/24935969
141. Soini, T., Hurskainen, R., Grenman, S., Maenpaa, J., Paavonen, J., Pukkala, E., Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland, Obstet Gynecol, 2014. 124: p. 292-9., https://www.ncbi.nlm.nih.gov/pubmed/25004338
142. Felix, A. S., Gaudet, M. M., La Vecchia, C., Nagle, C. M., Shu, X. O., Weiderpass, E., et.al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium, Int J Cancer, 2014. 136: p. E410-22., https://www.ncbi.nlm.nih.gov/pubmed/25242594
143. Ward, K. K., Roncancio, A. M., Shah, N. R., Davis, M. A., Saenz, C. C., McHale, M. T., et.al. Bariatric surgery decreases the risk of uterine malignancy, Gynecol Oncol, 2014. 133: p. 63-6., https://www.ncbi.nlm.nih.gov/pubmed/24680593
144. Neff, R., Havrilesky, L. J., Chino, J., O'Malley, D. M., Cohn, D. E., Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndrome, Gynecol Oncol, 2015. 138: p. 597-602., https://www.ncbi.nlm.nih.gov/pubmed/26232518
145. Ishihara, BP, Farah, D, Fonseca, MCM, Nazario, A, The risk of developing breast, ovarian, and endometrial cancer in obese women submitted to bariatric surgery: a meta-analysis., Surg Obes Relat Dis, 2020. 16 (10)(10): p. 1596-1602., https://pubmed.ncbi.nlm.nih.gov/32690459/
146. Raatz, H., Glinz, Dominik, Systematische Reviews und Bewertung der Qualität der Evidenz im Rahmen der S3-Leitlinie EndometriumkarzinomCEB, 2015. p. 1-45., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Endometriumkarzinom/Evidenzbericht_Screening_CEB_Basel.pdf
147. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, AWMF, S3-Leitlinie Hormontherapie in der Peri- und Postmenopause (HT), AWMF-Registernummer: 015/062, wird aktuell überarbeitet, 2009., http://www.awmf.org/leitlinien/detail/ll/015-062.html
148. Woolas, R., Talaat, A., Anderson, M., Brinkmann, D., Gardner, F., Gentry-Maharaj, A., et.al. Significant endometrial pathology detected during a transvaginal ultrasound screening trial for ovarian cancer, Gynecologic Oncology, 2011. 120, Supplement 1: p. S39.
149. Jacobs, I., Gentry-Maharaj, A., Burnell, M., Manchanda, R., Singh, N., Sharma, A., et.al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort, Lancet Oncol, 2010. 12: p. 38-48., https://www.ncbi.nlm.nih.gov/pubmed/21147030
150. Jacobs, I., Gentry-Maharaj, A., Burnell, M., Manchanda, R., Singh, N., Sharma, A., et.al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort, Lancet Oncol, 2010. 12: p. 38-48., https://www.ncbi.nlm.nih.gov/pubmed/21147030
151. Breijer, M. C., Peeters, J. A., Opmeer, B. C., Clark, T. J., Verheijen, R. H., Mol, B. W., et.al. Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis, Ultrasound Obstet Gynecol, 2012. 40: p. 621-9., https://www.ncbi.nlm.nih.gov/pubmed/23001905
152. Alcázar, JL, Bonilla, L, Marucco, J, Padilla, AI, Chacón, E, Manzour, N, et.al. Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥11 mm: A systematic review and meta-analysis., J Clin Ultrasound, 2018. 46 (9)(9): p. 565-570., https://pubmed.ncbi.nlm.nih.gov/30113073/
153. Smith-Bindman, R, Weiss, E, Feldstein, V, How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding., Ultrasound Obstet Gynecol, 2004. 24 (5)(5): p. 558-65., https://pubmed.ncbi.nlm.nih.gov/15386607/
154. Epstein, E, Fischerova, D, Valentin, L, Testa, AC, Franchi, D, Sladkevicius, P, et.al. Ultrasound characteristics of endometrial cancer as defined by International Endometrial Tumor Analysis (IETA) consensus nomenclature: prospective multicenter study., Ultrasound Obstet Gynecol, 2018. 51 (6)(6): p. 818-828., https://pubmed.ncbi.nlm.nih.gov/28944985/
155. Manchanda, R., Saridogan, E., Abdelraheim, A., Johnson, M., Rosenthal, A. N., Benjamin, E., et.al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS), Arch Gynecol Obstet, 2012. 286: p. 1555-62., https://www.ncbi.nlm.nih.gov/pubmed/22865035
156. Helder-Woolderink, J. M., De Bock, G. H., Sijmons, R. H., Hollema, H., Mourits, M. J., The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome, Gynecol Oncol, 2013. 131: p. 304-8., https://www.ncbi.nlm.nih.gov/pubmed/23769810
157. Raatz, H., Glinz, Dominik, Systematische Reviews und Bewertung der Qualität der Evidenz im Rahmen der S3-Leitlinie EndometriumkarzinomCEB, 2015. p. 1-45., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Endometriumkarzinom/Evidenzbericht_Screening_CEB_Basel.pdf
158. Vasen, H. F., Blanco, I., Aktan-Collan, K., Gopie, J. P., Alonso, A., Aretz, S., et.al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts, Gut, 2013. 62: p. 812-23., https://www.ncbi.nlm.nih.gov/pubmed/23408351
159. Bertelli, G., Valenzano, M., Costantini, S., Rissone, R., Angiolini, C., Signorini, A., et.al. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen, Gynecol Oncol, 2000. 78: p. 275-7., https://www.ncbi.nlm.nih.gov/pubmed/10985880
160. Fung, M. F., Reid, A., Faught, W., Le, T., Chenier, C., Verma, S., et.al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen, Gynecol Oncol, 2003. 91: p. 154-9., https://www.ncbi.nlm.nih.gov/pubmed/14529676
161. Gao, W. L., Zhang, L. P., Feng, L. M., Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen, Chin Med J (Engl), 2011. 124: p. 2335-9., https://www.ncbi.nlm.nih.gov/pubmed/21933565
162. Gerber, B., Krause, A., Muller, H., Reimer, T., Kulz, T., Makovitzky, J., et.al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound, J Clin Oncol, 2000. 18: p. 3464-70., https://www.ncbi.nlm.nih.gov/pubmed/11032586
163. Saccardi, C., Gizzo, S., Patrelli, T. S., Ancona, E., Anis, O., Di Gangi, S., et.al. Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study, Endocr Relat Cancer, 2013. 20: p. 455-62., https://www.ncbi.nlm.nih.gov/pubmed/23629476
164. Fleming, CA, Heneghan, HM, O'Brien, D, McCartan, DP, McDermott, EW, Prichard, RS, Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy., Br J Surg, 2018. 105 (9)(9): p. 1098-1106., https://pubmed.ncbi.nlm.nih.gov/29974455/
165. Gao, W. L., Zhang, L. P., Feng, L. M., Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen, Chin Med J (Engl), 2011. 124: p. 2335-9., https://www.ncbi.nlm.nih.gov/pubmed/21933565
166. Bertelli, G., Valenzano, M., Costantini, S., Rissone, R., Angiolini, C., Signorini, A., et.al. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen, Gynecol Oncol, 2000. 78: p. 275-7., https://www.ncbi.nlm.nih.gov/pubmed/10985880
167. Gerber, B., Krause, A., Muller, H., Reimer, T., Kulz, T., Makovitzky, J., et.al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound, J Clin Oncol, 2000. 18: p. 3464-70., https://www.ncbi.nlm.nih.gov/pubmed/11032586
168. Fung, M. F., Reid, A., Faught, W., Le, T., Chenier, C., Verma, S., et.al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen, Gynecol Oncol, 2003. 91: p. 154-9., https://www.ncbi.nlm.nih.gov/pubmed/14529676
169. Saccardi, C., Gizzo, S., Patrelli, T. S., Ancona, E., Anis, O., Di Gangi, S., et.al. Endometrial surveillance in tamoxifen users: role, timing and accuracy of hysteroscopic investigation: observational longitudinal cohort study, Endocr Relat Cancer, 2013. 20: p. 455-62., https://www.ncbi.nlm.nih.gov/pubmed/23629476
170. Van den Bosch, T., Van Schoubroeck, D., Ameye, L., De Brabanter, J., Van Huffel, S., Timmerman, D., Ultrasound assessment of endometrial thickness and endometrial polyps in women on hormonal replacement therapy, Am J Obstet Gynecol, 2003. 188: p. 1249-53., https://www.ncbi.nlm.nih.gov/pubmed/12748493
171. Pennant, M. E., Mehta, R., Moody, P., Hackett, G., Prentice, A., Sharp, S. J., et.al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer, BJOG, 2016. 124: p. 404-411., https://www.ncbi.nlm.nih.gov/pubmed/27766759
172. Clark, T. J., Mann, C. H., Shah, N., Khan, K. S., Song, F., Gupta, J. K., Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review (Structured abstract), BJOG. An International Journal of Obstetrics and Gynaecology, 2002. 109: p. 313-321., https://www.ncbi.nlm.nih.gov/pubmed/11950187
173. Huang, G. S., Gebb, J. S., Einstein, M. H., Shahabi, S., Novetsky, A. P., Goldberg, G. L., Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors, Am J Obstet Gynecol, 2007. 196: p. 243 e1-5., https://www.ncbi.nlm.nih.gov/pubmed/17346538
174. Leitao, M. M., Jr., Kehoe, S., Barakat, R. R., Alektiar, K., Gattoc, L. P., Rabbitt, C., et.al. Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma, Gynecol Oncol, 2008. 111: p. 244-8., https://www.ncbi.nlm.nih.gov/pubmed/18752842
175. Al-Azemi, M., Labib, N. S., Motawy, M. M., Temmim, L., Moussa, M. A., Omu, A. E., Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait, Med Princ Pract, 2003. 13: p. 30-4., https://www.ncbi.nlm.nih.gov/pubmed/14657616
176. Pennant, M. E., Mehta, R., Moody, P., Hackett, G., Prentice, A., Sharp, S. J., et.al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer, BJOG, 2016. 124: p. 404-411., https://www.ncbi.nlm.nih.gov/pubmed/27766759
177. Van Den Bosch, T, Verbakel, JY, Valentin, L, Wynants, L, De Cock, B, Pascual, MA, et.al. Typical ultrasound features of various endometrial pathologies described using International Endometrial Tumor Analysis (IETA) terminology in women with abnormal uterine bleeding., Ultrasound Obstet Gynecol, 2021. 57 (1)(1): p. 164-172., https://pubmed.ncbi.nlm.nih.gov/32484286/
178. Leone, FP, Timmerman, D, Bourne, T, Valentin, L, Epstein, E, Goldstein, SR, et.al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group., Ultrasound Obstet Gynecol, 2010. 35 (1)(1): p. 103-12., https://pubmed.ncbi.nlm.nih.gov/20014360/
179. Munro, MG, Critchley, HO, Broder, MS, Fraser, IS, FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age., Int J Gynaecol Obstet, 2011. 113 (1)(1): p. 3-13., https://pubmed.ncbi.nlm.nih.gov/21345435/
180. Wise, M. R., Gill, P., Lensen, S., Thompson, J. M., Farquhar, C. M., Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women, Am J Obstet Gynecol, 2016. 215: p. 598 e1-598 e8., https://www.ncbi.nlm.nih.gov/pubmed/27287687
181. Ge, L, Liu, G, Hu, K, Huang, K, Zhang, M, Zhou, J, et.al. A New Risk Index Combining d-Dimer, Fibrinogen, HE4, and CA199 Differentiates Suspecting Endometrial Cancer From Patients With Abnormal Vaginal Bleeding or Discharge., Technol Cancer Res Treat 19 (): p. 1533033819901117., https://pubmed.ncbi.nlm.nih.gov/32167027/
182. Li, J, Wang, X, Qu, W, Wang, J, Jiang, SW, Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis., Clin Chim Acta, 2019. 488 (): p. 215-220., https://pubmed.ncbi.nlm.nih.gov/30414437/
183. Matsuo, K., Opper, N. R., Ciccone, M. A., Garcia, J., Tierney, K. E., Baba, T., et.al. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome, Obstet Gynecol, 2015. 125: p. 424-33., https://www.ncbi.nlm.nih.gov/pubmed/25569000
184. Clark, T. J., Voit, D., Gupta, J. K., Hyde, C., Song, F., Khan, K. S., Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review, JAMA, 2002. 288: p. 1610-21., https://www.ncbi.nlm.nih.gov/pubmed/12350192
185. Svirsky, R., Smorgick, N., Rozowski, U., Sagiv, R., Feingold, M., Halperin, R., et.al. Can we rely on blind endometrial biopsy for detection of focal intrauterine pathology?, Am J Obstet Gynecol, 2008. 199: p. 115 e1-3., https://www.ncbi.nlm.nih.gov/pubmed/18456238
186. Leitao, M. M., Jr., Kehoe, S., Barakat, R. R., Alektiar, K., Gattoc, L. P., Rabbitt, C., et.al. Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma, Gynecol Oncol, 2008. 111: p. 244-8., https://www.ncbi.nlm.nih.gov/pubmed/18752842
187. Huang, G. S., Gebb, J. S., Einstein, M. H., Shahabi, S., Novetsky, A. P., Goldberg, G. L., Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors, Am J Obstet Gynecol, 2007. 196: p. 243 e1-5., https://www.ncbi.nlm.nih.gov/pubmed/17346538
188. Deckardt, R., Lueken, R. P., Gallinat, A., Möller, C. P., Busche, D., Nugent, W., et.al. Comparison of Transvaginal Ultrasound, Hysteroscopy, and Dilatation and Curettage in the Diagnosis of Abnormal Vaginal Bleeding and Intrauterine Pathology in Perimenopausal and Postmenopausal Women, The Journal of the American Association of Gynecologic Laparoscopists, 2002. 9(3): p. 277-282.
189. Dueholm, M., Hjorth, I. M., Secher, P., Jorgensen, A., Ortoft, G., Structured Hysteroscopic Evaluation of Endometrium in Women With Postmenopausal Bleeding, J Minim Invasive Gynecol, 2015. 22: p. 1215-24., https://www.ncbi.nlm.nih.gov/pubmed/26140830
190. Guido, R. S., Kanbour-Shakir, A., Rulin, M. C., Christopherson, W. A., Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer, J Reprod Med, 1995. 40: p. 553-5., https://www.ncbi.nlm.nih.gov/pubmed/7473450
191. Tanriverdi, H. A., Barut, A., Gun, B. D., Kaya, E., Is pipelle biopsy really adequate for diagnosing endometrial disease?, Med Sci Monit, 2004. 10: p. CR271-4., https://www.ncbi.nlm.nih.gov/pubmed/15173672
192. Del Priore, G., Williams, R., Harbatkin, C. B., Wan, L. S., Mittal, K., Yang, G. C., Endometrial brush biopsy for the diagnosis of endometrial cancer, J Reprod Med, 2001. 46: p. 439-43., https://www.ncbi.nlm.nih.gov/pubmed/11396369
193. Fakhar, S., Saeed, G., Khan, A. H., Alam, A. Y., Validity of pipelle endometrial sampling in patients with abnormal uterine bleeding, Ann Saudi Med, 2008. 28: p. 188-91., https://www.ncbi.nlm.nih.gov/pubmed/18500186
194. Abdelazim, I. A., Abdelrazak, K. M., Elbiaa, A. A., Al-Kadi, M., Yehia, A. H., Accuracy of endometrial sampling compared to conventional dilatation and curettage in women with abnormal uterine bleeding, Arch Gynecol Obstet, 2014. 291: p. 1121-6., https://www.ncbi.nlm.nih.gov/pubmed/25367600
195. Sanam, M., Majid, M. M., Comparison the Diagnostic Value of Dilatation and Curettage Versus Endometrial Biopsy by Pipelle--a Clinical Trial, Asian Pac J Cancer Prev, 2015. 16: p. 4971-5., https://www.ncbi.nlm.nih.gov/pubmed/26163624
196. Wu, H. H., Harshbarger, K. E., Berner, H. W., Elsheikh, T. M., Endometrial brush biopsy (Tao brush). Histologic diagnosis of 200 cases with complementary cytology: an accurate sampling technique for the detection of endometrial abnormalities, Am J Clin Pathol, 2000. 114: p. 412-8., https://www.ncbi.nlm.nih.gov/pubmed/10989642
197. Wu, H. H., Casto, B. D., Elsheikh, T. M., Endometrial brush biopsy. An accurate outpatient method of detecting endometrial malignancy, J Reprod Med, 2003. 48: p. 41-5., https://www.ncbi.nlm.nih.gov/pubmed/12611094
198. Williams, A. R., Brechin, S., Porter, A. J., Warner, P., Critchley, H. O., Factors affecting adequacy of Pipelle and Tao Brush endometrial sampling, BJOG, 2008. 115: p. 1028-36., https://www.ncbi.nlm.nih.gov/pubmed/18651884
199. Critchley, H. O., Warner, P., Lee, A. J., Brechin, S., Guise, J., Graham, B., Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status, Health Technol Assess, 2004. 8: p. iii-iv, 1-139., https://www.ncbi.nlm.nih.gov/pubmed/15361316
200. Al-Azemi, M., Labib, N. S., Motawy, M. M., Temmim, L., Moussa, M. A., Omu, A. E., Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait, Med Princ Pract, 2003. 13: p. 30-4., https://www.ncbi.nlm.nih.gov/pubmed/14657616
201. Narice, BF, Delaney, B, Dickson, JM, Endometrial sampling in low-risk patients with abnormal uterine bleeding: a systematic review and meta-synthesis., BMC Fam Pract, 2018. 19 (1)(1): p. 135., https://pubmed.ncbi.nlm.nih.gov/30060741/
202. Verdoodt, F, Jiang, X, Williams, M, Schnatz, PF, Arbyn, M, High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis., Int J Cancer, 2016. 138 (2)(2): p. 303-10., https://pubmed.ncbi.nlm.nih.gov/25583258/
203. Timmermans, A., Opmeer, B. C., Khan, K. S., Bachmann, L. M., Epstein, E., Clark, T. J., et.al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis, Obstet Gynecol, 2010. 116: p. 160-7., https://www.ncbi.nlm.nih.gov/pubmed/20567183
204. Clarke, MA, Long, BJ, Del Mar Morillo, A, Arbyn, M, Bakkum-Gamez, JN, Wentzensen, N, Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis., JAMA Intern Med, 2018. 178 (9)(9): p. 1210-1222., https://pubmed.ncbi.nlm.nih.gov/30083701/
205. Timmermans, A., Opmeer, B. C., Khan, K. S., Bachmann, L. M., Epstein, E., Clark, T. J., et.al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis, Obstet Gynecol, 2010. 116: p. 160-7., https://www.ncbi.nlm.nih.gov/pubmed/20567183
206. Bittencourt, CA, Dos Santos Simões, R, Bernardo, WM, Fuchs, LFP, Soares Júnior, JM, Pastore, AR, et.al. Accuracy of saline contrast sonohysterography in detection of endometrial polyps and submucosal leiomyomas in women of reproductive age with abnormal uterine bleeding: systematic review and meta-analysis., Ultrasound Obstet Gynecol, 2017. 50 (1)(1): p. 32-39., https://pubmed.ncbi.nlm.nih.gov/27862503/
207. Nieuwenhuis, LL, Hermans, FJ, Bij de Vaate, AJM, Leeflang, MM, Brölmann, HA, Hehenkamp, WJ, et.al. Three-dimensional saline infusion sonography compared to two-dimensional saline infusion sonography for the diagnosis of focal intracavitary lesions., Cochrane Database Syst Rev, 2017. 5 (): p. CD011126., https://pubmed.ncbi.nlm.nih.gov/28472862/
208. Vroom, AJ, Timmermans, A, Bongers, MY, van den Heuvel, ER, Geomini, PMAJ, van Hanegem, N, Diagnostic accuracy of saline contrast sonohysterography in detecting endometrial polyps in women with postmenopausal bleeding: systematic review and meta-analysis., Ultrasound Obstet Gynecol, 2019. 54 (1)(1): p. 28-34., https://pubmed.ncbi.nlm.nih.gov/30693579/
209. Endometriumcarcinoom, Endometriumcarcinoom, 2011., https://www.oncoline.nl/endometriumcarcinoom
210. Lalwani, N., Dubinsky, T., Javitt, M. C., Gaffney, D. K., Glanc, P., Elshaikh, M. A., et.al. ACR Appropriateness Criteria(®) pretreatment evaluation and follow-up of endometrial cancer, Ultrasound Q, 2014. 30: p. 21-8., https://www.ncbi.nlm.nih.gov/pubmed/24901775
211. Amkreutz, L. C., Mertens, H. J., Nurseta, T., Engelen, M. J., Bergmans, M., Nolting, E., et.al. The value of imaging of the lungs in the diagnostic workup of patients with endometrial cancer, Gynecol Oncol, 2013. 131: p. 147-50., https://www.ncbi.nlm.nih.gov/pubmed/23838035
212. Savelli, L., Ceccarini, M., Ludovisi, M., Fruscella, E., De Iaco, P. A., Salizzoni, E., et.al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging, Ultrasound Obstet Gynecol, 2008. 31: p. 560-6., https://www.ncbi.nlm.nih.gov/pubmed/18398926
213. Savelli, L., Ceccarini, M., Ludovisi, M., Fruscella, E., De Iaco, P. A., Salizzoni, E., et.al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging, Ultrasound Obstet Gynecol, 2008. 31: p. 560-6., https://www.ncbi.nlm.nih.gov/pubmed/18398926
214. Alcázar, JL, Pérez, L, Güell, O, Haro, N, Manzour, N, Chacon, E, et.al. Diagnostic Performance of Transvaginal Ultrasound for Detecting Cervical Invasion In Women With Endometrial Carcinoma: A Systematic Review and Meta-analysis., J Ultrasound Med, 2019. 38 (1)(1): p. 179-189., https://pubmed.ncbi.nlm.nih.gov/29732585/
215. Kakhki, V. R., Shahriari, S., Treglia, G., Hasanzadeh, M., Zakavi, S. R., Yousefi, Z., et.al. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature, Int J Gynecol Cancer, 2013. 23: p. 1536-43., https://www.ncbi.nlm.nih.gov/pubmed/24172090
216. Antonsen, S. L., Jensen, L. N., Loft, A., Berthelsen, A. K., Costa, J., Tabor, A., et.al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study, Gynecol Oncol, 2012. 128: p. 300-8.
217. Lalwani, N., Dubinsky, T., Javitt, M. C., Gaffney, D. K., Glanc, P., Elshaikh, M. A., et.al. ACR Appropriateness Criteria(®) pretreatment evaluation and follow-up of endometrial cancer, Ultrasound Q, 2014. 30: p. 21-8., https://www.ncbi.nlm.nih.gov/pubmed/24901775
218. Selman, T. J., Mann, C. H., Zamora, J., Khan, K. S., A systematic review of tests for lymph node status in primary endometrial cancer, BMC Womens Health, 2008. 8: p. 8., https://www.ncbi.nlm.nih.gov/pubmed/18457596
219. Endometriumcarcinoom, Endometriumcarcinoom, 2011., https://www.oncoline.nl/endometriumcarcinoom
220. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22305013
221. Nougaret, S, Horta, M, Sala, E, Lakhman, Y, Thomassin-Naggara, I, Kido, A, et.al. Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology., Eur Radiol, 2019. 29 (2)(2): p. 792-805., https://pubmed.ncbi.nlm.nih.gov/29995239/
222. Haldorsen, I. S., Gruner, R., Husby, J. A., Magnussen, I. J., Werner, H. M., Salvesen, O. O., et.al. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence, Eur Radiol, 2013. 23: p. 2916-25., https://www.ncbi.nlm.nih.gov/pubmed/23732687
223. Luomaranta, A., Leminen, A., Loukovaara, M., Magnetic Resonance Imaging in the Assessment of High-Risk Features of Endometrial Carcinoma: A Meta-Analysis, Int J Gynecol Cancer, 2014., https://www.ncbi.nlm.nih.gov/pubmed/25010040
224. Radiologic staging in patients with endometrial cancer: a meta-analysis., 1999., https://www.ncbi.nlm.nih.gov/pubmed/10478237
225. Andreano, A., Rechichi, G., Rebora, P., Sironi, S., Valsecchi, M. G., Galimberti, S., MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis, Eur Radiol, 2014. 24: p. 1327-38., https://www.ncbi.nlm.nih.gov/pubmed/24668009
226. Das, S. K., Niu, X. K., Wang, J. L., Zeng, L. C., Wang, W. X., Bhetuwal, A., et.al. Usefulness of DWI in preoperative assessment of deep myometrial invasion in patients with endometrial carcinoma: a systematic review and meta-analysis, Cancer Imaging, 2015. 14: p. 32., https://www.ncbi.nlm.nih.gov/pubmed/25608571
227. Tsili, A. C., Tsampoulas, C., Dalkalitsis, N., Stefanou, D., Paraskevaidis, E., Efremidis, S. C., Local staging of endometrial carcinoma: role of multidetector CT, Eur Radiol, 2008. 18: p. 1043-8., https://www.ncbi.nlm.nih.gov/pubmed/18175120
228. Kitajima, K., Suenaga, Y., Ueno, Y., Kanda, T., Maeda, T., Takahashi, S., et.al. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with (1)(8)F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI, Eur J Radiol, 2013. 82: p. 1672-6., https://www.ncbi.nlm.nih.gov/pubmed/23727380
229. N, e, t, w, o, r, et.al. Clinical Practice Guidelines in Oncology: Uterine NeoplasmsNational Comprehensive Cancer Network, 2015. 2016:
230. Luomaranta, A., Leminen, A., Loukovaara, M., Magnetic Resonance Imaging in the Assessment of High-Risk Features of Endometrial Carcinoma: A Meta-Analysis, Int J Gynecol Cancer, 2014., https://www.ncbi.nlm.nih.gov/pubmed/25010040
231. Chang, M. C., Chen, J. H., Liang, J. A., Yang, K. T., Cheng, K. Y., Kao, C. H., 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis, Eur J Radiol, 2012. 81: p. 3511-7.
232. Antonsen, S. L., Ulrich, L., Hogdall, C., Patients with atypical hyperplasia of the endometrium should be treated in oncological centers, Gynecol Oncol, 2011. 125: p. 124-8., https://www.ncbi.nlm.nih.gov/pubmed/22198048
233. Kakhki, V. R., Shahriari, S., Treglia, G., Hasanzadeh, M., Zakavi, S. R., Yousefi, Z., et.al. Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature, Int J Gynecol Cancer, 2013. 23: p. 1536-43., https://www.ncbi.nlm.nih.gov/pubmed/24172090
234. B, o, k, h, m, a, et.al. Two pathogenetic types of endometrial carcinoma, Gynecol Oncol, 1983. 15: p. 10-7., https://www.ncbi.nlm.nih.gov/pubmed/6822361
235. Board, WHO Classification of Tumours Editorial, Female Genital Tumours, 2020. 4:
236. Luchini, C, Bibeau, F, Ligtenberg, MJL, Singh, N, Nottegar, A, Bosse, T, et.al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach., Ann Oncol, 2019. 30 (8)(8): p. 1232-1243., https://pubmed.ncbi.nlm.nih.gov/31056702/
237. Concin, N, Matias-Guiu, X, Vergote, I, Cibula, D, Mirza, MR, Marnitz, S, et.al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma., Int J Gynecol Cancer, 2021. 31 (1)(1): p. 12-39., https://pubmed.ncbi.nlm.nih.gov/33397713/
238. Vermij, L, Smit, V, Nout, R, Bosse, T, Incorporation of molecular characteristics into endometrial cancer management., Histopathology, 2020. 76 (1)(1): p. 52-63., https://pubmed.ncbi.nlm.nih.gov/31846532/
239. Soslow, RA, Tornos, C, Park, KJ, Malpica, A, Matias-Guiu, X, Oliva, E, et.al. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S64-S74., https://pubmed.ncbi.nlm.nih.gov/30550484/
240. Malpica, A, Euscher, ED, Hecht, JL, Ali-Fehmi, R, Quick, CM, Singh, N, et.al. Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S9-S24., https://pubmed.ncbi.nlm.nih.gov/30550481/
241. Bell, DW, Ellenson, LH, Molecular Genetics of Endometrial Carcinoma., Annu Rev Pathol, 2019. 14 (): p. 339-367., https://pubmed.ncbi.nlm.nih.gov/30332563/
242. Bokhman, JV, Two pathogenetic types of endometrial carcinoma., Gynecol Oncol, 1983. 15 (1)(1): p. 10-7., https://pubmed.ncbi.nlm.nih.gov/6822361/
243. Lax, SF, Kurman, RJ, A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses., Verh Dtsch Ges Pathol, 1997. 81 (): p. 228-32., https://pubmed.ncbi.nlm.nih.gov/9474874/
244. Lax, SF, Kurman, RJ, Pizer, ES, Wu, L, Ronnett, BM, A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis., Am J Surg Pathol, 2000. 24 (9)(9): p. 1201-8., https://pubmed.ncbi.nlm.nih.gov/10976693/
245. Lax, SF, Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification., Virchows Arch, 2004. 444 (3)(3): p. 213-23., https://pubmed.ncbi.nlm.nih.gov/14747944/
246. Horn, L. C., Schnurrbusch, U., Bilek, K., Hentschel, B., Einenkel, J., Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment, Int J Gynecol Cancer, 2004. 14: p. 348-53., https://www.ncbi.nlm.nih.gov/pubmed/15086736
247. Semere, LG, Ko, E, Johnson, NR, Vitonis, AF, Phang, LJ, Cramer, DW, et.al. Endometrial intraepithelial neoplasia: clinical correlates and outcomes., Obstet Gynecol, 2011. 118 (1)(1): p. 21-28., https://pubmed.ncbi.nlm.nih.gov/21691159/
248. Lacey, J. V., Jr., Chia, V. M., Endometrial hyperplasia and the risk of progression to carcinoma, Maturitas, 2009. 63: p. 39-44., https://www.ncbi.nlm.nih.gov/pubmed/19285814
249. Yuan, L, Biscotti, CV, Zhu, H, Booth, CN, Abdul-Karim, FW, Zhang, Y, Significance of atypical endometrial cells in women younger than 40 years of age., J Am Soc Cytopathol 9 (1)(1): p. 33-37., https://pubmed.ncbi.nlm.nih.gov/PMID:, 31353256/
250. Vetter, MH, Smith, B, Benedict, J, Hade, EM, Bixel, K, Copeland, LJ, et.al. Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia., Am J Obstet Gynecol, 2020. 222 (1)(1): p. 60.e1-60.e7., https://pubmed.ncbi.nlm.nih.gov/31401259/
251. Bourdel, N, Chauvet, P, Tognazza, E, Pereira, B, Botchorishvili, R, Canis, M, Sampling in Atypical Endometrial Hyperplasia: Which Method Results in the Lowest Underestimation of Endometrial Cancer? A Systematic Review and Meta-analysis., J Minim Invasive Gynecol 23 (5)(5): p. 692-701., https://pubmed.ncbi.nlm.nih.gov/27058769/
252. Smith, BQ, Boone, JD, Thomas, ED, Turner, TB, McGwin, G, Stisher, AM, et.al. The Reliability of Intraoperative Assessment on Predicting Tumor Size, Myometrial Invasion, and Cervical Involvement in Patients With a Preoperative Diagnosis of Complex Atypical Hyperplasia or (Clinical Stage I) Endometrial Cancer: A Prospective Cohort Study., Am J Clin Oncol, 2020. 43 (2)(2): p. 122-127., https://pubmed.ncbi.nlm.nih.gov/31764025/
253. Wheeler, DT, Bell, KA, Kurman, RJ, Sherman, ME, Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation., Am J Surg Pathol, 2000. 24 (6)(6): p. 797-806., https://pubmed.ncbi.nlm.nih.gov/10843281/
254. Trinh, VQ, Pelletier, MP, Echelard, P, Warkus, T, Sauthier, P, Gougeon, F, et.al. Distinct Histologic, Immunohistochemical and Clinical Features Associated With Serous Endometrial Intraepithelial Carcinoma Involving Polyps., Int J Gynecol Pathol, 2020. 39 (2)(2): p. 128-135., https://pubmed.ncbi.nlm.nih.gov/30789501/
255. Mayr, Doris, Schmoeckel, Elisa, Höhn, Anne Kathrin, Hiller, Grit Gesine Ruth, Horn, Lars-Christian, Aktuelle WHO-Klassifikation des weiblichen Genitale, 2021. 42(3): p. 259 - 269., https://doi.org/10.1007/s00292-021-00933-w
256. Soslow, RA, High-grade endometrial carcinomas - strategies for typing., Histopathology, 2013. 62 (1)(1): p. 89-110., https://pubmed.ncbi.nlm.nih.gov/23240672/
257. Malpica, A, How to approach the many faces of endometrioid carcinoma., Mod Pathol, 2016. 29 Suppl 1 (): p. S29-44., https://pubmed.ncbi.nlm.nih.gov/26715172/
258. Murali, R, Davidson, B, Fadare, O, Carlson, JA, Crum, CP, Gilks, CB, et.al. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S40-S63., https://pubmed.ncbi.nlm.nih.gov/30550483/
259. Hu, S, Hinson, JL, Matnani, R, Cibull, ML, Karabakhtsian, RG, Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma., Mod Pathol, 2018. 31 (2)(2): p. 358-364., https://pubmed.ncbi.nlm.nih.gov/28984301/
260. Chen, W, Husain, A, Nelson, GS, Rambau, PF, Liu, S, Lee, CH, et.al. Immunohistochemical Profiling of Endometrial Serous Carcinoma., Int J Gynecol Pathol, 2017. 36 (2)(2): p. 128-139., https://pubmed.ncbi.nlm.nih.gov/27167671/
261. Stewart, CJR, Crum, CP, McCluggage, WG, Park, KJ, Rutgers, JK, Oliva, E, et.al. Guidelines to Aid in the Distinction of Endometrial and Endocervical Carcinomas, and the Distinction of Independent Primary Carcinomas of the Endometrium and Adnexa From Metastatic Spread Between These and Other Sites., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S75-S92., https://pubmed.ncbi.nlm.nih.gov/30550485/
262. Rabban, JT, Gilks, CB, Malpica, A, Matias-Guiu, X, Mittal, K, Mutter, GL, et.al. Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S25-S39., https://pubmed.ncbi.nlm.nih.gov/30550482/
263. Lax, SF, Pathology of Endometrial Carcinoma., Adv Exp Med Biol, 2017. 943 (): p. 75-96., https://pubmed.ncbi.nlm.nih.gov/PMID:, 27910065/
264. Bell, DW, Ellenson, LH, Molecular Genetics of Endometrial Carcinoma., Annu Rev Pathol, 2019. 14 (): p. 339-367., https://pubmed.ncbi.nlm.nih.gov/30332563/
265. Horn, LC, Höhn, AK, Krücken, I, Stiller, M, Obeck, U, Brambs, CE, Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma., J Cancer Res Clin Oncol, 2020. 146 (4)(4): p. 971-983., https://pubmed.ncbi.nlm.nih.gov/31927619/
266. Euscher, ED, Bassett, R, Duose, DY, Lan, C, Wistuba, I, Ramondetta, L, et.al. Mesonephric-like Carcinoma of the Endometrium: A Subset of Endometrial Carcinoma With an Aggressive Behavior., Am J Surg Pathol, 2020. 44 (4)(4): p. 429-443., https://pubmed.ncbi.nlm.nih.gov/31725471/
267. Horn, L. C., Dallacker, M., Bilek, K., [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors], Pathologe, 2009. 30: p. 292-301., https://www.ncbi.nlm.nih.gov/pubmed/19495763
268. Artioli, G, Wabersich, J, Ludwig, K, Gardiman, MP, Borgato, L, Garbin, F, Rare uterine cancer: carcinosarcomas. Review from histology to treatment., Crit Rev Oncol Hematol, 2015. 94 (1)(1): p. 98-104., https://pubmed.ncbi.nlm.nih.gov/25468677/
269. Zhao, S, Bellone, S, Lopez, S, Thakral, D, Schwab, C, English, DP, et.al. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition., Proc Natl Acad Sci U S A, 2016. 113 (43)(43): p. 12238-12243., https://pubmed.ncbi.nlm.nih.gov/27791010/
270. Lopez-Garcia, M. A., Palacios, J., Pathologic and molecular features of uterine carcinosarcomas, Semin Diagn Pathol, 2011. 27: p. 274-86., https://www.ncbi.nlm.nih.gov/pubmed/21309261
271. Denschlag, D., Thiel, F. C., Ackermann, S., Harter, P., Juhasz-Boess, I., Mallmann, P., et.al. Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015), Geburtshilfe Frauenheilkd, 2015. 75: p. 1028-1042., https://www.ncbi.nlm.nih.gov/pubmed/26640293
272. Plotkin, A, Kuzeljevic, B, De Villa, V, Thompson, EF, Gilks, CB, Clarke, BA, et.al. Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens., Int J Gynecol Pathol, 2020. 39 (6)(6): p. 537-545., https://pubmed.ncbi.nlm.nih.gov/32281774/
273. Casey, L, Singh, N, POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting., Int J Gynecol Pathol, 2021. 40 (1)(1): p. 5-16., https://pubmed.ncbi.nlm.nih.gov/33290350/
274. McCluggage, WG, Colgan, T, Duggan, M, Hacker, NF, Mulvany, N, Otis, C, et.al. Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia., Int J Gynecol Pathol, 2013. 32 (1)(1): p. 45-65., https://pubmed.ncbi.nlm.nih.gov/PMID:, 23202790/
275. Guerra, E, Matias-Guiu, X, Relevance of pathologic features in risk stratification for early-stage endometrial cancer., J Gynecol Oncol, 2021. 32 (4)(4): p. e67., https://pubmed.ncbi.nlm.nih.gov/34085800/
276. Hirschowitz, L, Nucci, M, Zaino, RJ, Problematic issues in the staging of endometrial, cervical and vulval carcinomas., Histopathology, 2013. 62 (1)(1): p. 176-202., https://pubmed.ncbi.nlm.nih.gov/PMID:, 23240675/
277. Horn, LC, Hoehn, AK, Processing and Histopathological Workup of Hysterectomy Specimens. In: Alkatout I, Mettler L (Hrsg) Hysterectomy. A Comprehensive Surgical Approach. Springer International Publishing, Cham, 2018. p. 259 - 295.
278. Argani, P., Cimino-Mathews, A., Intraoperative Frozen Sections. Diagnostic PitfallsDemos Medical Publishing, Consultant Pathology, 2014. 5:
279. Williams, J. W., Hirschowitz, L., Assessment of uterine wall thickness and position of the vascular plexus in the deep myometrium: implications for the measurement of depth of myometrial invasion of endometrial carcinomas, Int J Gynecol Pathol, 2005. 25: p. 59-64., https://www.ncbi.nlm.nih.gov/pubmed/16306786
280. Liebig, C., Ayala, G., Wilks, J. A., Berger, D. H., Albo, D., Perineural invasion in cancer: a review of the literature, Cancer, 2009. 115: p. 3379-91., https://www.ncbi.nlm.nih.gov/pubmed/19484787
281. Wittekind, C., Brierley, JD., Lee, A., van Eycken, E., TNM Supplement: A Commentary on Uniform Use, 5th Edition, 2019., https://www.wiley.com/en-us/TNM+Supplement%3A+A+Commentary+on+Uniform+Use%2C+5th+Edition-p-9781119263920
282. Singh, N, Hirschowitz, L, Zaino, R, Alvarado-Cabrero, I, Duggan, MA, Ali-Fehmi, R, et.al. Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade)., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S93-S113., https://pubmed.ncbi.nlm.nih.gov/30550486/
283. Folkins, AK, Nevadunsky, NS, Saleemuddin, A, Jarboe, EA, Muto, MG, Feltmate, CM, et.al. Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies., Mod Pathol, 2010. 23 (8)(8): p. 1073-9., https://pubmed.ncbi.nlm.nih.gov/20473276/
284. Wittekind, C, [Lymph nodes, tumour deposits, and TNM: are we getting better? 7th edition of UICC 2010 TNM classification of malignant tumors]., Strahlenther Onkol, 2012. 188 (2)(2): p. 191-2., https://pubmed.ncbi.nlm.nih.gov/22231635/
285. Seifi, F, Parkash, V, Clark, M, Menderes, G, Tierney, C, Silasi, DA, et.al. Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer., JSLS 23 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/31285650/
286. Peters, EEM, Bartosch, C, McCluggage, WG, Genestie, C, Lax, SF, Nout, R, et.al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer., Histopathology, 2019. 75 (1)(1): p. 128-136., https://pubmed.ncbi.nlm.nih.gov/31155736/
287. Qian, Y, Pollom, EL, Nwachukwu, C, Seiger, K, von Eyben, R, Folkins, AK, et.al. Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma., Gynecol Oncol, 2017. 147 (1)(1): p. 24-29., https://pubmed.ncbi.nlm.nih.gov/PMID:, 28709703/
288. Matsuo, K, Garcia-Sayre, J, Medeiros, F, Casabar, JK, Machida, H, Moeini, A, et.al. Impact of depth and extent of lymphovascular space invasion on lymph node metastasis and recurrence patterns in endometrial cancer., J Surg Oncol, 2015. 112 (6)(6): p. 669-76., https://pubmed.ncbi.nlm.nih.gov/26391212/
289. Bosse, T., Peters, E. E., Creutzberg, C. L., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Mens, J. W., et.al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials, Eur J Cancer, 2015. 51: p. 1742-50., https://www.ncbi.nlm.nih.gov/pubmed/26049688
290. Barnes, EA, Martell, K, Parra-Herran, C, Taggar, AS, Donovan, E, Leung, E, Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancer., Brachytherapy 20 (3)(3): p. 527-535., https://pubmed.ncbi.nlm.nih.gov/33485810/
291. Pifer, PM, Bhargava, R, Patel, AK, Ling, DC, Vargo, JA, Orr, BC, et.al. Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? - A single-institution study., Gynecol Oncol, 2020. 159 (1)(1): p. 23-29., https://pubmed.ncbi.nlm.nih.gov/32718729/
292. Winer, I, Ahmed, QF, Mert, I, Bandyopadhyay, S, Cote, M, Munkarah, AR, et.al. Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?, Int J Gynecol Pathol, 2015. 34 (1)(1): p. 47-56., https://pubmed.ncbi.nlm.nih.gov/PMID:, 25473753/
293. Wittekind C., H.J., Meyer, TNM Klassifikation maligner TumorenWiley-VCH, 2010., http://www.wiley-vch.de/publish/dt/books/bySubjectMD00/ISBN3-527-32759-2/
294. Fader, AN, Roque, DM, Siegel, E, Buza, N, Hui, P, Abdelghany, O, et.al. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis., Clin Cancer Res, 2020. 26 (15)(15): p. 3928-3935., https://pubmed.ncbi.nlm.nih.gov/32601075/
295. Buza, N, English, DP, Santin, AD, Hui, P, Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice., Mod Pathol, 2013. 26 (12)(12): p. 1605-12., https://pubmed.ncbi.nlm.nih.gov/23765245/
296. Quddus, MR, Hansen, K, Tantravahi, U, Sung, CJ, Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression., Gynecol Oncol Rep, 2020. 32 (): p. 100561., https://pubmed.ncbi.nlm.nih.gov/32258332/
297. Buza, N, HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting., Int J Gynecol Pathol, 2021. 40 (1)(1): p. 17-23., https://pubmed.ncbi.nlm.nih.gov/33290351/
298. Rottmann, D, Assem, H, Matsumoto, N, Wong, S, Hui, P, Buza, N, Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity., Int J Gynecol Pathol, 2021. 40 (3)(3): p. 263-271., https://pubmed.ncbi.nlm.nih.gov/PMID:, 32897955/
299. Jamieson, A, Thompson, EF, Huvila, J, Gilks, CB, McAlpine, JN, p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification., Int J Gynecol Cancer, 2021. 31 (6)(6): p. 907-913., https://pubmed.ncbi.nlm.nih.gov/33589443/
300. Jönsson, JM, Bååth, M, Björnheden, I, Sahin, ID, Måsbäck, A, Hedenfalk, I, Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer., Cancers (Basel), 2021. 13 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/33445465/
301. Ashley, CW, Da Cruz Paula, A, Kumar, R, Mandelker, D, Pei, X, Riaz, N, et.al. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression., Gynecol Oncol, 2019. 152 (1)(1): p. 11-19., https://pubmed.ncbi.nlm.nih.gov/30415991/
302. Stephan, J. M., Hansen, J., Samuelson, M., McDonald, M., Chin, Y., Bender, D., et.al. Intra-operative frozen section results reliably predict final pathology in endometrial cancer, Gynecol Oncol, 2014. 133: p. 499-505., https://www.ncbi.nlm.nih.gov/pubmed/24699308
303. Parkash, V, Matias-Guiu, X, Oliva, E, Malpica, A, McCluggage, WG, Current Practices in the Processing, Diagnosis, and Reporting of Endometrial Carcinoma: Results of a Web-based Survey by the International Society of Gynecological Pathologists (ISGyP)., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S3-S8., https://pubmed.ncbi.nlm.nih.gov/30550480/
304. Orezzoli, J. P., Sioletic, S., Olawaiye, A., Oliva, E., del Carmen, M. G., Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion, Gynecol Oncol, 2009. 113: p. 316-23., https://www.ncbi.nlm.nih.gov/pubmed/19345400
305. Zaino, R. J., Abendroth, C., Yemelyanova, A., Oliva, E., Lim, D., Soslow, R., et.al. Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible, Gynecol Oncol, 2012. 128: p. 83-7., https://www.ncbi.nlm.nih.gov/pubmed/23063759
306. Şenol, T, Polat, M, Özkaya, E, Karateke, A, Misinterpretation of Frozen Section in Endometrial Cancer Cases: Does It Have Any Effect on Disease-free and Overall Survival?, Int J Gynecol Pathol, 2017. 36 (6)(6): p. 550-554., https://pubmed.ncbi.nlm.nih.gov/PMID:, 28134667/
307. Blakely, M, Liu, Y, Rahaman, J, Prasad-Hayes, M, Tismenetsky, M, Wang, X, et.al. Sentinel Lymph Node Ultra-staging as a Supplement for Endometrial Cancer Intraoperative Frozen Section Deficiencies., Int J Gynecol Pathol, 2019. 38 (1)(1): p. 52-58., https://pubmed.ncbi.nlm.nih.gov/28968296/
308. Strickland, SV, Rendi, MH, Garcia, RL, Norquist, BS, Pennington, KP, Kilgore, MR, Evaluation of Intraoperative Assessments in the Management of Endometrial Carcinoma: A Retrospective Quality Assurance Review., Int J Gynecol Pathol, 2018. 37 (5)(5): p. 414-420., https://pubmed.ncbi.nlm.nih.gov/30102260/
309. Euscher, E., Fox, P., Bassett, R., Al-Ghawi, H., Ali-Fehmi, R., Barbuto, D., et.al. The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma, Am J Surg Pathol, 2013. 37: p. 1728-36., https://www.ncbi.nlm.nih.gov/pubmed/24061515
310. Nakao, Y., Yamasaki, F., Yokoyama, M., Aihara, S., Yasunaga, M., Iwasaka, T., Minimal deviation endometrioid adenocarcinoma of the endometrium and its MRI findings, Eur J Gynaecol Oncol, 2014. 35: p. 185-7., https://www.ncbi.nlm.nih.gov/pubmed/24772926
311. Bartosch, C., Manuel Lopes, J., Oliva, E., Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features, Adv Anat Pathol, 2011. 18: p. 415-37., https://www.ncbi.nlm.nih.gov/pubmed/21993268
312. Şenol, T, Polat, M, Özkaya, E, Karateke, A, Misinterpretation of Frozen Section in Endometrial Cancer Cases: Does It Have Any Effect on Disease-free and Overall Survival?, Int J Gynecol Pathol, 2017. 36 (6)(6): p. 550-554., https://pubmed.ncbi.nlm.nih.gov/28134667/
313. Fotiou, S, Vlahos, N, Kondi-Pafiti, A, Zarganis, P, Papakonstantinou, K, Creatsas, G, Intraoperative gross assessment of myometrial invasion and cervical involvement in endometrial cancer: Role of tumor grade and size., Gynecol Oncol, 2009. 112 (3)(3): p. 517-20., https://pubmed.ncbi.nlm.nih.gov/19117598/
314. Kumar, S, Bandyopadhyay, S, Semaan, A, Shah, JP, Mahdi, H, Morris, R, et.al. The role of frozen section in surgical staging of low risk endometrial cancer., PLoS One, 2011. 6 (9)(9): p. e21912., https://pubmed.ncbi.nlm.nih.gov/PMID:, 21912633/
315. Takano, M., Ochi, H., Takei, Y., Miyamoto, M., Hasumi, Y., Kaneta, Y., et.al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?, Br J Cancer, 2013. 109: p. 1760-5., https://www.ncbi.nlm.nih.gov/pubmed/24002604
316. Zaino, R. J., Abendroth, C., Yemelyanova, A., Oliva, E., Lim, D., Soslow, R., et.al. Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible, Gynecol Oncol, 2012. 128: p. 83-7., https://www.ncbi.nlm.nih.gov/pubmed/23063759
317. McCluggage, W. G., My approach to and thoughts on the typing of ovarian carcinomas, J Clin Pathol, 2008. 61: p. 152-63.
318. McCluggage, W. G., Hirschowitz, L., Wilson, G. E., Oliva, E., Soslow, R. A., Zaino, R. J., Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study, Am J Surg Pathol, 2011. 35: p. 289-94., https://www.ncbi.nlm.nih.gov/pubmed/21263250
319. Horn, L. C., Trost, M., Bilek, K., Staging of endometrial carcinoma: aspects of ovarian and cervical involvement, Int J Gynecol Pathol, 2009. 29: p. 63-6., https://www.ncbi.nlm.nih.gov/pubmed/19952935
320. Morotti, M, Menada, MV, Moioli, M, Sala, P, Maffeo, I, Abete, L, et.al. Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia., Gynecol Oncol, 2012. 125 (3)(3): p. 536-40., https://pubmed.ncbi.nlm.nih.gov/PMID:, 22361087/
321. Rakha, E, Wong, SC, Soomro, I, Chaudry, Z, Sharma, A, Deen, S, et.al. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature., Am J Surg Pathol, 2012. 36 (11)(11): p. 1683-90., https://pubmed.ncbi.nlm.nih.gov/PMID:, 23073327/
322. Torres, M. L., Weaver, A. L., Kumar, S., Uccella, S., Famuyide, A. O., Cliby, W. A., et.al. Risk factors for developing endometrial cancer after benign endometrial sampling, Obstet Gynecol, 2012. 120: p. 998-1004., https://www.ncbi.nlm.nih.gov/pubmed/23090515
323. Trimble, C. L., Method, M., Leitao, M., Lu, K., Ioffe, O., Hampton, M., et.al. Management of endometrial precancers, Obstet Gynecol, 2012. 120: p. 1160-75., https://www.ncbi.nlm.nih.gov/pubmed/23090535
324. Kumar, S., Bandyopadhyay, S., Semaan, A., Shah, J. P., Mahdi, H., Morris, R., et.al. The role of frozen section in surgical staging of low risk endometrial cancer, PLoS One, 2011. 6: p. e21912., https://www.ncbi.nlm.nih.gov/pubmed/21912633
325. Vidal, F., Rafii, A., Lymph node assessment in endometrial cancer: towards personalized medicine, Obstet Gynecol Int, 2013. 2013: p. 892465., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804440/
326. Taraboanta, C, Britton, H, Plotkin, A, Azordegan, N, Clement, PB, Gilks, CB, Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma., Int J Gynecol Pathol, 2020. 39 (1)(1): p. 19-25., https://pubmed.ncbi.nlm.nih.gov/31815891/
327. Emons, G, Beckmann, MW, Schmidt, D, Mallmann, P, New WHO Classification of Endometrial Hyperplasias., Geburtshilfe Frauenheilkd, 2015. 75 (2)(2): p. 135-136., https://pubmed.ncbi.nlm.nih.gov/25797956/
328. Singh, S, Best, C, Dunn, S, Leyland, N, Wolfman, WL, Abnormal uterine bleeding in pre-menopausal women., J Obstet Gynaecol Can, 2013. 35 (5)(5): p. 473-475., https://pubmed.ncbi.nlm.nih.gov/23756279/
329. Sakhdari, A, Moghaddam, PA, Liu, Y, Endometrial Samples From Postmenopausal Women: A Proposal for Adequacy Criteria., Int J Gynecol Pathol, 2016. 35 (6)(6): p. 525-530., https://pubmed.ncbi.nlm.nih.gov/26990506/
330. Juhasz-Böss,Ingolf, Ströder,Russalina, Schmidt,Gilda, Solomayer,Erich, Horn,Lars Christian, Herr,Daniel, Diagnostik und Therapie benigner und prämaligner Veränderungen des Endometriums, 2019///. 13(06): p. 511-529.
331. Phillips, V, McCluggage, WG, Results of a questionnaire regarding criteria for adequacy of endometrial biopsies., J Clin Pathol, 2005. 58 (4)(4): p. 417-9., https://pubmed.ncbi.nlm.nih.gov/15790709/
332. Zaino, RJ, FIGO staging of endometrial adenocarcinoma: a critical review and proposal., Int J Gynecol Pathol, 2009. 28 (1)(1): p. 1-9., https://pubmed.ncbi.nlm.nih.gov/19047915/
333. Horn, LC, Trost, M, Bilek, K, Staging of endometrial carcinoma: aspects of ovarian and cervical involvement., Int J Gynecol Pathol, 2010. 29 (1)(1): p. 63-6., https://pubmed.ncbi.nlm.nih.gov/19952935/
334. Movahedi-Lankarani, S., Gilks, C. B., Soslow, R., Oliva, E., Protocol for the Examination of Specimens from Patients with Carcinoma of the Endometrium, 2011.
335. R, o, b, b, o, y, et.al. Cutup – gross description and processing of specimens, in Robboy´s Pathology of the Female Reproductive Tract, Robboy Sj, Mutter G. L. Prat J. Bentley R. C. Russel P. Anderson M. C.2009, Elsevier: Edinburgh, London, New York, Oxford, Philadelphia, St. Louis, Sydney, Toronto.
336. Ahmed, QF, Gattoc, L, Al-Wahab, Z, Abdulfatah, E, Ruterbusch, JJ, Cote, M, et.al. Vanishing endometrial cancer in hysterectomy specimens: a myth or a fact., Am J Surg Pathol, 2015. 39 (2)(2): p. 221-6., https://pubmed.ncbi.nlm.nih.gov/25517962/
337. Kalyanasundaram, K, Ganesan, R, Perunovic, B, McCluggage, WG, Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis., Int J Surg Pathol, 2010. 18 (2)(2): p. 138-43., https://pubmed.ncbi.nlm.nih.gov/PMID:, 19117974/
338. Murray, SK, Young, RH, Scully, RE, Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance., Int J Gynecol Pathol, 2003. 22 (4)(4): p. 324-33., https://pubmed.ncbi.nlm.nih.gov/PMID:, 14501811/
339. Zaino, R., Carinelli, S. G., Ellenson, L. H., Tumours of the uterine Corpus: epithelial Tumours and Precursors, in WHO Classification of Tumours of Female Reproductive Tract, Kurman Rj, Carcangiu M. L. Herrington C. S. Young R. H.2014, IARC Press: Lyon. p. 125-126.
340. Han, G, Lim, D, Leitao, MM, Abu-Rustum, NR, Soslow, RA, Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma., Histopathology, 2014. 64 (3)(3): p. 389-98., https://pubmed.ncbi.nlm.nih.gov/PMID:, 24215212/
341. Jorge, S., Hou, J. Y., Tergas, A. I., Burke, W. M., Huang, Y., Hu, J. C., et.al. Magnitude of risk for nodal metastasis associated with lymphvascular space invasion for endometrial cancer, Gynecol Oncol, 2016. 140: p. 387-93., https://www.ncbi.nlm.nih.gov/pubmed/26768835
342. Wortman, BG, Creutzberg, CL, Putter, H, Jürgenliemk-Schulz, IM, Jobsen, JJ, Lutgens, LCHW, et.al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy., Br J Cancer, 2018. 119 (9)(9): p. 1067-1074., https://pubmed.ncbi.nlm.nih.gov/30356126/
343. Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., et.al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome, Am J Surg Pathol, 2006. 30: p. 230-6., https://www.ncbi.nlm.nih.gov/pubmed/16434898
344. Höhn, AK, Brambs, CE, Erber, R, Hiller, GGR, Mayr, D, Schmidt, D, et.al. [Reporting and handling of lymphonodectomy specimens in gynecologic malignancies and sentinel lymph nodes]., Pathologe, 2021. 42 (3)(3): p. 319-327., https://pubmed.ncbi.nlm.nih.gov/32700061/
345. Krizova, A, Clarke, BA, Bernardini, MQ, James, S, Kalloger, SE, Boerner, SL, et.al. Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review., Am J Surg Pathol, 2011. 35 (1)(1): p. 115-26., https://pubmed.ncbi.nlm.nih.gov/21164295/
346. Delair, D, Soslow, RA, Gardner, GJ, Barakat, RR, Leitao, MM, Tumoral displacement into fallopian tubes in patients undergoing robotically assisted hysterectomy for newly diagnosed endometrial cancer., Int J Gynecol Pathol, 2013. 32 (2)(2): p. 188-92., https://pubmed.ncbi.nlm.nih.gov/23370655/
347. Stewart, CJ, Doherty, DA, Havlat, M, Koay, MH, Leung, YC, Naran, A, et.al. Transtubal spread of endometrial carcinoma: correlation of intra-luminal tumour cells with tumour grade, peritoneal fluid cytology, and extra-uterine metastasis., Pathology, 2013. 45 (4)(4): p. 382-7., https://pubmed.ncbi.nlm.nih.gov/23635815/
348. Singh, R, Cho, KR, Serous Tubal Intraepithelial Carcinoma or Not? Metastases to Fallopian Tube Mucosa Can Masquerade as In Situ Lesions., Arch Pathol Lab Med, 2017. 141 (10)(10): p. 1313-1315., https://pubmed.ncbi.nlm.nih.gov/28968160/
349. Albright, BB, Black, JD, Passarelli, R, Gysler, S, Whicker, M, Altwerger, G, et.al. Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer., Gynecol Oncol Rep, 2018. 23 (): p. 28-33., https://pubmed.ncbi.nlm.nih.gov/29387776/
350. Fedda, FA, Euscher, ED, Ramalingam, P, Malpica, A, Prophylactic Risk-reducing Hysterectomies and Bilateral Salpingo-oophorectomies in Patients With Lynch Syndrome: A Clinicopathologic Study of 29 Cases and Review of the Literature., Int J Gynecol Pathol, 2020. 39 (4)(4): p. 313-320., https://pubmed.ncbi.nlm.nih.gov/31851061/
351. Downes, MR, Allo, G, McCluggage, WG, Sy, K, Ferguson, SE, Aronson, M, et.al. Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing., Histopathology, 2014. 65 (2)(2): p. 228-39., https://pubmed.ncbi.nlm.nih.gov/24495259/
352. Lachiewicz, MP, Kravochuck, SE, O'Malley, MM, Heald, B, Church, JM, Kalady, MF, et.al. Prevalence of occult gynecologic malignancy at the time of risk reducing and nonprophylactic surgery in patients with Lynch syndrome., Gynecol Oncol, 2014. 132 (2)(2): p. 434-7., https://pubmed.ncbi.nlm.nih.gov/24211399/
353. Karamurzin, Y, Soslow, RA, Garg, K, Histologic evaluation of prophylactic hysterectomy and oophorectomy in Lynch syndrome., Am J Surg Pathol, 2013. 37 (4)(4): p. 579-85., https://pubmed.ncbi.nlm.nih.gov/23426126/
354. Lucas, E, Chen, H, Molberg, K, Castrillon, DH, Rivera Colon, G, Li, L, et.al. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?, Int J Gynecol Pathol, 2019. 38 (6)(6): p. 533-542., https://pubmed.ncbi.nlm.nih.gov/30383610/
355. de Leeuw, WJ, Dierssen, J, Vasen, HF, Wijnen, JT, Kenter, GG, Meijers-Heijboer, H, et.al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients., J Pathol, 2000. 192 (3)(3): p. 328-35., https://pubmed.ncbi.nlm.nih.gov/11054716/
356. Nieminen, TT, Gylling, A, Abdel-Rahman, WM, Nuorva, K, Aarnio, M, Renkonen-Sinisalo, L, et.al. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia., Clin Cancer Res, 2009. 15 (18)(18): p. 5772-83., https://pubmed.ncbi.nlm.nih.gov/19723644/
357. Ichikawa, Y, Tsunoda, H, Takano, K, Oki, A, Yoshikawa, H, Microsatellite instability and immunohistochemical analysis of MLH1 and MSH2 in normal endometrium, endometrial hyperplasia and endometrial cancer from a hereditary nonpolyposis colorectal cancer patient., Jpn J Clin Oncol, 2002. 32 (3)(3): p. 110-2., https://pubmed.ncbi.nlm.nih.gov/11956307/
358. Vierkoetter, KR, Kagami, LA, Ahn, HJ, Shimizu, DM, Terada, KY, Loss of Mismatch Repair Protein Expression in Unselected Endometrial Adenocarcinoma Precursor Lesions., Int J Gynecol Cancer, 2016. 26 (2)(2): p. 228-32., https://pubmed.ncbi.nlm.nih.gov/26807560/
359. León-Castillo, A, de Boer, SM, Powell, ME, Mileshkin, LR, Mackay, HJ, Leary, A, et.al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy., J Clin Oncol, 2020. 38 (29)(29): p. 3388-3397., https://pubmed.ncbi.nlm.nih.gov/32749941/
360. Mills, AM, Longacre, TA, Lynch Syndrome Screening in the Gynecologic Tract: Current State of the Art., Am J Surg Pathol, 2016. 40 (4)(4): p. e35-44., https://pubmed.ncbi.nlm.nih.gov/26872009/
361. Cho, KR, Cooper, K, Croce, S, Djordevic, B, Herrington, S, Howitt, B, et.al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S114-S122., https://pubmed.ncbi.nlm.nih.gov/29521846/
362. Eggink, FA, Van Gool, IC, Leary, A, Pollock, PM, Crosbie, EJ, Mileshkin, L, et.al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies , Oncoimmunology 6 (2)(2): p. e1264565., https://pubmed.ncbi.nlm.nih.gov/28344870/
363. Green, A. K., Feinberg, J., Makker, V., A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer, Am Soc Clin Oncol Educ Book, 2020. 40: p. 1-7., https://pubmed.ncbi.nlm.nih.gov/32213091/
364. Reijnen, C, Küsters-Vandevelde, HVN, Prinsen, CF, Massuger, LFAG, Snijders, MPML, Kommoss, S, et.al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer., Gynecol Oncol, 2019. 154 (1)(1): p. 124-130., https://pubmed.ncbi.nlm.nih.gov/31103324/
365. Zakhour, M, Cohen, JG, Gibson, A, Walts, AE, Karimian, B, Baltayan, A, et.al. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series., BJOG, 2017. 124 (10)(10): p. 1576-1583., https://pubmed.ncbi.nlm.nih.gov/28128512/
366. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Kolorektales Karzinom, Version 2.1, Januar 2019, AWMF-Registernummer: 021/007OL, 2019., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Kolorektales_Karzinom/Version_2/LL_KRK_Langversion_2.1.pdf
367. Ryan, NAJ, McMahon, R, Tobi, S, Snowsill, T, Esquibel, S, Wallace, AJ, et.al. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study., PLoS Med, 2020. 17 (9)(9): p. e1003263., https://pubmed.ncbi.nlm.nih.gov/32941469/
368. Stelloo, E, Jansen, AML, Osse, EM, Nout, RA, Creutzberg, CL, Ruano, D, et.al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer., Ann Oncol, 2017. 28 (1)(1): p. 96-102., https://pubmed.ncbi.nlm.nih.gov/27742654/
369. Niu, BT, Hammond, RFL, Leen, SLS, Gilks, CB, Singh, N, Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma., Histopathology, 2019. 75 (3)(3): p. 442-445., https://pubmed.ncbi.nlm.nih.gov/31077605/
370. Josef Rüschoff, Gustavo Baretton, Hendrik Bläker et al., MSI-Testung. Was ist neu? Was ist zu beachten?, Der Pathologe, 2021. 42: p. 414–423.
371. Raffone, A, Travaglino, A, Cerbone, M, Gencarelli, A, Mollo, A, Insabato, L, et.al. Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer., Pathol Oncol Res, 2020. 26 (3)(3): p. 1417-1427., https://pubmed.ncbi.nlm.nih.gov/32377987/
372. Amirkaveh Mojtahed, Iris Schrijver, James M Ford et al., A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas, Modern Pathology, 2011. 24: p. 1004–1014.
373. Sari, A, Pollett, A, Eiriksson, LR, Lumsden-Johanson, B, Van de Laar, E, Kazerouni, H, et.al. Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas., Am J Surg Pathol, 2019. 43 (5)(5): p. 591-600., https://pubmed.ncbi.nlm.nih.gov/30864976/
374. Stinton, C, Fraser, H, Al-Khudairy, L, Court, R, Jordan, M, Grammatopoulos, D, et.al. Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy., Gynecol Oncol, 2021. 160 (1)(1): p. 148-160., https://pubmed.ncbi.nlm.nih.gov/33190932/
375. Timmerman, S, Van Rompuy, AS, Van Gorp, T, Vanden Bempt, I, Brems, H, Van Nieuwenhuysen, E, et.al. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D., Gynecol Oncol, 2020. 157 (1)(1): p. 245-251., https://pubmed.ncbi.nlm.nih.gov/31980219/
376. Bruegl, AS, Kernberg, A, Broaddus, RR, Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer., Adv Anat Pathol, 2017. 24 (6)(6): p. 372-378., https://pubmed.ncbi.nlm.nih.gov/28820751/
377. Engel, KB, Moore, HM, Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue., Arch Pathol Lab Med, 2011. 135 (5)(5): p. 537-43., https://pubmed.ncbi.nlm.nih.gov/21526952/
378. Bass, BP, Engel, KB, Greytak, SR, Moore, HM, A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen?, Arch Pathol Lab Med, 2014. 138 (11)(11): p. 1520-30., https://pubmed.ncbi.nlm.nih.gov/25357115/
379. Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., et.al. Mutational landscape and significance across 12 major cancer types, Nature, 2013. 502: p. 333-9., https://www.ncbi.nlm.nih.gov/pubmed/24132290
380. Stelloo, E, Nout, RA, Osse, EM, Jürgenliemk-Schulz, IJ, Jobsen, JJ, Lutgens, LC, et.al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts., Clin Cancer Res, 2016. 22 (16)(16): p. 4215-24., https://pubmed.ncbi.nlm.nih.gov/27006490/
381. Burleigh, A., Talhouk, A., Gilks, C. B., McAlpine, J. N., Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors, Gynecol Oncol, 2015. 138: p. 141-6., https://www.ncbi.nlm.nih.gov/pubmed/25870916
382. Pilarski, R, None, Cancers (Basel), 2019. 11 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/31216739/
383. de Jonge, MM, Ritterhouse, LL, de Kroon, CD, Vreeswijk, MPG, Segal, JP, Puranik, R, et.al. Germline , Clin Cancer Res, 2019. 25 (24)(24): p. 7517-7526., https://pubmed.ncbi.nlm.nih.gov/31492746/
384. Vietri, MT, D'Elia, G, Caliendo, G, Casamassimi, A, Federico, A, Passariello, L, et.al. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer., Med Oncol, 2021. 38 (2)(2): p. 13., https://pubmed.ncbi.nlm.nih.gov/33484353/
385. Lawrence, J, Richer, L, Arseneau, J, Zeng, X, Chong, G, Weber, E, et.al. Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian Cohort., Curr Oncol, 2021. 28 (1)(1): p. 509-522., https://pubmed.ncbi.nlm.nih.gov/33467402/
386. Kahn, RM, Gordhandas, S, Maddy, BP, Baltich Nelson, B, Askin, G, Christos, PJ, et.al. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?, Cancer, 2019. 125 (18)(18): p. 3172-3183., https://pubmed.ncbi.nlm.nih.gov/31150123/
387. Ferguson, S. E., Aronson, M., Pollett, A., Eiriksson, L. R., Oza, A. M., Gallinger, S., et.al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing, Cancer, 2014. 120: p. 3932-9., https://www.ncbi.nlm.nih.gov/pubmed/25081409
388. Pasanen, A, Loukovaara, M, Bützow, R, Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma., Mod Pathol, 2020. 33 (7)(7): p. 1443-1452., https://pubmed.ncbi.nlm.nih.gov/32060377/
389. Dillon, JL, Gonzalez, JL, DeMars, L, Bloch, KJ, Tafe, LJ, Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome., Hum Pathol, 2017. 70 (): p. 121-128., https://pubmed.ncbi.nlm.nih.gov/29107668/
390. Spinosa, D, Acosta, T, Wong, J, Kurtovic, K, Mewshaw, J, Collins, S, et.al. Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative., Gynecol Oncol, 2021. 160 (1)(1): p. 169-174., https://pubmed.ncbi.nlm.nih.gov/33393478/
391. Weinstein, JN, Collisson, EA, Mills, GB, Shaw, KR, Ozenberger, BA, Ellrott, K, et.al. The Cancer Genome Atlas Pan-Cancer analysis project., Nat Genet, 2013. 45 (10)(10): p. 1113-20., https://pubmed.ncbi.nlm.nih.gov/24071849/
392. Talhouk, A, McConechy, MK, Leung, S, Li-Chang, HH, Kwon, JS, Melnyk, N, et.al. A clinically applicable molecular-based classification for endometrial cancers., Br J Cancer, 2015. 113 (2)(2): p. 299-310., https://pubmed.ncbi.nlm.nih.gov/26172027/
393. Carlson, J, McCluggage, WG, Reclassifying endometrial carcinomas with a combined morphological and molecular approach., Curr Opin Oncol, 2019. 31 (5)(5): p. 411-419., https://pubmed.ncbi.nlm.nih.gov/31261170/
394. DeLair, DF, Burke, KA, Selenica, P, Lim, RS, Scott, SN, Middha, S, et.al. The genetic landscape of endometrial clear cell carcinomas., J Pathol, 2017. 243 (2)(2): p. 230-241., https://pubmed.ncbi.nlm.nih.gov/28718916/
395. Lax, Sigurd F., Pathology of Endometrial Carcinoma, in Molecular Genetics of Endometrial Carcinoma, Hedrick Ellenson, Lora , Editor. 2017, Springer International Publishing: Cham. p. 75-96., https://doi.org/10.1007/978-3-319-43139-0_3
396. Talhouk, A., Hoang, L. N., McConechy, M. K., Nakonechny, Q., Leo, J., Cheng, A., et.al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment, Gynecol Oncol, 2016. 143: p. 46-53., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421949/
397. Kommoss, S, McConechy, MK, Kommoss, F, Leung, S, Bunz, A, Magrill, J, et.al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series., Ann Oncol, 2018. 29 (5)(5): p. 1180-1188., https://pubmed.ncbi.nlm.nih.gov/29432521/
398. Brett, MA, Atenafu, EG, Singh, N, Ghatage, P, Clarke, BA, Nelson, GS, et.al. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma., Int J Gynecol Pathol, 2021. 40 (2)(2): p. 116-123., https://pubmed.ncbi.nlm.nih.gov/32265358/
399. Wortman, B. G., Bosse, T., Nout, R. A., Lutgens, Lchw, van der Steen-Banasik, E. M., Westerveld, H., et.al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial, Gynecol Oncol, 2018. 151(1): p. 69-75.
400. Marnitz, S, Walter, T, Schömig-Markiefka, B, Engler, T, Kommoss, S, Brucker, SY, A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?, Cancers (Basel), 2020. 12 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/32927671/
401. Van Gool, IC, Rayner, E, Osse, EM, Nout, RA, Creutzberg, CL, Tomlinson, IPM, et.al. Adjuvant Treatment for , Clin Cancer Res, 2018. 24 (13)(13): p. 3197-3203., https://pubmed.ncbi.nlm.nih.gov/29559562/
402. Kim, SR, Cloutier, BT, Leung, S, Cochrane, D, Britton, H, Pina, A, et.al. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification., Gynecol Oncol, 2020. 158 (1)(1): p. 3-11., https://pubmed.ncbi.nlm.nih.gov/32331700/
403. Travaglino, A, Raffone, A, Gencarelli, A, Mollo, A, Guida, M, Insabato, L, et.al. TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma., Pathol Oncol Res, 2020. 26 (4)(4): p. 2067-2073., https://pubmed.ncbi.nlm.nih.gov/32472441/
404. Travaglino, A, Raffone, A, Mollo, A, Borrelli, G, Alfano, P, Zannoni, GF, et.al. TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma., Arch Gynecol Obstet, 2020. 301 (5)(5): p. 1117-1125., https://pubmed.ncbi.nlm.nih.gov/32253551/
405. Coll-de la Rubia, E, Martinez-Garcia, E, Dittmar, G, Gil-Moreno, A, Cabrera, S, Colas, E, Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis., J Clin Med, 2020. 9 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/32560580/
406. León-Castillo, A, de Boer, SM, Powell, ME, Mileshkin, LR, Mackay, HJ, Leary, A, et.al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy., J Clin Oncol, 2020. 38 (29)(29): p. 3388-3397., https://pubmed.ncbi.nlm.nih.gov/32749941/
407. Wortman, BG, Creutzberg, CL, Putter, H, Jürgenliemk-Schulz, IM, Jobsen, JJ, Lutgens, LCHW, et.al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy., Br J Cancer, 2018. 119 (9)(9): p. 1067-1074., https://pubmed.ncbi.nlm.nih.gov/30356126/
408. Bosse, T, Nout, RA, McAlpine, JN, McConechy, MK, Britton, H, Hussein, YR, et.al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups., Am J Surg Pathol, 2018. 42 (5)(5): p. 561-568., https://pubmed.ncbi.nlm.nih.gov/29505428/
409. Van Gool, IC, Ubachs, JEH, Stelloo, E, de Kroon, CD, Goeman, JJ, Smit, VTHBM, et.al. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing., Histopathology, 2018. 72 (2)(2): p. 248-258., https://pubmed.ncbi.nlm.nih.gov/28795426/
410. Devereaux, K., Steiner, D., Ho, C., A multiplex ANaPshot assay is a rapid and cost-effective method for detecting POLE mutations in endometrial carcinoma, Mod Pathol, 2020. 33 (Suppl2): p. 1040.
411. Köbel, M, Kang, EY, The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting., Int J Gynecol Pathol, 2021. 40 (1)(1): p. 32-40., https://pubmed.ncbi.nlm.nih.gov/33290354/
412. Singh, N, Piskorz, AM, Bosse, T, Jimenez-Linan, M, Rous, B, Brenton, JD, et.al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies., J Pathol, 2020. 250 (3)(3): p. 336-345., https://pubmed.ncbi.nlm.nih.gov/31829441/
413. Tashiro, K, Nakano, T, Honjo, T, Signal sequence trap. Expression cloning method for secreted proteins and type 1 membrane proteins., Methods Mol Biol, 1997. 69 (): p. 203-19., https://pubmed.ncbi.nlm.nih.gov/9116854/
414. Köbel, M, Ronnett, BM, Singh, N, Soslow, RA, Gilks, CB, McCluggage, WG, Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility., Int J Gynecol Pathol, 2019. 38 Suppl 1 (): p. S123-S131., https://pubmed.ncbi.nlm.nih.gov/29517499/
415. Nastic, D, Shanwell, E, Wallin, KL, Valla, M, Måsbäck, A, Mateoiu, C, et.al. A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis., Int J Gynecol Pathol, 2017. 36 (4)(4): p. 339-347., https://pubmed.ncbi.nlm.nih.gov/28244894/
416. Singh, N, Piskorz, AM, Bosse, T, Jimenez-Linan, M, Rous, B, Brenton, JD, et.al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies., J Pathol, 2020. 250 (3)(3): p. 336-345., https://pubmed.ncbi.nlm.nih.gov/31829441/
417. van Esterik, M, Van Gool, IC, de Kroon, CD, Nout, RA, Creutzberg, CL, Smit, VTHBM, et.al. Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer., Oncotarget, 2017. 8 (15)(15): p. 25542-25551., https://pubmed.ncbi.nlm.nih.gov/28424422/
418. Moroney, MR, Davies, KD, Wilberger, AC, Sheeder, J, Post, MD, Berning, AA, et.al. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers., Gynecol Oncol, 2019. 153 (3)(3): p. 517-520., https://pubmed.ncbi.nlm.nih.gov/30910249/
419. Costigan, DC, Dong, F, Nucci, MR, Howitt, BE, Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma., Int J Gynecol Pathol, 2020. 39 (2)(2): p. 119-127., https://pubmed.ncbi.nlm.nih.gov/30702464/
420. van den Heerik, ASVM, Horeweg, N, Nout, RA, Lutgens, LCHW, van der Steen-Banasik, EM, Westerveld, GH, et.al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer., Int J Gynecol Cancer, 2020. 30 (12)(12): p. 2002-2007., https://pubmed.ncbi.nlm.nih.gov/33046573/
421. De Leo, A, de Biase, D, Lenzi, J, Barbero, G, Turchetti, D, Grillini, M, et.al. None, Cancers (Basel), 2021. 13 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/33668727/
422. Kommoss, FK, Karnezis, AN, Kommoss, F, Talhouk, A, Taran, FA, Staebler, A, et.al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile., Br J Cancer, 2018. 119 (4)(4): p. 480-486., https://pubmed.ncbi.nlm.nih.gov/30050154/
423. Kandoth, C, Schultz, N, Cherniack, AD, Akbani, R, Liu, Y, Shen, H, et.al. Integrated genomic characterization of endometrial carcinoma., Nature, 2013. 497 (7447)(7447): p. 67-73., https://pubmed.ncbi.nlm.nih.gov/23636398/
424. Stelloo, E, Nout, RA, Naves, LC, Ter Haar, NT, Creutzberg, CL, Smit, VT, et.al. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma., Gynecol Oncol, 2014. 133 (2)(2): p. 197-204., https://pubmed.ncbi.nlm.nih.gov/24556061/
425. Fumet, JD, Limagne, E, Thibaudin, M, Truntzer, C, Bertaut, A, Rederstorff, E, et.al. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment., BMC Cancer, 2020. 20 (1)(1): p. 748., https://pubmed.ncbi.nlm.nih.gov/32778095/
426. Sloan, EA, Ring, KL, Willis, BC, Modesitt, SC, Mills, AM, PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors., Am J Surg Pathol, 2017. 41 (3)(3): p. 326-333., https://pubmed.ncbi.nlm.nih.gov/27984238/
427. Kir, G, Olgun, ZC, Soylemez, T, Aydin, A, Demircan, B, Kaya, IA, et.al. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups., Int J Gynecol Pathol, 2020. Publish Ahead of Print ():, https://pubmed.ncbi.nlm.nih.gov/33332859/
428. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR), 2015., https://www.ncbi.nlm.nih.gov/pubmed/26089092
429. Skala, S. L., Hagemann, I. S., Optimal sampling of grossly normal omentum in staging of gynecologic malignancies, Int J Gynecol Pathol, 2015. 34: p. 281-7., https://www.ncbi.nlm.nih.gov/pubmed/25760907
430. Gilks, C. B., Movahedi-Lankarani, S., Baker, P. M., Otis, C. N., Protocol for the Examination of Specimens From Patients With Primary Tumors of the Ovary or Fallopian Tube, 2016.
431. McCluggage, WG, Judge, MJ, Clarke, BA, Davidson, B, Gilks, CB, Hollema, H, et.al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)., Mod Pathol, 2015. 28 (8)(8): p. 1101-22., https://pubmed.ncbi.nlm.nih.gov/26089092/
432. Ulker, V, Tunca, A, Numanoglu, C, Akbayir, O, Akyol, A, Erim, A, et.al. Should omentectomy be a part of surgical staging in patients with endometrioid adenocarcinoma of the uterine corpus?, Gynecol Obstet Invest, 2014. 77 (1)(1): p. 58-63., https://pubmed.ncbi.nlm.nih.gov/24356379/
433. Sakai, K., Yamagami, W., Susumu, N., Nomura, H., Kataoka, F., Banno, K., et.al. Pathological factors associated with omental metastases in endometrial cancer, Eur J Gynaecol Oncol, 2015. 36: p. 397-401., https://www.ncbi.nlm.nih.gov/pubmed/26390690
434. Horn, LC, Beckmann, MW, Follmann, M, Koch, MC, Mallmann, P, Marnitz, S, et.al. [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology]., Pathologe, 2015. 36 (6)(6): p. 585-93., https://pubmed.ncbi.nlm.nih.gov/26483249/
435. Multinu, F, Casarin, J, Cappuccio, S, Keeney, GL, Glaser, GE, Cliby, WA, et.al. Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer., Gynecol Oncol, 2019. 154 (1)(1): p. 60-64., https://pubmed.ncbi.nlm.nih.gov/31126637/
436. Ignatov, A, Lebius, C, Ignatov, T, Ivros, S, Knueppel, R, Papathemelis, T, et.al. Lymph node micrometastases and outcome of endometrial cancer., Gynecol Oncol, 2019. 154 (3)(3): p. 475-479., https://pubmed.ncbi.nlm.nih.gov/31345606/
437. Plante, M, Stanleigh, J, Renaud, MC, Sebastianelli, A, Grondin, K, Grégoire, J, Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?, Gynecol Oncol, 2017. 146 (2)(2): p. 240-246., https://pubmed.ncbi.nlm.nih.gov/28577885/
438. García Pineda, V, Hernández Gutiérrez, A, Gracia Segovia, M, Siegrist Ridruejo, J, Diestro Tejeda, MD, Zapardiel, I, Low-Volume Nodal Metastasis in Endometrial Cancer: Risk Factors and Prognostic Significance., J Clin Med, 2020. 9 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/32630498/
439. Rossi, EC, Kowalski, LD, Scalici, J, Cantrell, L, Schuler, K, Hanna, RK, et.al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study., Lancet Oncol, 2017. 18 (3)(3): p. 384-392., https://pubmed.ncbi.nlm.nih.gov/28159465/
440. Bogani, G, Murgia, F, Ditto, A, Raspagliesi, F, Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis., Gynecol Oncol, 2019. 153 (3)(3): p. 676-683., https://pubmed.ncbi.nlm.nih.gov/30952370/
441. Zanfagnin, V, Huang, Y, Mc Gree, ME, Weaver, AL, Casarin, J, Multinu, F, et.al. Predictors of extensive lymphatic dissemination and recurrences in node-positive endometrial cancer., Gynecol Oncol, 2019. 154 (3)(3): p. 480-486., https://pubmed.ncbi.nlm.nih.gov/31324453/
442. McCluggage, W. G., Colgan, T., Duggan, M., Hacker, N. F., Mulvany, N., Otis, C., et.al. Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia, Int J Gynecol Pathol, 2012. 32: p. 45-65., https://www.ncbi.nlm.nih.gov/pubmed/23202790
443. Euscher, ED, Malpica, A, Gynaecological malignancies and sentinel lymph node mapping: an update., Histopathology, 2020. 76 (1)(1): p. 139-150., https://pubmed.ncbi.nlm.nih.gov/31846525/
444. Abu-Rustum, NR, Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging., J Natl Compr Canc Netw, 2014. 12 (2)(2): p. 288-97., https://pubmed.ncbi.nlm.nih.gov/24586087/
445. Euscher, E, Sui, D, Soliman, P, Westin, S, Ramalingam, P, Bassett, R, et.al. Ultrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods., Int J Gynecol Pathol, 2018. 37 (3)(3): p. 242-251., https://pubmed.ncbi.nlm.nih.gov/28700425/
446. Burg, LC, Hengeveld, EM, In 't Hout, J, Bulten, J, Bult, P, Zusterzeel, PLM, Ultrastaging methods of sentinel lymph nodes in endometrial cancer - a systematic review., Int J Gynecol Cancer, 2021. 31 (5)(5): p. 744-753., https://pubmed.ncbi.nlm.nih.gov/33187974/
447. Holloway, RW, Abu-Rustum, NR, Backes, FJ, Boggess, JF, Gotlieb, WH, Jeffrey Lowery, W, et.al. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations., Gynecol Oncol, 2017. 146 (2)(2): p. 405-415., https://pubmed.ncbi.nlm.nih.gov/28566221/
448. Tu, H, Gu, HF, Huang, H, Liu, KJ, Yun, JP, Chen, JP, et.al. Sectioning protocol determines accuracy of intraoperative pathological examination of sentinel lymph node in cervical cancer: A systematic review and meta-analysis., Gynecol Oncol, 2020. 158 (2)(2): p. 489-497., https://pubmed.ncbi.nlm.nih.gov/32507651/
449. Abu-Rustum, NR, Yashar, CM, Bradley, K, Campos, SM, Chino, J, Chon, HS, et.al. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021., J Natl Compr Canc Netw, 2021. 19 (8)(8): p. 888-895., https://pubmed.ncbi.nlm.nih.gov/34416706/
450. Pacaut, C, Bourmaud, A, Rivoirard, R, Moriceau, G, Guy, JB, Collard, O, et.al. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy., Am J Clin Oncol, 2015. 38 (3)(3): p. 272-7., https://pubmed.ncbi.nlm.nih.gov/23751320/
451. Oz, M, Korkmaz, V, Meydanli, MM, Sari, ME, Cuylan, ZF, Gungor, T, Is Tumor Size Really Important for Prediction of Lymphatic Dissemination in Grade 1 Endometrial Carcinoma With Superficial Myometrial Invasion?, Int J Gynecol Cancer, 2017. 27 (7)(7): p. 1393-1398., https://pubmed.ncbi.nlm.nih.gov/28604451/
452. Tejerizo-Garcia, A., Jimenez-Lopez, J. S., Munoz-Gonzalez, J. L., Bartolome-Sotillos, S., Marqueta-Marques, L., Lopez-Gonzalez, G., et.al. Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients, Onco Targets Ther, 2013. 9: p. 1305-13., https://www.ncbi.nlm.nih.gov/pubmed/24092993
453. Morice, P, Leary, A, Creutzberg, C, Abu-Rustum, N, Darai, E, Endometrial cancer., Lancet, 2016. 387 (10023)(10023): p. 1094-1108., https://pubmed.ncbi.nlm.nih.gov/26354523/
454. Kihara, A, Yoshida, H, Watanabe, R, Takahashi, K, Kato, T, Ino, Y, et.al. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma., Am J Surg Pathol, 2017. 41 (7)(7): p. 896-905., https://pubmed.ncbi.nlm.nih.gov/28418994/
455. Joehlin-Price, AS, McHugh, KE, Stephens, JA, Li, Z, Backes, FJ, Cohn, DE, et.al. The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas., Am J Surg Pathol, 2017. 41 (1)(1): p. 49-55., https://pubmed.ncbi.nlm.nih.gov/27740968/
456. Rau, TT, Bettschen, E, Büchi, C, Christe, L, Rohner, A, Müller, MD, et.al. Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups., Mod Pathol, 2021. 34 (1)(1): p. 222-232., https://pubmed.ncbi.nlm.nih.gov/32728223/
457. Steiner, E., Einenkel, J., Schmidt, D., Horn, L. C., Prädiktive und prognostische Marker beim Endometriumkarzinom, Der Onkologe, 2012., https://www.researchgate.net/publication/257455370_Pradiktive_und_prognostische_Marker_beim_Endometriumkarzinom
458. Zhang, Y, Zhao, D, Gong, C, Zhang, F, He, J, Zhang, W, et.al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis., World J Surg Oncol, 2015. 13 (): p. 208., https://pubmed.ncbi.nlm.nih.gov/26108802/
459. Creutzberg, C. L., van Stiphout, R. G., Nout, R. A., Lutgens, L. C., Jurgenliemk-Schulz, I. M., Jobsen, J. J., et.al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials, Int J Radiat Oncol Biol Phys, 2015. 91: p. 530-9., https://www.ncbi.nlm.nih.gov/pubmed/25680597
460. Miller, MD, Salinas, EA, Newtson, AM, Sharma, D, Keeney, ME, Warrier, A, et.al. An integrated prediction model of recurrence in endometrial endometrioid cancers., Cancer Manag Res, 2019. 11 (): p. 5301-5315., https://pubmed.ncbi.nlm.nih.gov/31239780/
461. Salinas, EA, Miller, MD, Newtson, AM, Sharma, D, McDonald, ME, Keeney, ME, et.al. A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables., Int J Mol Sci, 2019. 20 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/30857319/
462. Travaglino, A, Raffone, A, Saccone, G, D'Alessandro, P, Arduino, B, de Placido, G, et.al. Significant risk of occult cancer in complex non-atypical endometrial hyperplasia., Arch Gynecol Obstet, 2019. 300 (5)(5): p. 1147-1154., https://pubmed.ncbi.nlm.nih.gov/31531779/
463. Antonsen, S. L., Ulrich, L., Hogdall, C., Patients with atypical hyperplasia of the endometrium should be treated in oncological centers, Gynecol Oncol, 2011. 125: p. 124-8., https://www.ncbi.nlm.nih.gov/pubmed/22198048
464. Chan, J. K., Wu, H., Cheung, M. K., Shin, J. Y., Osann, K., Kapp, D. S., The outcomes of 27,063 women with unstaged endometrioid uterine cancer, Gynecol Oncol, 2007. 106: p. 282-8., https://www.ncbi.nlm.nih.gov/pubmed/17662377
465. Trimble, C. L., Method, M., Leitao, M., Lu, K., Ioffe, O., Hampton, M., et.al. Management of endometrial precancers, Obstet Gynecol, 2012. 120: p. 1160-75., https://www.ncbi.nlm.nih.gov/pubmed/23090535
466. S3-Leitlinie Indikation und Methodik der Hysterektomie bei benignen Erkrankungen, Langversion 1.2, 2015., https://www.awmf.org/leitlinien/detail/ll/015-070.html
467. Polcher, M., Hauptmann, S., Fotopoulou, C., Schmalfeldt, B., Meinhold-Heerlein, I., Mustea, A., et.al. Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO, Arch Gynecol Obstet, 2015. 292: p. 231-4., https://www.ncbi.nlm.nih.gov/pubmed/25914073
468. Sun, C., Chen, G., Yang, Z., Jiang, J., Yang, X., Li, N., et.al. Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis, Fertil Steril, 2013. 100: p. 782-7., https://www.ncbi.nlm.nih.gov/pubmed/23830105
469. Gu, Y., Zhou, X., Zhang, S. L., Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk, Genet Mol Res, 2011. 10: p. 3609-19.
470. Baker, J., Obermair, A., Gebski, V., Janda, M., Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature, Gynecol Oncol, 2012. 125: p. 263-70., https://www.ncbi.nlm.nih.gov/pubmed/22196499
471. Koskas, M., Uzan, J., Luton, D., Rouzier, R., Darai, E., Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis, Fertil Steril, 2014. 101: p. 785-94., https://www.ncbi.nlm.nih.gov/pubmed/24388202
472. Gallos, I. D., Yap, J., Rajkhowa, M., Luesley, D. M., Coomarasamy, A., Gupta, J. K., Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis, Am J Obstet Gynecol, 2012. 207: p. 266.e1-12., https://www.ncbi.nlm.nih.gov/pubmed/23021687
473. Gunderson, C. C., Fader, A. N., Carson, K. A., Bristow, R. E., Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review, Gynecol Oncol, 2012. 125: p. 477-82., https://www.ncbi.nlm.nih.gov/pubmed/22245711
474. Luo, L., Luo, B., Zheng, Y., Zhang, H., Li, J., Sidell, N., Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia, Cochrane Database Syst Rev, 2013. 6: p. CD009458., https://www.ncbi.nlm.nih.gov/pubmed/23737032
475. Luo, L., Luo, B., Zheng, Y., Zhang, H., Li, J., Sidell, N., Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia, Cochrane Database Syst Rev, 2013. 6: p. CD009458., https://www.ncbi.nlm.nih.gov/pubmed/23737032
476. Gunderson, C. C., Fader, A. N., Carson, K. A., Bristow, R. E., Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review, Gynecol Oncol, 2012. 125: p. 477-82., https://www.ncbi.nlm.nih.gov/pubmed/22245711
477. Gallos, I. D., Yap, J., Rajkhowa, M., Luesley, D. M., Coomarasamy, A., Gupta, J. K., Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis, Am J Obstet Gynecol, 2012. 207: p. 266.e1-12., https://www.ncbi.nlm.nih.gov/pubmed/23021687
478. Baker, J., Obermair, A., Gebski, V., Janda, M., Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature, Gynecol Oncol, 2012. 125: p. 263-70., https://www.ncbi.nlm.nih.gov/pubmed/22196499
479. Koskas, M., Uzan, J., Luton, D., Rouzier, R., Darai, E., Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis, Fertil Steril, 2014. 101: p. 785-94., https://www.ncbi.nlm.nih.gov/pubmed/24388202
480. Mandelbaum, RS, Ciccone, MA, Nusbaum, DJ, Khoshchehreh, M, Purswani, H, Morocco, EB, et.al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy., Am J Obstet Gynecol, 2020. 223 (1)(1): p. 103.e1-103.e13., https://pubmed.ncbi.nlm.nih.gov/31978437/
481. Clement, NS, Oliver, TR, Shiwani, H, Sanner, JR, Mulvaney, CA, Atiomo, W, Metformin for endometrial hyperplasia., Cochrane Database Syst Rev, 2017. 10 (): p. CD012214., https://pubmed.ncbi.nlm.nih.gov/29077194/
482. Tehranian, A, Ghahghaei-Nezamabadi, A, Arab, M, Khalagi, K, Aghajani, R, Sadeghi, S, The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial., J Gynecol Obstet Hum Reprod, 2021. 50 (6)(6): p. 101863., https://pubmed.ncbi.nlm.nih.gov/32652300/
483. Matsuo, K, Mandelbaum, RS, Ciccone, M, Khoshchehreh, M, Pursuwani, H, Morocco, EB, et.al. Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia., Int J Gynecol Cancer, 2020. 30 (9)(9): p. 1331-1339., https://pubmed.ncbi.nlm.nih.gov/32376736/
484. Yang, BY, Gulinazi, Y, Du, Y, Ning, CC, Cheng, YL, Shan, WW, et.al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial., BJOG, 2020. 127 (7)(7): p. 848-857., https://pubmed.ncbi.nlm.nih.gov/31961463/
485. Chan, J. K., Wu, H., Cheung, M. K., Shin, J. Y., Osann, K., Kapp, D. S., The outcomes of 27,063 women with unstaged endometrioid uterine cancer, Gynecol Oncol, 2007. 106: p. 282-8., https://www.ncbi.nlm.nih.gov/pubmed/17662377
486. Walsh, C., Holschneider, C., Hoang, Y., Tieu, K., Karlan, B., Cass, I., Coexisting ovarian malignancy in young women with endometrial cancer, Obstet Gynecol, 2005. 106: p. 693-9., https://www.ncbi.nlm.nih.gov/pubmed/16199623
487. Williams, M. G., Bandera, E. V., Demissie, K., Rodriguez-Rodriguez, L., Synchronous primary ovarian and endometrial cancers: a population-based assessment of survival, Obstet Gynecol, 2009. 113: p. 783-9., https://www.ncbi.nlm.nih.gov/pubmed/19305320
488. Oranratanaphan, S., Manchana, T., Sirisabya, N., Clinicopathologic variables and survival comparison of patients with synchronous endometrial and ovarian cancers versus primary endometrial cancer with ovarian metastasis, Asian Pac J Cancer Prev, 2008. 9: p. 403-7., https://www.ncbi.nlm.nih.gov/pubmed/18990010
489. Akbayir, O., Kuru, O., Goksedef, P., Numanoglu, C., Corbacioglu, A., Cetin, A., Coexisting ovarian malignancy in patients with clinical stage I endometrial carcinoma, Arch Gynecol Obstet, 2012. 286: p. 1241-5., https://www.ncbi.nlm.nih.gov/pubmed/22688443
490. Duska, L. R., Garrett, A., Rueda, B. R., Haas, J., Chang, Y., Fuller, A. F., Endometrial cancer in women 40 years old or younger, Gynecol Oncol, 2001. 83: p. 388-93., https://www.ncbi.nlm.nih.gov/pubmed/11606102
491. Dogan, A., Schultheis, B., Rezniczek, G. A., Hilal, Z., Cetin, C., Hausler, G., et.al. Synchronous Endometrial and Ovarian Cancer in Young Women: Case Report and Review of the Literature, Anticancer Res, 2017. 37: p. 969-978., https://www.ncbi.nlm.nih.gov/pubmed/28314254
492. Anglesio, M. S., Wang, Y. K., Maassen, M., Horlings, H. M., Bashashati, A., Senz, J., et.al. Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality, J Natl Cancer Inst, 2016. 108: p. djv428., https://www.ncbi.nlm.nih.gov/pubmed/26832771
493. Goyal, A., Masand, R. P., Roma, A. A., Value of PAX-8 and SF-1 Immunohistochemistry in the Distinction Between Female Adnexal Tumor of Probable Wolffian Origin and its Mimics, Int J Gynecol Pathol, 2015. 35: p. 167-75., https://www.ncbi.nlm.nih.gov/pubmed/26352548
494. Batte, B. A., Bruegl, A. S., Daniels, M. S., Ring, K. L., Dempsey, K. M., Djordjevic, B., et.al. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome, Gynecol Oncol, 2014. 134: p. 319-25., https://www.ncbi.nlm.nih.gov/pubmed/24933100
495. Ruiz, MP, Huang, Y, Hou, JY, Tergas, AI, Burke, WM, Ananth, CV, et.al. All-cause mortality in young women with endometrial cancer receiving progesterone therapy., Am J Obstet Gynecol, 2017. 217 (6)(6): p. 669.e1-669.e13., https://pubmed.ncbi.nlm.nih.gov/28844824/
496. Gonthier, C, Trefoux-Bourdet, A, Koskas, M, Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium., Int J Gynecol Cancer, 2017. 27 (3)(3): p. 493-499., https://pubmed.ncbi.nlm.nih.gov/28187090/
497. Greenwald, ZR, Huang, LN, Wissing, MD, Franco, EL, Gotlieb, WH, Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?, Cancer, 2017. 123 (9)(9): p. 1545-1554., https://pubmed.ncbi.nlm.nih.gov/28026855/
498. Guillon, S, Popescu, N, Phelippeau, J, Koskas, M, A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma., Int J Gynaecol Obstet, 2019. 146 (3)(3): p. 277-288., https://pubmed.ncbi.nlm.nih.gov/31197826/
499. Raffone, A, Travaglino, A, Saccone, G, Insabato, L, Mollo, A, De Placido, G, et.al. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis., Arch Gynecol Obstet, 2019. 299 (5)(5): p. 1233-1242., https://pubmed.ncbi.nlm.nih.gov/30810881/
500. Thigpen, J. T., Brady, M. F., Alvarez, R. D., Adelson, M. D., Homesley, H. D., Manetta, A., et.al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group, J Clin Oncol, 1999. 17: p. 1736-44., https://www.ncbi.nlm.nih.gov/pubmed/10561210
501. Lentz, S. S., Brady, M. F., Major, F. J., Reid, G. C., Soper, J. T., High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study, J Clin Oncol, 1996. 14: p. 357-61., https://www.ncbi.nlm.nih.gov/pubmed/8636744
502. Liu, T, Tu, H, Li, Y, Liu, Z, Liu, G, Gu, H, Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis., Ann Surg Oncol, 2019. 26 (9)(9): p. 2933-2942., https://pubmed.ncbi.nlm.nih.gov/31147990/
503. Cohn, D. E., Woeste, E. M., Cacchio, S., Zanagnolo, V. L., Havrilesky, L. J., Mariani, A., et.al. Clinical and pathologic correlates in surgical stage II endometrial carcinoma, Obstet Gynecol, 2007. 109: p. 1062-7., https://www.ncbi.nlm.nih.gov/pubmed/17470583
504. Tamussino, K. F., Reich, O., Gucer, F., Moser, F., Zivkovic, F., Lang, P. F., et.al. Parametrial spread in patients with endometrial carcinoma undergoing radical hysterectomy, Int J Gynecol Cancer, 2001. 10: p. 313-317., https://www.ncbi.nlm.nih.gov/pubmed/11240692
505. Frost, J. A., Webster, K. E., Bryant, A., Morrison, J., Lymphadenectomy for the management of endometrial cancer, Cochrane Database Syst Rev, 2017. 10(10): p. Cd007585.
506. Sueoka, K., Umayahara, K., Abe, A., Usami, T., Yamamoto, A., Nomura, H., et.al. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy, Int J Gynecol Cancer, 2014. 25: p. 81-6., https://www.ncbi.nlm.nih.gov/pubmed/25347094
507. Sirisabya, N., Manchana, T., Worasethsin, P., Khemapech, N., Lertkhachonsuk, R., Sittisomwong, T., et.al. Is complete surgical staging necessary in clinically early-stage endometrial carcinoma?, Int J Gynecol Cancer, 2009. 19: p. 1057-61., https://www.ncbi.nlm.nih.gov/pubmed/19820368
508. Garg, G., Morris, R. T., Solomon, L., Toy, E. P., Kruger, M., Clary, K., et.al. Evaluating the significance of location of lymph node metastasis and extranodal disease in women with stage IIIC endometrial cancer, Gynecol Oncol, 2011. 123: p. 208-13., https://www.ncbi.nlm.nih.gov/pubmed/21821278
509. Kapp, D. S., Kiet, T. K., Chan, J. K., Prognostic discrimination of subgrouping node-positive endometrioid uterine cancer: location vs nodal extent, Br J Cancer, 2011. 105: p. 1137-43., https://www.ncbi.nlm.nih.gov/pubmed/21915131
510. Creasman, W. T., Morrow, C. P., Bundy, B. N., Homesley, H. D., Graham, J. E., Heller, P. B., Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study, Cancer, 1987. 60: p. 2035-41., https://www.ncbi.nlm.nih.gov/pubmed/3652025
511. Frost, J. A., Webster, K. E., Bryant, A., Morrison, J., Lymphadenectomy for the management of endometrial cancer, Cochrane Database Syst Rev, 2017. 10(10): p. Cd007585.
512. Kitchener, H., Swart, A. M., Qian, Q., Amos, C., Parmar, M. K., Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study, Lancet, 2008. 373: p. 125-36., https://www.ncbi.nlm.nih.gov/pubmed/19070889
513. Benedetti Panici, P., Basile, S., Maneschi, F., Alberto Lissoni, A., Signorelli, M., Scambia, G., et.al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial, J Natl Cancer Inst, 2008. 100: p. 1707-16., https://www.ncbi.nlm.nih.gov/pubmed/19033573
514. Frost, J. A., Webster, K. E., Bryant, A., Morrison, J., Lymphadenectomy for the management of endometrial cancer, Cochrane Database Syst Rev, 2015. 2015(9): p. Cd007585.
515. Eltabbakh, G. H., Piver, M. S., Hempling, R. E., Shin, K. H., Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial, Int J Radiat Oncol Biol Phys, 1997. 38: p. 373-80., https://www.ncbi.nlm.nih.gov/pubmed/9226326
516. Mariani, A., Webb, M. J., Keeney, G. L., Haddock, M. G., Calori, G., Podratz, K. C., Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?, Am J Obstet Gynecol, 2000. 182: p. 1506-19., https://www.ncbi.nlm.nih.gov/pubmed/10871473
517. Dowdy, S. C., Borah, B. J., Bakkum-Gamez, J. N., Weaver, A. L., McGree, M. E., Haas, L. R., et.al. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer, Gynecol Oncol, 2012. 127: p. 5-10., https://www.ncbi.nlm.nih.gov/pubmed/22771890
518. Bendifallah, S., Koskas, M., Ballester, M., Genin, A. S., Darai, E., Rouzier, R., The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis, Am J Obstet Gynecol, 2012. 206: p. 500.e1-11., https://www.ncbi.nlm.nih.gov/pubmed/22546083
519. Mariani, A., Dowdy, S. C., Cliby, W. A., Gostout, B. S., Jones, M. B., Wilson, T. O., et.al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging, Gynecol Oncol, 2008. 109: p. 11-8., https://www.ncbi.nlm.nih.gov/pubmed/18304622
520. Johnson, N., Bryant, A., Miles, T., Hogberg, T., Cornes, P., Adjuvant chemotherapy for endometrial cancer after hysterectomy, Cochrane Database Syst Rev, 2011. p. Cd003175., https://www.ncbi.nlm.nih.gov/pubmed/21975736
521. Kim, H. S., Suh, D. H., Kim, M. K., Chung, H. H., Park, N. H., Song, Y. S., Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis, Jpn J Clin Oncol, 2012. 42: p. 405-12., https://www.ncbi.nlm.nih.gov/pubmed/22396619
522. Smith, D. C., Macdonald, O. K., Lee, C. M., Gaffney, D. K., Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis, Int J Gynecol Cancer, 2007. 18: p. 255-61., https://www.ncbi.nlm.nih.gov/pubmed/17624991
523. Schlappe, BA, Weaver, AL, McGree, ME, Ducie, J, Zahl Eriksson, AG, Dowdy, SC, et.al. Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma., Gynecol Oncol, 2020. 156 (1)(1): p. 62-69., https://pubmed.ncbi.nlm.nih.gov/31776037/
524. Kogan, L, Matanes, E, Wissing, M, Mitric, C, How, J, Amajoud, Z, et.al. The added value of sentinel node mapping in endometrial cancer., Gynecol Oncol, 2020. 158 (1)(1): p. 84-91., https://pubmed.ncbi.nlm.nih.gov/32349874/
525. Cusimano, MC, Vicus, D, Pulman, K, Maganti, M, Bernardini, MQ, Bouchard-Fortier, G, et.al. Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging., JAMA Surg, 2021. 156 (2)(2): p. 157-164., https://pubmed.ncbi.nlm.nih.gov/33175109/
526. Body, N, Grégoire, J, Renaud, MC, Sebastianelli, A, Grondin, K, Plante, M, Tips and tricks to improve sentinel lymph node mapping with Indocyanin green in endometrial cancer., Gynecol Oncol, 2018. 150 (2)(2): p. 267-273., https://pubmed.ncbi.nlm.nih.gov/29909967/
527. Lambrou, N. C., Gomez-Marin, O., Mirhashemi, R., Beach, H., Salom, E., Almeida-Parra, Z., et.al. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival, Gynecol Oncol, 2004. 93: p. 653-8., https://www.ncbi.nlm.nih.gov/pubmed/15196860
528. Shih, K. K., Yun, E., Gardner, G. J., Barakat, R. R., Chi, D. S., Leitao, M. M., Jr., Surgical cytoreduction in stage IV endometrioid endometrial carcinoma, Gynecol Oncol, 2011. 122: p. 608-11., https://www.ncbi.nlm.nih.gov/pubmed/21664663
529. Nemani, D., Mitra, N., Guo, M., Lin, L., Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis, Gynecol Oncol, 2008. 111: p. 82-8., https://www.ncbi.nlm.nih.gov/pubmed/18674808
530. Versluis, MAC, Pielsticker, C, van der Aa, MA, de Bruyn, M, Hollema, H, Nijman, HW, Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study., Oncology, 2018. 95 (2)(2): p. 100-108., https://pubmed.ncbi.nlm.nih.gov/29791913/
531. Bogani, G, Casarin, J, Leone Roberti Maggiore, U, Ditto, A, Pinelli, C, Dell'acqua, A, et.al. Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone: Long-term results of a propensity-matched analysis., Gynecol Oncol, 2020. 158 (1)(1): p. 77-83., https://pubmed.ncbi.nlm.nih.gov/32389376/
532. Setiawan, V. W., Yang, H. P., Pike, M. C., McCann, S. E., Yu, H., Xiang, Y. B., et.al. Type I and II endometrial cancers: have they different risk factors?, J Clin Oncol, 2013. 31: p. 2607-18., https://www.ncbi.nlm.nih.gov/pubmed/23733771
533. Todo, Y., Kato, H., Kaneuchi, M., Watari, H., Takeda, M., Sakuragi, N., Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis, Lancet, 2010. 375: p. 1165-72., https://www.ncbi.nlm.nih.gov/pubmed/20188410
534. Bodurtha Smith, AJ, Fader, AN, Tanner, EJ, Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis., Am J Obstet Gynecol, 2017. 216 (5)(5): p. 459-476.e10., https://pubmed.ncbi.nlm.nih.gov/27871836/
535. Guo, W, Cai, J, Li, M, Wang, H, Shen, Y, Survival benefits of pelvic lymphadenectomy versus pelvic and para-aortic lymphadenectomy in patients with endometrial cancer: A meta-analysis., Medicine (Baltimore), 2018. 97 (1)(1): p. e9520., https://pubmed.ncbi.nlm.nih.gov/29505525/
536. Odagiri, T., Watari, H., Kato, T., Mitamura, T., Hosaka, M., Sudo, S., et.al. Distribution of lymph node metastasis sites in endometrial cancer undergoing systematic pelvic and para-aortic lymphadenectomy: a proposal of optimal lymphadenectomy for future clinical trials, Ann Surg Oncol, 2014. 21: p. 2755-61., https://www.ncbi.nlm.nih.gov/pubmed/24705578
537. Alay, I., Turan, T., Ureyen, I., Karalok, A., Tasci, T., Ozfuttu, A., et.al. Lymphadenectomy should be performed up to the renal vein in patients with intermediate-high risk endometrial cancer, Pathol Oncol Res, 2015. 21: p. 803-10., https://www.ncbi.nlm.nih.gov/pubmed/25564000
538. Cosgrove, CM, Cohn, DE, Rhoades, J, Felix, AS, The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment., Gynecol Oncol, 2019. 153 (3)(3): p. 505-510., https://pubmed.ncbi.nlm.nih.gov/30935714/
539. Cantrell, L. A., Blank, S. V., Duska, L. R., Uterine carcinosarcoma: A review of the literature, Gynecol Oncol, 2015. 137: p. 581-8., https://www.ncbi.nlm.nih.gov/pubmed/25805398
540. Torne, A., Pahisa, J., Vidal-Sicart, S., Martinez-Roman, S., Paredes, P., Puerto, B., et.al. Transvaginal ultrasound-guided myometrial injection of radiotracer (TUMIR): a new method for sentinel lymph node detection in endometrial cancer, Gynecol Oncol, 2013. 128: p. 88-94., https://www.ncbi.nlm.nih.gov/pubmed/23085461
541. Lopez-De la Manzanara Cano, C., Cordero Garcia, J. M., Martin-Francisco, C., Pascual-Ramirez, J., Parra, C. P., Cespedes Casas, C., Sentinel lymph node detection using 99mTc combined with methylene blue cervical injection for endometrial cancer surgical management: a prospective study, Int J Gynecol Cancer, 2014. 24: p. 1048-53., https://www.ncbi.nlm.nih.gov/pubmed/24927249
542. Ballester, M., Dubernard, G., Lecuru, F., Heitz, D., Mathevet, P., Marret, H., et.al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO), Lancet Oncol, 2011. 12: p. 469-76., https://www.ncbi.nlm.nih.gov/pubmed/21489874
543. Ballester, M., Naoura, I., Chereau, E., Seror, J., Bats, A. S., Bricou, A., et.al. Sentinel node biopsy upstages patients with presumed low- and intermediate-risk endometrial cancer: results of a multicenter study, Ann Surg Oncol, 2012. 20: p. 407-12., https://www.ncbi.nlm.nih.gov/pubmed/23054119
544. Koskas, M., Chereau, E., Ballester, M., Dubernard, G., Lecuru, F., Heitz, D., et.al. Accuracy of a nomogram for prediction of lymph-node metastasis detected with conventional histopathology and ultrastaging in endometrial cancer, Br J Cancer, 2013. 108: p. 1267-72., https://www.ncbi.nlm.nih.gov/pubmed/23481184
545. Darai, E., Dubernard, G., Bats, A. S., Heitz, D., Mathevet, P., Marret, H., et.al. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study, Gynecol Oncol, 2014. 136: p. 54-9., https://www.ncbi.nlm.nih.gov/pubmed/25450151
546. Cormier, B., Rozenholc, A. T., Gotlieb, W., Plante, M., Giede, C., Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research, Gynecol Oncol, 2015. 138: p. 478-85., https://www.ncbi.nlm.nih.gov/pubmed/26047592
547. Mueller, JJ, Pedra Nobre, S, Braxton, K, Alektiar, KM, Leitao, MM, Aghajanian, C, et.al. Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma., Gynecol Oncol, 2020. 157 (3)(3): p. 619-623., https://pubmed.ncbi.nlm.nih.gov/32247604/
548. Imboden, S, Mereu, L, Siegenthaler, F, Pellegrini, A, Papadia, A, Tateo, S, et.al. Oncological safety and perioperative morbidity in low-risk endometrial cancer with sentinel lymph-node dissection., Eur J Surg Oncol, 2019. 45 (9)(9): p. 1638-1643., https://pubmed.ncbi.nlm.nih.gov/31229377/
549. Zheng, Y, Yang, X, Liang, Y, Zhang, T, Chen, J, Li, Y, et.al. Effects of lymphadenectomy among women with stage IA endometrial cancer: a SEER database analysis., Future Oncol, 2019. 15 (19)(19): p. 2251-2266., https://pubmed.ncbi.nlm.nih.gov/31094582/
550. Ouldamer, L, Bendifallah, S, Body, G, Canlorbe, G, Touboul, C, Graesslin, O, et.al. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group., Ann Surg Oncol, 2017. 24 (6)(6): p. 1660-1666., https://pubmed.ncbi.nlm.nih.gov/28058558/
551. Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., et.al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up, Int J Gynecol Cancer, 2015. 26: p. 2-30., https://www.ncbi.nlm.nih.gov/pubmed/26634381
552. Bogani, G, Dowdy, SC, Cliby, WA, Ghezzi, F, Rossetti, D, Mariani, A, Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence., J Obstet Gynaecol Res, 2014. 40 (2)(2): p. 301-11., https://pubmed.ncbi.nlm.nih.gov/24472047/
553. Papadia, A, Gasparri, ML, Buda, A, Mueller, MD, Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue., J Cancer Res Clin Oncol, 2017. 143 (10)(10): p. 2039-2048., https://pubmed.ncbi.nlm.nih.gov/28828528/
554. Sinno, AK, Peijnenburg, E, Fader, AN, Temkin, SM, Stone, R, Levinson, K, et.al. Reducing overtreatment: A comparison of lymph node assessment strategies for endometrial cancer., Gynecol Oncol, 2016. 143 (2)(2): p. 281-286., https://pubmed.ncbi.nlm.nih.gov/27568279/
555. Ditto, A, Casarin, J, Pinelli, C, Perrone, AM, Scollo, P, Martinelli, F, et.al. Corrigendum to "Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group" [European Journal of Cancer. Volume 140, November 2020, Pages 1-10]., Eur J Cancer, 2021. 144 (): p. 399., https://pubmed.ncbi.nlm.nih.gov/33342624/
556. Persson, J, Salehi, S, Bollino, M, Lönnerfors, C, Falconer, H, Geppert, B, Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging., Eur J Cancer, 2019. 116 (): p. 77-85., https://pubmed.ncbi.nlm.nih.gov/31181536/
557. Asher, R, Obermair, A, Janda, M, Gebski, V, Disease-Free and Survival Outcomes for Total Laparoscopic Hysterectomy Compared With Total Abdominal Hysterectomy in Early-Stage Endometrial Carcinoma: A Meta-analysis., Int J Gynecol Cancer, 2018. 28 (3)(3): p. 529-538., https://pubmed.ncbi.nlm.nih.gov/29369119/
558. Galaal, K., Bryant, A., Fisher, A. D., Al-Khaduri, M., Kew, F., Lopes, A. D., Laparoscopy versus laparotomy for the management of early stage endometrial cancer, Cochrane Database Syst Rev, 2012. 9: p. Cd006655., https://www.ncbi.nlm.nih.gov/pubmed/22972096
559. Galaal, K, Donkers, H, Bryant, A, Lopes, AD, Laparoscopy versus laparotomy for the management of early stage endometrial cancer., Cochrane Database Syst Rev, 2018. 10 (): p. CD006655., https://pubmed.ncbi.nlm.nih.gov/30379327/
560. Walker, J. L., Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., et.al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2, J Clin Oncol, 2009. 27: p. 5331-6., https://www.ncbi.nlm.nih.gov/pubmed/19805679
561. Walker, J. L., Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., et.al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study, J Clin Oncol, 2012. 30: p. 695-700., https://www.ncbi.nlm.nih.gov/pubmed/22291074
562. Zullo, F., Falbo, A., Palomba, S., Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials, Am J Obstet Gynecol, 2012. 207: p. 94-100., https://www.ncbi.nlm.nih.gov/pubmed/22340944
563. Philp, L, Tannenbaum, S, Haber, H, Saini, A, Laurent, JS, James, K, et.al. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer., Gynecol Oncol, 2021. 160 (2)(2): p. 389-395., https://pubmed.ncbi.nlm.nih.gov/33358198/
564. Padilla-Iserte, P., Lago, V., Tauste, C., Díaz-Feijoo, B., Gil-Moreno, A., Oliver, R., et.al. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery, Am J Obstet Gynecol, 2021. 224(1): p. 65.e1-65.e11.
565. Cusimano, MC, Simpson, AN, Dossa, F, Liani, V, Kaur, Y, Acuna, SA, et.al. Laparoscopic and robotic hysterectomy in endometrial cancer patients with obesity: a systematic review and meta-analysis of conversions and complications., Am J Obstet Gynecol, 2019. 221 (5)(5): p. 410-428.e19., https://pubmed.ncbi.nlm.nih.gov/31082383/
566. Wang, L, Liu, F, Meta-analysis of laparoscopy sentinel lymph node mapping in endometrial cancer., Arch Gynecol Obstet, 2018. 298 (3)(3): p. 505-510., https://pubmed.ncbi.nlm.nih.gov/30008031/
567. Ind, T, Laios, A, Hacking, M, Nobbenhuis, M, A comparison of operative outcomes between standard and robotic laparoscopic surgery for endometrial cancer: A systematic review and meta-analysis., Int J Med Robot, 2017. 13 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/28762635/
568. Wright, J. D., Burke, W. M., Wilde, E. T., Lewin, S. N., Charles, A. S., Kim, J. H., et.al. Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer, J Clin Oncol, 2012. 30: p. 783-91., https://www.ncbi.nlm.nih.gov/pubmed/22291073
569. Ran, L., Jin, J., Xu, Y., Bu, Y., Song, F., Comparison of robotic surgery with laparoscopy and laparotomy for treatment of endometrial cancer: a meta-analysis, PLoS One, 2014. 9: p. e108361., https://www.ncbi.nlm.nih.gov/pubmed/25259856
570. Chan, J. K., Gardner, A. B., Taylor, K., Thompson, C. A., Blansit, K., Yu, X., et.al. Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients - a comparative analysis of total charges and complication rates, Gynecol Oncol, 2015. 139: p. 300-5., https://www.ncbi.nlm.nih.gov/pubmed/26363212
571. O'Malley, D. M., Smith, B., Fowler, J. M., The role of robotic surgery in endometrial cancer, J Surg Oncol, 2015. 112: p. 761-8., https://www.ncbi.nlm.nih.gov/pubmed/26385835
572. Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., Darai, E., Endometrial cancer, Lancet, 2015. 387: p. 1094-108., https://www.ncbi.nlm.nih.gov/pubmed/26354523
573. Tanner, E. J., Leitao, M. M., Jr., Garg, K., Chi, D. S., Sonoda, Y., Gardner, G. J., et.al. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma, Gynecol Oncol, 2011. 123: p. 548-52., https://www.ncbi.nlm.nih.gov/pubmed/21945551
574. Barlin, J. N., Puri, I., Bristow, R. E., Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis, Gynecol Oncol, 2010. 118: p. 14-8., https://www.ncbi.nlm.nih.gov/pubmed/20434198
575. de Lange, NM, Ezendam, NPM, Kwon, JS, Vandenput, I, Mirchandani, D, Amant, F, et.al. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer., Curr Oncol, 2019. 26 (2)(2): p. e226-e232., https://pubmed.ncbi.nlm.nih.gov/31043831/
576. Kong, A., Johnson, N., Kitchener, H. C., Lawrie, T. A., Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis, J Natl Cancer Inst, 2012. 104: p. 1625-34., https://www.ncbi.nlm.nih.gov/pubmed/22962693
577. Klopp, A., Smith, B. D., Alektiar, K., Cabrera, A., Damato, A. L., Erickson, B., et.al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American society for radiation oncology evidence-based guideline (Provisional abstract), Database of Abstracts of Reviews of Effects, 2014. p. 137-144., https://www.ncbi.nlm.nih.gov/pubmed/24766678
578. Sorbe, B., Nordstrom, B., Maenpaa, J., Kuhelj, J., Kuhelj, D., Okkan, S., et.al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study, Int J Gynecol Cancer, 2009. 19: p. 873-8., https://www.ncbi.nlm.nih.gov/pubmed/19574776
579. Kong, A., Johnson, N., Kitchener, H. C., Lawrie, T. A., Adjuvant radiotherapy for stage I endometrial cancer, Cochrane Database Syst Rev, 2012. 4: p. CD003916., https://www.ncbi.nlm.nih.gov/pubmed/22513918
580. Kong, A., Johnson, N., Kitchener, H. C., Lawrie, T. A., Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis, J Natl Cancer Inst, 2012. 104: p. 1625-34., https://www.ncbi.nlm.nih.gov/pubmed/22962693
581. Klopp, A., Smith, B. D., Alektiar, K., Cabrera, A., Damato, A. L., Erickson, B., et.al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American society for radiation oncology evidence-based guideline (Provisional abstract), Database of Abstracts of Reviews of Effects, 2014. p. 137-144., https://www.ncbi.nlm.nih.gov/pubmed/24766678
582. TNM-Klassifikation maligner Tumoren. EndometriumkarzinomWiley-VCH, TNM-Klassifikation maligner Tumoren, 2010.
583. C, ., , W, i, t, et.al. TNM-Klassifikation maligner Tumoren, 2017.
584. Nout, R. A., van de Poll-Franse, L. V., Lybeert, M. L., Warlam-Rodenhuis, C. C., Jobsen, J. J., Mens, J. W., et.al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial, J Clin Oncol, 2011. 29: p. 1692-700., https://www.ncbi.nlm.nih.gov/pubmed/21444867
585. Creutzberg, C. L., Nout, R. A., Lybeert, M. L., Warlam-Rodenhuis, C. C., Jobsen, J. J., Mens, J. W., et.al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma, Int J Radiat Oncol Biol Phys, 2011. 81: p. e631-8., https://www.ncbi.nlm.nih.gov/pubmed/21640520
586. Aalders, J., Abeler, V., Kolstad, P., Onsrud, M., Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients, Obstet Gynecol, 1980. 56: p. 419-27., https://www.ncbi.nlm.nih.gov/pubmed/6999399
587. Onsrud, M., Cvancarova, M., Hellebust, T. P., Trope, C. G., Kristensen, G. B., Lindemann, K., Long-term outcomes after pelvic radiation for early-stage endometrial cancer, J Clin Oncol, 2013. 31: p. 3951-6., https://www.ncbi.nlm.nih.gov/pubmed/24019546
588. Wiltink, L. M., Nout, R. A., Fiocco, M., Meershoek-Klein Kranenbarg, E., Jurgenliemk-Schulz, I. M., Jobsen, J. J., et.al. No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials, J Clin Oncol, 2014. 33: p. 1640-6., https://www.ncbi.nlm.nih.gov/pubmed/25534376
589. Creutzberg, C. L., van Putten, W. L., Warlam-Rodenhuis, C. C., van den Bergh, A. C., de Winter, K. A., Koper, P. C., et.al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial, J Clin Oncol, 2004. 22: p. 1234-41., https://www.ncbi.nlm.nih.gov/pubmed/15051771
590. Keys, H. M., Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., et.al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, 2004. 92: p. 744-51., https://www.ncbi.nlm.nih.gov/pubmed/14984936
591. T, h, e, ,, , A, et.al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis, 2009. 373: p. 137-146., https://www.ncbi.nlm.nih.gov/pubmed/19070891
592. Scholten, A. N., van Putten, W. L., Beerman, H., Smit, V. T., Koper, P. C., Lybeert, M. L., et.al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review, Int J Radiat Oncol Biol Phys, 2005. 63: p. 834-8., https://www.ncbi.nlm.nih.gov/pubmed/15927414
593. Bosse, T., Peters, E. E., Creutzberg, C. L., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Mens, J. W., et.al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials, Eur J Cancer, 2015. 51: p. 1742-50., https://www.ncbi.nlm.nih.gov/pubmed/26049688
594. Ortoft, G., Hansen, E. S., Bertelsen, K., Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study, Int J Gynecol Cancer, 2013. 23: p. 1429-37., https://www.ncbi.nlm.nih.gov/pubmed/24257557
595. Nout, R. A., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C., van der Steen-Banasik, E. M., et.al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial, J Clin Oncol, 2009. 27: p. 3547-56., https://www.ncbi.nlm.nih.gov/pubmed/19546404
596. Nout, R. A., Smit, V. T., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C., et.al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial, Lancet, 2010. 375: p. 816-23., https://www.ncbi.nlm.nih.gov/pubmed/20206777
597. Nout, R. A., van de Poll-Franse, L. V., Lybeert, M. L., Warlam-Rodenhuis, C. C., Jobsen, J. J., Mens, J. W., et.al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial, J Clin Oncol, 2011. 29: p. 1692-700., https://www.ncbi.nlm.nih.gov/pubmed/21444867
598. AlHilli, M, Amarnath, S, Elson, P, Rybicki, L, Dowdy, S, Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma., Int J Gynecol Cancer, 2020. 30 (6)(6): p. 789-796., https://pubmed.ncbi.nlm.nih.gov/32184268/
599. Nout, R. A., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C., van der Steen-Banasik, E. M., et.al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial, J Clin Oncol, 2009. 27: p. 3547-56., https://www.ncbi.nlm.nih.gov/pubmed/19546404
600. Nout, R. A., Smit, V. T., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C., et.al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial, Lancet, 2010. 375: p. 816-23., https://www.ncbi.nlm.nih.gov/pubmed/20206777
601. de Boer, SM, Powell, ME, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, et.al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial., Lancet Oncol, 2016. 17 (8)(8): p. 1114-1126., https://pubmed.ncbi.nlm.nih.gov/27397040/
602. de Boer, SM, Powell, ME, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, et.al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial., Lancet Oncol, 2019. 20 (9)(9): p. 1273-1285., https://pubmed.ncbi.nlm.nih.gov/31345626/
603. de Boer, SM, Powell, ME, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, et.al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial., Lancet Oncol, 2018. 19 (3)(3): p. 295-309., https://pubmed.ncbi.nlm.nih.gov/29449189/
604. Ørtoft, G, Høgdall, C, Hansen, ES, Dueholm, M, Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study., J Gynecol Oncol, 2020. 31 (2)(2): p. e22., https://pubmed.ncbi.nlm.nih.gov/31912677/
605. Narasimhulu, DM, Cope, A, Riaz, IB, Petersen, I, Cilby, W, Langstraat, C, et.al. External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis., Int J Gynecol Cancer, 2020. 30 (6)(6): p. 797-805., https://pubmed.ncbi.nlm.nih.gov/32221021/
606. Matei, D, Filiaci, V, Randall, ME, Mutch, D, Steinhoff, MM, DiSilvestro, PA, et.al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer., N Engl J Med, 2019. 380 (24)(24): p. 2317-2326., https://pubmed.ncbi.nlm.nih.gov/31189035/
607. Bertelsen, K., Ortoft, G., Hansen, E. S., Survival of Danish patients with endometrial cancer in the intermediate-risk group not given postoperative radiotherapy: the Danish Endometrial Cancer Study (DEMCA), Int J Gynecol Cancer, 2011. 21: p. 1191-9., https://www.ncbi.nlm.nih.gov/pubmed/21885985
608. Nagar, H., Boothe, D., Parikh, A., Yondorf, M., Parashar, B., Gupta, D., et.al. Administration of concurrent vaginal brachytherapy during chemotherapy for treatment of endometrial cancer, Int J Radiat Oncol Biol Phys, 2013. 87: p. 665-9., https://www.ncbi.nlm.nih.gov/pubmed/24138915
609. Sorbe, B., Nordstrom, B., Maenpaa, J., Kuhelj, J., Kuhelj, D., Okkan, S., et.al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study, Int J Gynecol Cancer, 2009. 19: p. 873-8., https://www.ncbi.nlm.nih.gov/pubmed/19574776
610. Rydzewski, NR, Strohl, AE, Donnelly, ED, Kanis, MJ, Lurain, JR, Nieves-Neira, W, et.al. Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study., Cancer, 2016. 122 (23)(23): p. 3724-3731., https://pubmed.ncbi.nlm.nih.gov/27509082/
611. Ortoft, G., Hansen, E. S., Bertelsen, K., Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study, Int J Gynecol Cancer, 2013. 23: p. 1429-37., https://www.ncbi.nlm.nih.gov/pubmed/24257557
612. Maggi, R., Lissoni, A., Spina, F., Melpignano, M., Zola, P., Favalli, G., et.al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial, Br J Cancer, 2006. 95: p. 266-71., https://www.ncbi.nlm.nih.gov/pubmed/16868539
613. Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., et.al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study, J Clin Oncol, 2005. 24: p. 36-44., https://www.ncbi.nlm.nih.gov/pubmed/16330675
614. Hogberg, T., Signorelli, M., de Oliveira, C. F., Fossati, R., Lissoni, A. A., Sorbe, B., et.al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies, Eur J Cancer, 2010. 46: p. 2422-31., https://www.ncbi.nlm.nih.gov/pubmed/20619634
615. Xiang, M, English, DP, Kidd, EA, Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma., Gynecol Oncol, 2019. 154 (3)(3): p. 487-494., https://pubmed.ncbi.nlm.nih.gov/31257010/
616. Goodman, CR, Hatoum, S, Seagle, BL, Donnelly, ED, Barber, EL, Shahabi, S, et.al. Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer., Gynecol Oncol, 2019. 153 (1)(1): p. 41-48., https://pubmed.ncbi.nlm.nih.gov/30660345/
617. Mitra, D., Klopp, A. H., Viswanathan, A. N., Pros and cons of vaginal brachytherapy after external beam radiation therapy in endometrial cancer, Gynecol Oncol, 2015. 140: p. 167-75., https://www.ncbi.nlm.nih.gov/pubmed/26432041
618. Randall, M. E., Filiaci, V., McMeekin, D. S., von Gruenigen, V., Huang, H., Yashar, C. M., et.al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer, J Clin Oncol, 2019. 37(21): p. 1810-1818.
619. Lin, Y., Zhou, J., Cheng, Y., Zhao, L., Yang, Y., Wang, J., Comparison of Survival Benefits of Combined Chemotherapy and Radiotherapy Versus Chemotherapy Alone for Uterine Serous Carcinoma: A Meta-analysis, Int J Gynecol Cancer, 2016. 27: p. 93-101., https://www.ncbi.nlm.nih.gov/pubmed/28005619
620. van der Steen-Banasik, E., Christiaens, M., Shash, E., Coens, C., Casado, A., Herrera, F. G., et.al. Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma, Eur J Cancer, 2016. 65: p. 172-81., https://www.ncbi.nlm.nih.gov/pubmed/27501506
621. Reed, N. S., Mangioni, C., Malmstrom, H., Scarfone, G., Poveda, A., Pecorelli, S., et.al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874), Eur J Cancer, 2008. 44: p. 808-18., https://www.ncbi.nlm.nih.gov/pubmed/18378136
622. Reed, N. S., Mangioni, C., Malmstrom, H., Scarfone, G., Poveda, A., Pecorelli, S., et.al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874), Eur J Cancer, 2008. 44: p. 808-18., https://www.ncbi.nlm.nih.gov/pubmed/18378136
623. Wolfson, A. H., Brady, M. F., Rocereto, T., Mannel, R. S., Lee, Y. C., Futoran, R. J., et.al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus, Gynecol Oncol, 2007. 107: p. 177-85., https://www.ncbi.nlm.nih.gov/pubmed/17822748
624. Sampath, S., Schultheiss, T. E., Ryu, J. K., Wong, J. Y., The role of adjuvant radiation in uterine sarcomas, Int J Radiat Oncol Biol Phys, 2009. 76: p. 728-34., https://www.ncbi.nlm.nih.gov/pubmed/19700247
625. Wright, J. D., Seshan, V. E., Shah, M., Schiff, P. B., Burke, W. M., Cohen, C. J., et.al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma, Am J Obstet Gynecol, 2008. 199: p. 536 e1-8., https://www.ncbi.nlm.nih.gov/pubmed/18511017
626. Nemani, D., Mitra, N., Guo, M., Lin, L., Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis, Gynecol Oncol, 2008. 111: p. 82-8., https://www.ncbi.nlm.nih.gov/pubmed/18674808
627. Vordermark, D, Medenwald, D, Izaguirre, V, Sieker, F, Marnitz, S, The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus., Cancers (Basel), 2020. 12 (12)(12):, https://pubmed.ncbi.nlm.nih.gov/33265910/
628. L, e, i, t, l, i, et.al. S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen, Langversion 1.1 – April 2017, AWMF-Registernummer: 032/054OL, 2017., https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie/
629. E, u, r, o, p, e, et.al. PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF sodium butyrate (rectal use) for the prevention of radiation proctitis, 2005., https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/05/284-public-summary-positive-opinion-orphan-designation-sodium-butyrate-rectal-use-prevention_en.pdf
630. Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., et.al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants, J Clin Oncol, 2008. 27: p. 127-45., https://www.ncbi.nlm.nih.gov/pubmed/19018081
631. Martin-Hirsch, P. P. L., Bryant, Andrew, Keep Sarah, L., Kitchener Henry, C., Lilford, Richard, Adjuvant progestagens for endometrial cancerJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2011., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238061/
632. Martin-Hirsch, P. P. L., Bryant, Andrew, Keep Sarah, L., Kitchener Henry, C., Lilford, Richard, Adjuvant progestagens for endometrial cancerJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2011., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238061/
633. Galaal, K., Al Moundhri, M., Bryant, A., Lopes, A. D., Lawrie, T. A., Adjuvant chemotherapy for advanced endometrial cancer, Cochrane Database Syst Rev, 2014. 5: p. Cd010681., https://www.ncbi.nlm.nih.gov/pubmed/24832785
634. de Boer, P., Adam, J. A., Buist, M. R., van de Vijver, M. J., Rasch, C. R., Stoker, J., et.al. Role of MRI in detecting involvement of the uterine internal os in uterine cervical cancer: systematic review of diagnostic test accuracy, Eur J Radiol, 2013. 82: p. e422-8.
635. Nomura, H, Aoki, D, Michimae, H, Mizuno, M, Nakai, H, Arai, M, et.al. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial., JAMA Oncol, 2019. 5 (6)(6): p. 833-840., https://pubmed.ncbi.nlm.nih.gov/30896757/
636. Miller, D. S., Filiaci, V. L., Mannel, R. S., Cohn, D. E., Matsumoto, T., Tewari, K. S., et.al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209), J Clin Oncol, 2020. 38(33): p. 3841-3850., https://pubmed.ncbi.nlm.nih.gov/33078978/
637. Miller, DS, Filiaci, VL, Mannel, RS, Cohn, DE, Matsumoto, T, Tewari, KS, et.al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)., J Clin Oncol, 2020. 38 (33)(33): p. 3841-3850., https://pubmed.ncbi.nlm.nih.gov/33078978/
638. van den Heerik, ASVM, Horeweg, N, Nout, RA, Lutgens, LCHW, van der Steen-Banasik, EM, Westerveld, GH, et.al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer., Int J Gynecol Cancer, 2020. 30 (12)(12): p. 2002-2007., https://pubmed.ncbi.nlm.nih.gov/33046573/
639. Cantrell, L. A., Havrilesky, L., Moore, D. T., O'Malley, D., Liotta, M., Secord, A. A., et.al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma, Gynecol Oncol, 2012. 127: p. 22-6., https://www.ncbi.nlm.nih.gov/pubmed/22727985
640. Galaal, K., van der Heijden, E., Godfrey, K., Naik, R., Kucukmetin, A., Bryant, A., et.al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma, Cochrane Database Syst Rev, 2013. 2: p. Cd006812., https://www.ncbi.nlm.nih.gov/pubmed/23450572
641. Homesley, H. D., Filiaci, V., Markman, M., Bitterman, P., Eaton, L., Kilgore, L. C., et.al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study, J Clin Oncol, 2007. 25: p. 526-31., https://www.ncbi.nlm.nih.gov/pubmed/17290061
642. Sutton, G., Brunetto, V. L., Kilgore, L., Soper, J. T., McGehee, R., Olt, G., et.al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study, Gynecol Oncol, 2000. 79: p. 147-53., https://www.ncbi.nlm.nih.gov/pubmed/11063636
643. Cantrell, L. A., Havrilesky, L., Moore, D. T., O'Malley, D., Liotta, M., Secord, A. A., et.al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma, Gynecol Oncol, 2012. 127: p. 22-6., https://www.ncbi.nlm.nih.gov/pubmed/22727985
644. Cantrell, L. A., Blank, S. V., Duska, L. R., Uterine carcinosarcoma: A review of the literature, Gynecol Oncol, 2015. 137: p. 581-8., https://www.ncbi.nlm.nih.gov/pubmed/25805398
645. Sutton, G., Brunetto, V. L., Kilgore, L., Soper, J. T., McGehee, R., Olt, G., et.al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study, Gynecol Oncol, 2000. 79: p. 147-53., https://www.ncbi.nlm.nih.gov/pubmed/11063636
646. Homesley, H. D., Filiaci, V., Markman, M., Bitterman, P., Eaton, L., Kilgore, L. C., et.al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study, J Clin Oncol, 2007. 25: p. 526-31., https://www.ncbi.nlm.nih.gov/pubmed/17290061
647. Galaal, K., van der Heijden, E., Godfrey, K., Naik, R., Kucukmetin, A., Bryant, A., et.al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma, Cochrane Database Syst Rev, 2013. 2: p. Cd006812., https://www.ncbi.nlm.nih.gov/pubmed/23450572
648. Powell, Matthew A., Filiaci, Virginia L., Hensley, Martee Leigh, Huang, Helen Q, Moore, Kathleen N., Tewari, Krishnansu Sujata, et.al. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.Wolters Kluwer, Journal of Clinical Oncology, 2019. 37(15_suppl): p. 5500 - 5500., https://doi.org/10.1200/JCO.2019.37.15_suppl.5500
649. Fung-Kee-Fung, M., Dodge, J., Elit, L., Lukka, H., Chambers, A., Oliver, T., Follow-up after primary therapy for endometrial cancer: a systematic review, Gynecol Oncol, 2006. 101: p. 520-9., https://www.ncbi.nlm.nih.gov/pubmed/16556457
650. Bristow, R. E., Purinton, S. C., Santillan, A., Diaz-Montes, T. P., Gardner, G. J., Giuntoli, R. L., Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance, Gynecologic Oncology, 2006. 103: p. 709-713., https://www.ncbi.nlm.nih.gov/pubmed/16797686
651. Carrara, L., Gadducci, A., Landoni, F., Maggino, T., Scambia, G., Galletto, L., et.al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis, Int J Gynecol Cancer, 2012. 22: p. 1013-9., https://www.ncbi.nlm.nih.gov/pubmed/22706226
652. Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Warlam-Rodenhuis, C. C., et.al. Survival after relapse in patients with endometrial cancer: results from a randomized trial, Gynecol Oncol, 2003. 89: p. 201-9., https://www.ncbi.nlm.nih.gov/pubmed/12713981
653. Gadducci, A., Cosio, S., Fanucchi, A., Cristofani, R., Genazzani, A. R., An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer, Anticancer Res, 2000. 20: p. 1977-84., https://www.ncbi.nlm.nih.gov/pubmed/10928137
654. Reddoch, J. M., Burke, T. W., Morris, M., Tornos, C., Levenback, C., Gershenson, D. M., Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme, Gynecol Oncol, 1995. 59: p. 221-5., https://www.ncbi.nlm.nih.gov/pubmed/7590477
655. Salani, R., Nagel, C. I., Drennen, E., Bristow, R. E., Recurrence patterns and surveillance for patients with early stage endometrial cancer, Gynecol Oncol, 2011. 123: p. 205-7., https://www.ncbi.nlm.nih.gov/pubmed/21820709
656. Sartori, E., Pasinetti, B., Carrara, L., Gambino, A., Odicino, F., Pecorelli, S., Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients, Gynecol Oncol, 2007. 107: p. S241-7., https://www.ncbi.nlm.nih.gov/pubmed/17826824
657. Smith, C. J., Heeren, M., Nicklin, J. L., Perrin, L. C., Land, R., Crandon, A. J., et.al. Efficacy of routine follow-up in patients with recurrent uterine cancer, Gynecol Oncol, 2007. 107: p. 124-9., https://www.ncbi.nlm.nih.gov/pubmed/17655917
658. Fung-Kee-Fung, M., Dodge, J., Elit, L., Lukka, H., Chambers, A., Oliver, T., Follow-up after primary therapy for endometrial cancer: a systematic review, Gynecol Oncol, 2006. 101: p. 520-9., https://www.ncbi.nlm.nih.gov/pubmed/16556457
659. Carrara, L., Gadducci, A., Landoni, F., Maggino, T., Scambia, G., Galletto, L., et.al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis, Int J Gynecol Cancer, 2012. 22: p. 1013-9., https://www.ncbi.nlm.nih.gov/pubmed/22706226
660. Yalamanchi, P., Shabason, J. E., Zhang, X., Ko, E. M., Lin, L. L., Use of Aggressive Surveillance for Locoregional Endometrial Cancer After Local Therapy, Int J Gynecol Cancer, 2018. 28(7): p. 1264-1270., https://pubmed.ncbi.nlm.nih.gov/30036223/
661. Nomura, H., Aoki, D., Susumu, N., Mizuno, M., Nakai, H., Arai, M., et.al. Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial, Gynecol Oncol, 2019. 155(3): p. 413-419., https://pubmed.ncbi.nlm.nih.gov/31601493/
662. Testa, A. C., Fruscella, E., Ludovisi, M., De Vincenzo, R., Malaggese, M., Corrado, G., et.al. The role of sonographic examination in the follow-up of gynecological neoplasms, Gynecol Oncol, 2005. 99: p. 696-703., https://www.ncbi.nlm.nih.gov/pubmed/16140365
663. Zola, P., Fuso, L., Mazzola, S., Gadducci, A., Landoni, F., Maggino, T., et.al. Follow-up strategies in gynecological oncology: searching appropriateness, Int J Gynecol Cancer, 2007. 17(6): p. 1186-93., https://pubmed.ncbi.nlm.nih.gov/17466042/
664. Beaver, K, Williamson, S, Sutton, C, Hollingworth, W, Gardner, A, Allton, B, et.al. Comparing hospital and telephone follow-up for patients treated for stage-I endometrial cancer (ENDCAT trial): a randomised, multicentre, non-inferiority trial., BJOG, 2017. 124 (1)(1): p. 150-160., https://pubmed.ncbi.nlm.nih.gov/27062690/
665. Jeppesen, MM, Jensen, PT, Hansen, DG, Christensen, RD, Mogensen, O, Patient-initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer., BJOG, 2018. 125 (13)(13): p. 1705-1714., https://pubmed.ncbi.nlm.nih.gov/29978593/
666. Morrison, V, Spencer, LH, Totton, N, Pye, K, Yeo, ST, Butterworth, C, et.al. Trial of Optimal Personalised Care After Treatment-Gynaecological Cancer (TOPCAT-G): A Randomized Feasibility Trial., Int J Gynecol Cancer, 2018. 28 (2)(2): p. 401-411., https://pubmed.ncbi.nlm.nih.gov/29324539/
667. Høeg, B. L., Bidstrup, P. E., Karlsen, R. V., Friberg, A. S., Albieri, V., Dalton, S. O., et.al. Follow-up strategies following completion of primary cancer treatment in adult cancer survivors, Cochrane Database Syst Rev, 2019. 2019(11):, https://pubmed.ncbi.nlm.nih.gov/31750936/
668. Nicolaije, KA, Ezendam, NP, Vos, MC, Pijnenborg, JM, Boll, D, Boss, EA, et.al. Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial., J Clin Oncol, 2015. 33 (31)(31): p. 3550-9., https://pubmed.ncbi.nlm.nih.gov/26304900/
669. Kadkhodayan, S., Shahriari, S., Treglia, G., Yousefi, Z., Sadeghi, R., Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature, Gynecol Oncol, 2013. 128: p. 397-404., https://www.ncbi.nlm.nih.gov/pubmed/23107613
670. Kadkhodayan, S., Shahriari, S., Treglia, G., Yousefi, Z., Sadeghi, R., Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature, Gynecol Oncol, 2013. 128: p. 397-404., https://www.ncbi.nlm.nih.gov/pubmed/23107613
671. Bollineni, V. R., Ytre-Hauge, S., Bollineni-Balabay, O., Salvesen, H. B., Haldorsen, I. S., High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature, J Nucl Med, 2016. 57(6): p. 879-85., https://pubmed.ncbi.nlm.nih.gov/26823564/
672. Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Warlam-Rodenhuis, C. C., et.al. Survival after relapse in patients with endometrial cancer: results from a randomized trial, Gynecol Oncol, 2003. 89: p. 201-9., https://www.ncbi.nlm.nih.gov/pubmed/12713981
673. Vargo, J. A., Kim, H., Houser, C. J., Berhane, H., Sukumvanich, P., Olawaiye, A. B., et.al. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification, Radiother Oncol, 2014. 113: p. 126-31., https://www.ncbi.nlm.nih.gov/pubmed/25241996
674. Hardarson, H. A., Heidemann, L. N., dePont Christensen, R., Mogensen, O., Jochumsen, K. M., Vaginal vault recurrences of endometrial cancer in non-irradiated patients - Radiotherapy or surgery, Gynecol Oncol Rep, 2015. 11: p. 26-30., https://www.ncbi.nlm.nih.gov/pubmed/26076091
675. Jereczek-Fossa, B., Badzio, A., Jassem, J., Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy, Int J Radiat Oncol Biol Phys, 2000. 48: p. 405-13., https://www.ncbi.nlm.nih.gov/pubmed/10974454
676. Ng, T. Y., Perrin, L. C., Nicklin, J. L., Cheuk, R., Crandon, A. J., Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy, Gynecol Oncol, 2000. 79: p. 490-4., https://www.ncbi.nlm.nih.gov/pubmed/11104626
677. Chapman, C. H., Maghsoudi, K., Littell, R. D., Chen, L. M., Hsu, I. C., Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy, Brachytherapy, 2017. 16(6): p. 1152-1158., https://pubmed.ncbi.nlm.nih.gov/28802913/
678. Ang, C., Bryant, A., Barton, D. P., Pomel, C., Naik, R., Exenterative surgery for recurrent gynaecological malignancies, Cochrane Database Syst Rev, 2014. 2: p. Cd010449., https://www.ncbi.nlm.nih.gov/pubmed/24497188
679. Andikyan, V., Khoury-Collado, F., Sonoda, Y., Gerst, S. R., Alektiar, K. M., Sandhu, J. S., et.al. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery, Gynecol Oncol, 2012. 125: p. 404-8., https://www.ncbi.nlm.nih.gov/pubmed/22285844
680. Chiantera, V., Rossi, M., De Iaco, P., Koehler, C., Marnitz, S., Gallotta, V., et.al. Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients, Int J Gynecol Cancer, 2014. 24: p. 880-4., https://www.ncbi.nlm.nih.gov/pubmed/24685828
681. Chiantera, V., Rossi, M., De Iaco, P., Koehler, C., Marnitz, S., Fagotti, A., et.al. Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients, Int J Gynecol Cancer, 2013. 24: p. 156-64., https://www.ncbi.nlm.nih.gov/pubmed/24362721
682. Bhambhvani, H. P., Zhou, O., Cattle, C., Taiwo, R., Diver, E., Hayden Gephart, M., Brain Metastases from Endometrial Cancer: Clinical Characteristics, Outcomes, and Review of the Literature, World Neurosurg, 2021. 147: p. e32-e39., https://pubmed.ncbi.nlm.nih.gov/33321250/
683. Beucler, N., Sellier, A., Bernard, C., Joubert, C., Desse, N., Dagain, A., Brain metastases in endometrial cancer: A systematic review of the surgical prognostic factors, Eur J Obstet Gynecol Reprod Biol, 2021. 258: p. 240-252.
684. Kokka, F., Brockbank, E., Oram, D., Gallagher, C., Bryant, A., Hormonal therapy in advanced or recurrent endometrial cancer, Cochrane Database Syst Rev, 2010. p. Cd007926., https://www.ncbi.nlm.nih.gov/pubmed/21154390
685. Thigpen, J. T., Brady, M. F., Alvarez, R. D., Adelson, M. D., Homesley, H. D., Manetta, A., et.al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group, J Clin Oncol, 1999. 17: p. 1736-44., https://www.ncbi.nlm.nih.gov/pubmed/10561210
686. Ethier, JL, Desautels, DN, Amir, E, MacKay, H, Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis., Gynecol Oncol, 2017. 147 (1)(1): p. 158-166., https://pubmed.ncbi.nlm.nih.gov/28689667/
687. Jerzak, KJ, Duska, L, MacKay, HJ, Endocrine therapy in endometrial cancer: An old dog with new tricks., Gynecol Oncol, 2019. 153 (1)(1): p. 175-183., https://pubmed.ncbi.nlm.nih.gov/30616900/
688. Covens, A. L., Filiaci, V., Gersell, D., Lutman, C. V., Bonebrake, A., Lee, Y. C., Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, 2010. 120: p. 185-8., https://www.ncbi.nlm.nih.gov/pubmed/21075433
689. Kokka, F., Brockbank, E., Oram, D., Gallagher, C., Bryant, A., Hormonal therapy in advanced or recurrent endometrial cancer, Cochrane Database Syst Rev, 2010. p. Cd007926., https://www.ncbi.nlm.nih.gov/pubmed/21154390
690. Roncolato, F., Lindemann, K., Willson, M. L., Martyn, J., Mileshkin, L., PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer, Cochrane Database Syst Rev, 2019. 10(10): p. Cd012160., https://pubmed.ncbi.nlm.nih.gov/31588998/
691. Vale, C. L., Tierney, J., Bull, S. J., Symonds, P. R., Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma, Cochrane Database Syst Rev, 2012. 8: p. CD003915., https://www.ncbi.nlm.nih.gov/pubmed/22895938
692. Vale, C. L., Tierney, J., Bull, S. J., Symonds, P. R., Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma, Cochrane Database Syst Rev, 2012. 8: p. CD003915., https://www.ncbi.nlm.nih.gov/pubmed/22895938
693. Nagao, S., Nishio, S., Okada, S., Otsuki, T., Fujiwara, K., Tanabe, H., et.al. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study, Cancer Chemother Pharmacol, 2015. 76: p. 335-42., https://www.ncbi.nlm.nih.gov/pubmed/26092322
694. Makker, V, Taylor, MH, Aghajanian, C, Oaknin, A, Mier, J, Cohn, AL, et.al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer., J Clin Oncol, 2020. 38 (26)(26): p. 2981-2992., https://pubmed.ncbi.nlm.nih.gov/32167863/
695. Makker, V, Colombo, N, Casado Herráez, A, Santin, AD, Colomba, E, Miller, DS, et.al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer., N Engl J Med, 2022. 386 (5)(5): p. 437-448., https://pubmed.ncbi.nlm.nih.gov/35045221/
696. Le, DT, Durham, JN, Smith, KN, Wang, H, Bartlett, BR, Aulakh, LK, et.al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade., Science, 2017. 357 (6349)(6349): p. 409-413., https://pubmed.ncbi.nlm.nih.gov/28596308/
697. Marabelle, A, Le, DT, Ascierto, PA, Di Giacomo, AM, De Jesus-Acosta, A, Delord, JP, et.al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study., J Clin Oncol, 2020. 38 (1)(1): p. 1-10., https://pubmed.ncbi.nlm.nih.gov/31682550/
698. Oaknin, A, Tinker, AV, Gilbert, L, Samouëlian, V, Mathews, C, Brown, J, et.al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial., JAMA Oncol, 2020. 6 (11)(11): p. 1766-1772., https://pubmed.ncbi.nlm.nih.gov/33001143/
699. Konstantinopoulos, PA, Luo, W, Liu, JF, Gulhan, DC, Krasner, C, Ishizuka, JJ, et.al. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer., J Clin Oncol, 2019. 37 (30)(30): p. 2786-2794., https://pubmed.ncbi.nlm.nih.gov/31461377/
700. Lee, Y. K., Chung, H. H., Kim, J. W., Park, N. H., Song, Y. S., Kang, S. B., Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial, Obstet Gynecol, 2011. 117: p. 922-7., https://www.ncbi.nlm.nih.gov/pubmed/21422866
701. Morris, L., Do, V., Chard, J., Brand, A. H., Radiation-induced vaginal stenosis: current perspectives, Int J Womens Health, 2017. 9: p. 273-279., https://pubmed.ncbi.nlm.nih.gov/28496367/
702. Lester, J., Pahouja, G., Andersen, B., Lustberg, M., Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue, J Pers Med, 2015. 5: p. 50-66., https://www.ncbi.nlm.nih.gov/pubmed/25815692
703. G, u, i, d, o, z, et.al. Estrogen therapy in gynecological cancer survivors, Climacteric, 2013. 16: p. 611-7., https://www.ncbi.nlm.nih.gov/pubmed/23952524
704. Shim, S. H., Lee, S. J., Kim, S. N., Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis, Eur J Cancer, 2014. 50(9): p. 1628-37., https://pubmed.ncbi.nlm.nih.gov/24685478/
705. Simon, J., Nachtigall, L., Ulrich, L. G., Eugster-Hausmann, M., Gut, R., Endometrial safety of ultra-low-dose estradiol vaginal tablets, Obstet Gynecol, 2010. 116(4): p. 876-883., https://pubmed.ncbi.nlm.nih.gov/20859151/
706. Lester, J., Pahouja, G., Andersen, B., Lustberg, M., Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue, J Pers Med, 2015. 5: p. 50-66., https://www.ncbi.nlm.nih.gov/pubmed/25815692
707. Lee, Y. K., Chung, H. H., Kim, J. W., Park, N. H., Song, Y. S., Kang, S. B., Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial, Obstet Gynecol, 2011. 117: p. 922-7., https://www.ncbi.nlm.nih.gov/pubmed/21422866
708. Pitkin, R. M., VanVoorhis, L. W., Postirradiation vaginitis. An evaluation of prophylaxis with topical estrogen, Radiology, 1971. 99: p. 417-21., https://www.ncbi.nlm.nih.gov/pubmed/5553582
709. Denton, A. S., Maher, E. J., Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy, Cochrane Database Syst Rev, 2003. p. CD003750., https://www.ncbi.nlm.nih.gov/pubmed/12535485
710. Hintz, B. L., Kagan, A. R., Gilbert, H. A., Rao, A. R., Chan, P., Nussbaum, H., Systemic absorption of conjugated estrogenic cream by the irradiated vagina, Gynecol Oncol, 1981. 12: p. 75-82., https://www.ncbi.nlm.nih.gov/pubmed/6268486
711. Bartl, W., Breitenecker, G., Kemeter, P., Tatra, G., [The absorption of conjugated oestrogens from the irradiated and non-irradiated vagina (author's transl)], Geburtshilfe Frauenheilkd, 1980. 40(4): p. 319-25., https://pubmed.ncbi.nlm.nih.gov/6247239/
712. G, u, i, d, o, z, et.al. Estrogen therapy in gynecological cancer survivors, Climacteric, 2013. 16: p. 611-7., https://www.ncbi.nlm.nih.gov/pubmed/23952524
713. Singh, P., Oehler, M. K., Hormone replacement after gynaecological cancer, Maturitas, 2009. 65: p. 190-7., https://www.ncbi.nlm.nih.gov/pubmed/20018467
714. Edey, K. A., Rundle, S., Hickey, M., Hormone replacement therapy for women previously treated for endometrial cancer, Cochrane Database Syst Rev, 2018. 5(5): p. Cd008830., https://pubmed.ncbi.nlm.nih.gov/29763969/
715. Nout, R. A., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C., van der Steen-Banasik, E. M., et.al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data, Eur J Cancer, 2011. 48: p. 1638-48., https://www.ncbi.nlm.nih.gov/pubmed/22176868
716. Miles, T., Johnson, N., Vaginal dilator therapy for women receiving pelvic radiotherapy, Cochrane Database Syst Rev, 2014. 9: p. CD007291., https://www.ncbi.nlm.nih.gov/pubmed/20824858
717. N, a, t, i, o, n, et.al. NCCN Guideline - Uterine Neoplasms, 2020., https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1473
718. Akbaba, S., Oelmann-Avendano, J. T., Krug, D., Arians, N., Bostel, T., Hoerner-Rieber, J., et.al. The impact of vaginal dilator use on vaginal stenosis and sexual quality of life in women treated with adjuvant radiotherapy for endometrial cancer, Strahlenther Onkol, 2019. 195(10): p. 902-912., https://pubmed.ncbi.nlm.nih.gov/30997541/
719. Stahl, J. M., Qian, J. M., Tien, C. J., Carlson, D. J., Chen, Z., Ratner, E. S., et.al. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy, Support Care Cancer, 2019. 27(4): p. 1425-1433., https://pubmed.ncbi.nlm.nih.gov/30187220/
720. Cerentini, T. M., Schlöttgen, J., Viana da Rosa, P., La Rosa, V. L., Vitale, S. G., Giampaolino, P., et.al. Clinical and Psychological Outcomes of the Use of Vaginal Dilators After Gynaecological Brachytherapy: a Randomized Clinical Trial, Adv Ther, 2019. 36(8): p. 1936-1949., https://pubmed.ncbi.nlm.nih.gov/31209699/
721. Hanlon, A., Small, W., Jr., Strauss, J., Lin, L. L., Hanisch, L., Huang, L., et.al. Dilator Use After Vaginal Brachytherapy for Endometrial Cancer: A Randomized Feasibility and Adherence Study, Cancer Nurs, 2018. 41(3): p. 200-209., https://pubmed.ncbi.nlm.nih.gov/28437283/
722. Perrone, A. M., Tesei, M., Ferioli, M., De Terlizzi, F., Della Gatta, A. N., Boussedra, S., et.al. Results of a Phase I-II Study on Laser Therapy for Vaginal Side Effects after Radiotherapy for Cancer of Uterine Cervix or Endometrium, Cancers (Basel), 2020. 12(6):, https://pubmed.ncbi.nlm.nih.gov/32575821/
723. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2, 2020, AWMF-Registernummer: 128/001OL, 2020., http://leitlinienprogramm-onkologie.de/Palliativmedizin.80.0.html
724. Buchanan, D. D., Tan, Y. Y., Walsh, M. D., Clendenning, M., Metcalf, A. M., Ferguson, K., et.al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing, J Clin Oncol, 2013. 32: p. 90-100., https://www.ncbi.nlm.nih.gov/pubmed/24323032
725. Carcangiu, M. L., Radice, P., Casalini, P., Bertario, L., Merola, M., Sala, P., Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types, Int J Surg Pathol, 2009. 18: p. 21-6., https://www.ncbi.nlm.nih.gov/pubmed/19443869
726. Dowty, J. G., Win, A. K., Buchanan, D. D., Lindor, N. M., Macrae, F. A., Clendenning, M., et.al. Cancer risks for MLH1 and MSH2 mutation carriers, Hum Mutat, 2012. 34: p. 490-7., https://www.ncbi.nlm.nih.gov/pubmed/23255516
727. Egoavil, C., Alenda, C., Castillejo, A., Paya, A., Peiro, G., Sanchez-Heras, A. B., et.al. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers, PLoS One, 2013. 8: p. e79737., https://www.ncbi.nlm.nih.gov/pubmed/24244552
728. Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., et.al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients, Cancer Res, 2006. 66: p. 7810-7., https://www.ncbi.nlm.nih.gov/pubmed/16885385
729. Leenen, C. H., van Lier, M. G., van Doorn, H. C., van Leerdam, M. E., Kooi, S. G., de Waard, J., et.al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer , Gynecol Oncol, 2012. 125: p. 414-20., https://www.ncbi.nlm.nih.gov/pubmed/22306203
730. Lu, K. H., Schorge, J. O., Rodabaugh, K. J., Daniels, M. S., Sun, C. C., Soliman, P. T., et.al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer, J Clin Oncol, 2007. 25: p. 5158-64., https://www.ncbi.nlm.nih.gov/pubmed/17925543
731. ten Broeke, S. W., Brohet, R. M., Tops, C. M., van der Klift, H. M., Velthuizen, M. E., Bernstein, I., et.al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk, J Clin Oncol, 2014. 33: p. 319-25., https://www.ncbi.nlm.nih.gov/pubmed/25512458
732. Westin, S. N., Lacour, R. A., Urbauer, D. L., Luthra, R., Bodurka, D. C., Lu, K. H., et.al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome, J Clin Oncol, 2008. 26: p. 5965-71., https://www.ncbi.nlm.nih.gov/pubmed/19001318
733. Win, A. K., Lindor, N. M., Winship, I., Tucker, K. M., Buchanan, D. D., Young, J. P., et.al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome, J Natl Cancer Inst, 2013. 105: p. 274-9., https://www.ncbi.nlm.nih.gov/pubmed/23385444
734. ten Broeke, S. W., Brohet, R. M., Tops, C. M., van der Klift, H. M., Velthuizen, M. E., Bernstein, I., et.al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk, J Clin Oncol, 2014. 33: p. 319-25., https://www.ncbi.nlm.nih.gov/pubmed/25512458
735. Dowty, J. G., Win, A. K., Buchanan, D. D., Lindor, N. M., Macrae, F. A., Clendenning, M., et.al. Cancer risks for MLH1 and MSH2 mutation carriers, Hum Mutat, 2012. 34: p. 490-7., https://www.ncbi.nlm.nih.gov/pubmed/23255516
736. Westin, S. N., Lacour, R. A., Urbauer, D. L., Luthra, R., Bodurka, D. C., Lu, K. H., et.al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome, J Clin Oncol, 2008. 26: p. 5965-71., https://www.ncbi.nlm.nih.gov/pubmed/19001318
737. Hampel, H, de la Chapelle, A, The search for unaffected individuals with Lynch syndrome: do the ends justify the means?, Cancer Prev Res (Phila), 2011. 4 (1)(1): p. 1-5., https://pubmed.ncbi.nlm.nih.gov/21205737/
738. Win, AK, Jenkins, MA, Dowty, JG, Antoniou, AC, Lee, A, Giles, GG, et.al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer., Cancer Epidemiol Biomarkers Prev, 2017. 26 (3)(3): p. 404-412., https://pubmed.ncbi.nlm.nih.gov/27799157/
739. Nelen, M. R., Kremer, H., Konings, I. B., Schoute, F., van Essen, A. J., Koch, R., et.al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations, Eur J Hum Genet, 1999. 7: p. 267-73., https://www.ncbi.nlm.nih.gov/pubmed/10234502
740. Ryan, NAJ, Glaire, MA, Blake, D, Cabrera-Dandy, M, Evans, DG, Crosbie, EJ, The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis., Genet Med, 2019. 21 (10)(10): p. 2167-2180., https://pubmed.ncbi.nlm.nih.gov/31086306/
741. Snowsill, TM, Ryan, NAJ, Crosbie, EJ, Frayling, IM, Evans, DG, Hyde, CJ, Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting., PLoS One, 2019. 14 (8)(8): p. e0221419., https://pubmed.ncbi.nlm.nih.gov/31469860/
742. Dominguez-Valentin, M, Sampson, JR, Seppälä, TT, Ten Broeke, SW, Plazzer, JP, Nakken, S, et.al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database., Genet Med, 2020. 22 (1)(1): p. 15-25., https://pubmed.ncbi.nlm.nih.gov/31337882/
743. Riegert-Johnson, D. L., Gleeson, F. C., Roberts, M., Tholen, K., Youngborg, L., Bullock, M., et.al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients, Hered Cancer Clin Pract, 2010. 8: p. 6., https://www.ncbi.nlm.nih.gov/pubmed/20565722
744. Tan, M. H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., Eng, C., Lifetime cancer risks in individuals with germline PTEN mutations, Clin Cancer Res, 2012. 18: p. 400-7., https://www.ncbi.nlm.nih.gov/pubmed/22252256
745. Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., et.al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients, Cancer Res, 2006. 66: p. 7810-7., https://www.ncbi.nlm.nih.gov/pubmed/16885385
746. Leenen, C. H., van Lier, M. G., van Doorn, H. C., van Leerdam, M. E., Kooi, S. G., de Waard, J., et.al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer , Gynecol Oncol, 2012. 125: p. 414-20., https://www.ncbi.nlm.nih.gov/pubmed/22306203
747. Bubien, V., Bonnet, F., Brouste, V., Hoppe, S., Barouk-Simonet, E., David, A., et.al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome, J Med Genet, 2013. 50: p. 255-63., https://www.ncbi.nlm.nih.gov/pubmed/23335809
748. Clarke, B. A., Cooper, K., Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas, Adv Anat Pathol, 2012. 19: p. 231-8., https://www.ncbi.nlm.nih.gov/pubmed/22692286
749. Lamberti, C., Mangold, E., Pagenstecher, C., Jungck, M., Schwering, D., Bollmann, M., et.al. Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany, Digestion, 2006. 74: p. 58-67., https://www.ncbi.nlm.nih.gov/pubmed/17095871
750. Chen, S., Wang, W., Lee, S., Nafa, K., Lee, J., Romans, K., et.al. Prediction of germline mutations and cancer risk in the Lynch syndrome, JAMA, 2006. 296: p. 1479-87., https://www.ncbi.nlm.nih.gov/pubmed/17003396
751. Hampel, Heather, Panescu, Jenny, Lockman, Janet, Sotamaa, Kaisa, Fix, Daniel, Comeras, Ilene, et.al. Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients, Cancer Research, 2007. 67: p. 9603-9603., http://cancerres.aacrjournals.org/content/66/15/7810.short
752. Buchanan, D. D., Tan, Y. Y., Walsh, M. D., Clendenning, M., Metcalf, A. M., Ferguson, K., et.al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing, J Clin Oncol, 2013. 32: p. 90-100., https://www.ncbi.nlm.nih.gov/pubmed/24323032
753. Egoavil, C., Alenda, C., Castillejo, A., Paya, A., Peiro, G., Sanchez-Heras, A. B., et.al. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers, PLoS One, 2013. 8: p. e79737., https://www.ncbi.nlm.nih.gov/pubmed/24244552
754. Lu, K. H., Schorge, J. O., Rodabaugh, K. J., Daniels, M. S., Sun, C. C., Soliman, P. T., et.al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer, J Clin Oncol, 2007. 25: p. 5158-64., https://www.ncbi.nlm.nih.gov/pubmed/17925543
755. Lynch, H. T., Harris, R. E., Lynch, P. M., Guirgis, H. A., Lynch, J. F., Bardawil, W. A., Role of heredity in multiple primary cancer, Cancer, 1977. 40: p. 1849-54., https://www.ncbi.nlm.nih.gov/pubmed/907988
756. Barrow, E., Hill, J., Evans, D. G., Cancer risk in Lynch Syndrome, Fam Cancer, 2013. 12: p. 229-40., https://www.ncbi.nlm.nih.gov/pubmed/23604856
757. Mecklin, J. P., Jarvinen, H. J., Clinical features of colorectal carcinoma in cancer family syndrome, Dis Colon Rectum, 1986. 29: p. 160-4., https://www.ncbi.nlm.nih.gov/pubmed/3943429
758. Win, A. K., Lindor, N. M., Winship, I., Tucker, K. M., Buchanan, D. D., Young, J. P., et.al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome, J Natl Cancer Inst, 2013. 105: p. 274-9., https://www.ncbi.nlm.nih.gov/pubmed/23385444
759. Lu, K. H., Dinh, M., Kohlmann, W., Watson, P., Green, J., Syngal, S., et.al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome, Obstet Gynecol, 2005. 105: p. 569-74., https://www.ncbi.nlm.nih.gov/pubmed/15738026
760. Ferguson, S. E., Aronson, M., Pollett, A., Eiriksson, L. R., Oza, A. M., Gallinger, S., et.al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing, Cancer, 2014. 120: p. 3932-9., https://www.ncbi.nlm.nih.gov/pubmed/25081409
761. N, c, c, n, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2016, 2016. 2:, https://www.genomeweb.com/sites/default/files/nccn_2017.pdf
762. N, c, c, n, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2016, 2016.
763. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities., 1998., https://www.ncbi.nlm.nih.gov/pubmed/9809732
764. Tabor, A., Watt, H. C., Wald, N. J., Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding, Obstet Gynecol, 2002. 99: p. 663-70., https://www.ncbi.nlm.nih.gov/pubmed/12039131
765. Carcangiu, M. L., Radice, P., Casalini, P., Bertario, L., Merola, M., Sala, P., Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types, Int J Surg Pathol, 2009. 18: p. 21-6., https://www.ncbi.nlm.nih.gov/pubmed/19443869
766. Pagon, R. A., Adam, M. P., Ardinger, H. H., Wallace, S. E., Amemiya, A., Bean, L. J. H., et.al. GeneReviewsUniversity of Washington, Seattle, 1993.
767. Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., et.al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst, 2004. 96: p. 261-8., https://www.ncbi.nlm.nih.gov/pubmed/14970275
768. Vasen, H. F., Mecklin, J. P., Khan, P. M., Lynch, H. T., The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC), Dis Colon Rectum, 1991. 34: p. 424-5., https://www.ncbi.nlm.nih.gov/pubmed/2022152
769. Steinke, V., Holzapfel, S., Loeffler, M., Holinski-Feder, E., Morak, M., Schackert, H. K., et.al. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families, Int J Cancer, 2014. 135: p. 69-77., https://www.ncbi.nlm.nih.gov/pubmed/24493211
770. Barrow, P., Khan, M., Lalloo, F., Evans, D. G., Hill, J., Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome, Br J Surg, 2013. 100: p. 1719-31., https://www.ncbi.nlm.nih.gov/pubmed/24227356
771. Barrow, P., Green, K., Clancy, T., Lalloo, F., Hill, J., Evans, D. G., Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey, Clin Genet, 2015. 87: p. 517-24., https://www.ncbi.nlm.nih.gov/pubmed/25652327
772. Backes, F. J., Mitchell, E., Hampel, H., Cohn, D. E., Endometrial cancer patients and compliance with genetic counseling: room for improvement, Gynecol Oncol, 2011. 123: p. 532-6., https://www.ncbi.nlm.nih.gov/pubmed/21968342
773. Aktan-Collan, K., Kaariainen, H., Jarvinen, H., Peltomaki, P., Pylvanainen, K., Mecklin, J. P., et.al. Psychosocial consequences of predictive genetic testing for Lynch syndrome and associations to surveillance behaviour in a 7-year follow-up study, Fam Cancer, 2013. 12: p. 639-46., https://www.ncbi.nlm.nih.gov/pubmed/23512527
774. Eliezer, D., Hadley, D. W., Koehly, L. M., Exploring psychological responses to genetic testing for Lynch Syndrome within the family context, Psychooncology, 2014. 23: p. 1292-9., https://www.ncbi.nlm.nih.gov/pubmed/24872228
775. Esplen, M. J., Wong, J., Aronson, M., Butler, K., Rothenmund, H., Semotiuk, K., et.al. Long-term psychosocial and behavioral adjustment in individuals receiving genetic test results in Lynch syndrome, Clin Genet, 2014. 87: p. 525-32., https://www.ncbi.nlm.nih.gov/pubmed/25297893
776. Galiatsatos, P., Rothenmund, H., Aubin, S., Foulkes, W. D., Psychosocial Impact of Lynch Syndrome on Affected Individuals and Families, Dig Dis Sci, 2015. 60: p. 2246-50., https://www.ncbi.nlm.nih.gov/pubmed/25786861
777. Hirschberg, A. M., Chan-Smutko, G., Pirl, W. F., Psychiatric implications of cancer genetic testing, Cancer, 2014. 121: p. 341-60., https://www.ncbi.nlm.nih.gov/pubmed/25234846
778. H, o, l, t, h, a, et.al. Psychische Aspekte im Zusammenhang mit tumorgenetischer Beratung, PSYCH up2date, 2014. 8: p. 225-240., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0034-1370167
779. K, e, l, l, e, r, et.al. Erbliche Tumorerkrankungen - psychosoziale und familiäre Aspekte, Psychotherapie im Dialog, 2010. p. 151-154.
780. Landsbergen, K. M., Prins, J. B., Brunner, H. G., Kraaimaat, F. W., Hoogerbrugge, N., Genetic testing for Lynch syndrome in the first year of colorectal cancer: a review of the psychological impact, Fam Cancer, 2009. 8: p. 325-37., https://www.ncbi.nlm.nih.gov/pubmed/19330464
781. Landsbergen, K. M., Prins, J. B., Brunner, H. G., van Duijvendijk, P., Nagengast, F. M., van Krieken, J. H., et.al. Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist's initiative, Fam Cancer, 2012. 11: p. 259-67., https://www.ncbi.nlm.nih.gov/pubmed/22311584
782. Gesetz über genetische Untersuchungen bei Menschen (Gendiagnostikgesetz - GenDG), 2010., http://www.gesetze-im-internet.de/gendg/
783. R, o, b, e, r, t, et.al. Richtlinien der Gendiagnostik-Kommission (GEKO) zur genetischen Untersuchung bei nicht-einwilligungsfähigen Personen nach § 14 in Verbindung mit § 23 Abs. 2 Nr. 1c GenDG, Bundesgesundheitsbl, 2011. 54: p. 1248–1256., https://www.rki.de/DE/Content/Kommissionen/GendiagnostikKommission/Richtlinien/Richtlinien_node.html
784. Duncan, R. E., Gillam, L., Savulescu, J., Williamson, R., Rogers, J. G., Delatycki, M. B., The challenge of developmentally appropriate care: predictive genetic testing in young people for familial adenomatous polyposis, Fam Cancer, 2009. 9: p. 27-35., https://www.ncbi.nlm.nih.gov/pubmed/19760114
785. Snowsill, T., Huxley, N., Hoyle, M., Jones-Hughes, T., Coelho, H., Cooper, C., et.al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome, Health Technol Assess, 2014. 18: p. 1-406., https://www.ncbi.nlm.nih.gov/pubmed/25244061
786. Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., et.al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res, 1998. 58: p. 5248-57., https://www.ncbi.nlm.nih.gov/pubmed/9823339
787. Hegde, M., Ferber, M., Mao, R., Samowitz, W., Ganguly, A., ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis), Genet Med, 2013. 16: p. 101-16., https://www.ncbi.nlm.nih.gov/pubmed/24310308
788. Backes, F. J., Leon, M. E., Ivanov, I., Suarez, A., Frankel, W. L., Hampel, H., et.al. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer, Gynecol Oncol, 2009. 114: p. 486-90., https://www.ncbi.nlm.nih.gov/pubmed/19515405
789. Moline, J., Mahdi, H., Yang, B., Biscotti, C., Roma, A. A., Heald, B., et.al. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center, Gynecol Oncol, 2013. 130: p. 121-6., https://www.ncbi.nlm.nih.gov/pubmed/23612316
790. Gausachs, M., Mur, P., Corral, J., Pineda, M., Gonzalez, S., Benito, L., et.al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study, Eur J Hum Genet, 2012. 20: p. 762-8., https://www.ncbi.nlm.nih.gov/pubmed/22274583
791. Deng, G., Bell, I., Crawley, S., Gum, J., Terdiman, J. P., Allen, B. A., et.al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer, Clin Cancer Res, 2004. 10: p. 191-5., https://www.ncbi.nlm.nih.gov/pubmed/14734469
792. Kawaguchi, M., Yanokura, M., Banno, K., Kobayashi, Y., Kuwabara, Y., Kobayashi, M., et.al. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer, Int J Oncol, 2009. 34: p. 1541-7., https://www.ncbi.nlm.nih.gov/pubmed/19424571
793. Bellido, F, Pineda, M, Aiza, G, Valdés-Mas, R, Navarro, M, Puente, DA, et.al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance., Genet Med, 2016. 18 (4)(4): p. 325-32., https://pubmed.ncbi.nlm.nih.gov/26133394/
794. Snowsill, T., Huxley, N., Hoyle, M., Jones-Hughes, T., Coelho, H., Cooper, C., et.al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome, Health Technol Assess, 2014. 18: p. 1-406., https://www.ncbi.nlm.nih.gov/pubmed/25244061
795. Richtlinien zur prädiktiven genetischen Diagnostik, 2003.
796. Zertifizierte medizinische Fortbildung: Indikationen zur molekulargenetischen Diagnostik bei erblichen Krankheiten, 2006., https://www.aerzteblatt.de/archiv/50438/Zertifizierte-medizinische-Fortbildung-Indikationen-zur-molekulargenetischen-Diagnostik-bei-erblichen-Krankheiten
797. Plon, SE, Eccles, DM, Easton, D, Foulkes, WD, Genuardi, M, Greenblatt, MS, et.al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results., Hum Mutat, 2008. 29 (11)(11): p. 1282-91., https://pubmed.ncbi.nlm.nih.gov/18951446/
798. S2k-Leitlinie Humangenetische Diagnostik und genetische Beratung, 2011., http://www.awmf.org/leitlinien/detail/ll/078-015.html
799. Burn, J, Sheth, H, Elliott, F, Reed, L, Macrae, F, Mecklin, JP, et.al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial., Lancet, 2020. 395 (10240)(10240): p. 1855-1863., https://pubmed.ncbi.nlm.nih.gov/32534647/
800. Auranen, A., Joutsiniemi, T., A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families, Acta Obstet Gynecol Scand, 2011. 90: p. 437-44., https://www.ncbi.nlm.nih.gov/pubmed/21306348
801. Lecuru, F., Le Frere Belda, M. A., Bats, A. S., Tulpin, L., Metzger, U., Olschwang, S., et.al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study, Int J Gynecol Cancer, 2008. 18: p. 1326-31., https://www.ncbi.nlm.nih.gov/pubmed/18217965
802. Lu, K. H., Daniels, M., Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention, Fam Cancer, 2013. 12: p. 273-7., https://www.ncbi.nlm.nih.gov/pubmed/23765559
803. Auranen, A., Joutsiniemi, T., A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families, Acta Obstet Gynecol Scand, 2011. 90: p. 437-44., https://www.ncbi.nlm.nih.gov/pubmed/21306348
804. Dove-Edwin, I., Boks, D., Goff, S., Kenter, G. G., Carpenter, R., Vasen, H. F., et.al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma, Cancer, 2002. 94: p. 1708-12., https://www.ncbi.nlm.nih.gov/pubmed/11920532
805. Rijcken, F. E., Mourits, M. J., Kleibeuker, J. H., Hollema, H., van der Zee, A. G., Gynecologic screening in hereditary nonpolyposis colorectal cancer, Gynecol Oncol, 2003. 91: p. 74-80., https://www.ncbi.nlm.nih.gov/pubmed/14529665
806. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome, 2006., https://www.ncbi.nlm.nih.gov/pubmed/17096354
807. Lecuru, F., Le Frere Belda, M. A., Bats, A. S., Tulpin, L., Metzger, U., Olschwang, S., et.al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study, Int J Gynecol Cancer, 2008. 18: p. 1326-31., https://www.ncbi.nlm.nih.gov/pubmed/18217965
808. Manchanda, R., Saridogan, E., Abdelraheim, A., Johnson, M., Rosenthal, A. N., Benjamin, E., et.al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS), Arch Gynecol Obstet, 2012. 286: p. 1555-62., https://www.ncbi.nlm.nih.gov/pubmed/22865035
809. Helder-Woolderink, J. M., De Bock, G. H., Sijmons, R. H., Hollema, H., Mourits, M. J., The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome, Gynecol Oncol, 2013. 131: p. 304-8., https://www.ncbi.nlm.nih.gov/pubmed/23769810
810. Møller, P, Seppälä, T, Bernstein, I, Holinski-Feder, E, Sala, P, Evans, DG, et.al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database., Gut, 2017. 66 (3)(3): p. 464-472., https://pubmed.ncbi.nlm.nih.gov/26657901/
811. Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. B., et.al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome, N Engl J Med, 2006. 354: p. 261-9., https://www.ncbi.nlm.nih.gov/pubmed/16421367
812. Helder-Woolderink, JM, Blok, EA, Vasen, HF, Hollema, H, Mourits, MJ, De Bock, GH, Ovarian cancer in Lynch syndrome; a systematic review., Eur J Cancer, 2016. 55 (): p. 65-73., https://pubmed.ncbi.nlm.nih.gov/26773421/
813. Seppälä, T, Pylvänäinen, K, Evans, DG, Järvinen, H, Renkonen-Sinisalo, L, Bernstein, I, et.al. Colorectal cancer incidence in , Hered Cancer Clin Pract, 2017. 15 (): p. 18., https://pubmed.ncbi.nlm.nih.gov/29046738/
814. L, e, i, t, l, i, et.al. S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Version 1.1, Januar 2014, AWMF-Registernummer: 032/051OL, 2014., https://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie/
815. Reuter, K., Raugust, S., Marschner, N., Harter, M., Differences in prevalence rates of psychological distress and mental disorders in inpatients and outpatients with breast and gynaecological cancer, Eur J Cancer Care (Engl), 2007. 16: p. 222-30., https://www.ncbi.nlm.nih.gov/pubmed/17508941
816. Steele, R., Fitch, M. I., Supportive care needs of women with gynecologic cancer, Cancer Nurs, 2008. 31: p. 284-91., https://www.ncbi.nlm.nih.gov/pubmed/18600115
817. Mehnert, A., Brahler, E., Faller, H., Harter, M., Keller, M., Schulz, H., et.al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities, J Clin Oncol, 2014. 32: p. 3540-6., https://www.ncbi.nlm.nih.gov/pubmed/25287821
818. Roth, A. J.; Carter, J.; Nelson, C. J., Sexuality After Cancer, in Psycho-Oncology, Jimmie C. Holland, William S. Breitbart, Paul B. Jacobsen, Matthew J. Loscalzo, Ruth McCorkle, and Phyllis N. Butow , Editor. 2010, Oxford University Press: New York. p. 245-250.
819. Brown, L. F., Kroenke, K., Cancer-related fatigue and its associations with depression and anxiety: a systematic review, Psychosomatics, 2009. 50: p. 440-7., https://www.ncbi.nlm.nih.gov/pubmed/19855028
820. Hodgkinson, K, Butow, P, Fuchs, A, Hunt, GE, Stenlake, A, Hobbs, KM, et.al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes., Gynecol Oncol, 2007. 104 (2)(2): p. 381-9., https://pubmed.ncbi.nlm.nih.gov/17027072/
821. Mehnert, A., Lehmann, C., Cao, P., Koch, U., Die Erfassung psychosozialer Belastungen und Ressourcen in der Onkologie - Ein Literaturüberblick zu Screeningmethoden und Entwicklungstrends [Assessment of psychosocial distress and resources in oncology - a literature review about screening measures and current developments], Psychother Psychosom Med Psychol, 2006. 56: p. 462-79.
822. Singer, S., Schwarz, R., [Psychosocial aftercare of patients with endometrial or cervical cancer], Zentralbl Gynakol, 2002. 124: p. 64-70., https://www.ncbi.nlm.nih.gov/pubmed/11873318
823. Sporn, NJ, Smith, KB, Pirl, WF, Lennes, IT, Hyland, KA, Park, ER, Sexual health communication between cancer survivors and providers: how frequently does it occur and which providers are preferred?, Psychooncology, 2015. 24 (9)(9): p. 1167-73., https://pubmed.ncbi.nlm.nih.gov/25534170/
824. Donovan, K. A., Boyington, A. R., Judson, P. L., Wyman, J. F., Bladder and bowel symptoms in cervical and endometrial cancer survivors, Psychooncology, 2014. 23: p. 672-8., https://www.ncbi.nlm.nih.gov/pubmed/24481859
825. Jeppesen, M. M., Mogensen, O., Dehn, P., Jensen, P. T., Needs and priorities of women with endometrial and cervical cancer, J Psychosom Obstet Gynaecol, 2015. 36: p. 122-32., https://www.ncbi.nlm.nih.gov/pubmed/26123123
826. Karabuga, H., Gultekin, M., Tulunay, G., Yuce, K., Ayhan, A., Yuce, D., et.al. Assessing the Quality of Life in Patients With Endometrial Cancer Treated With Adjuvant Radiotherapy, Int J Gynecol Cancer, 2015. 25: p. 1526-33., https://www.ncbi.nlm.nih.gov/pubmed/26207785
827. Lee, W. L., Lee, F. K., Su, W. H., Tsui, K. H., Kuo, C. D., Hsieh, S. L., et.al. Hormone therapy for younger patients with endometrial cancer, Taiwan J Obstet Gynecol, 2013. 51: p. 495-505., https://www.ncbi.nlm.nih.gov/pubmed/23276551
828. Honerlaw, K. R., Rumble, M. E., Rose, S. L., Coe, C. L., Costanzo, E. S., Biopsychosocial predictors of pain among women recovering from surgery for endometrial cancer, Gynecol Oncol, 2015. 140: p. 301-6., https://www.ncbi.nlm.nih.gov/pubmed/26363211
829. Erekson, E. A., Sung, V. W., DiSilvestro, P. A., Myers, D. L., Urinary symptoms and impact on quality of life in women after treatment for endometrial cancer, Int Urogynecol J Pelvic Floor Dysfunct, 2008. 20: p. 159-63., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887706/
830. Wiggins, D. L., Wood, R., Granai, C. O., Dizon, D. S., Sex, intimacy, and the gynecologic oncologists: survey results of the New England Association of Gynecologic Oncologists (NEAGO), J Psychosoc Oncol, 2007. 25: p. 61-70., https://www.ncbi.nlm.nih.gov/pubmed/18032265
831. Klee, M., Thranov, I., Machin Prof, D., The patients' perspective on physical symptoms after radiotherapy for cervical cancer, Gynecol Oncol, 2000. 76: p. 14-23., https://www.ncbi.nlm.nih.gov/pubmed/10620435
832. Deutsches Institut für Medizinische Dokumentation und Information (DIMDI), ICD-10-GM 2018 Systematisches Verzeichnis : Internationale statistische Klassifikation der Krankheiten und verwandter GesundheitsproblemeDeutscher Ärzte-Verlag, 2017, im Druck.
833. Sanjida, Saira, Kissane, David, McPhail, Steven M., Obermair, Andreas, Janda, Monika, Anxiety and depression in patients with early stage endometrial cancer: A longitudinal analysis from before surgery to 6-month post-surgery, Journal of Psychosocial Oncology Research and Practice, 2019. 1(3):, https://journals.lww.com/jporp/Fulltext/2019/12000/Anxiety_and_depression_in_patients_with_early.1.aspx
834. Sanjida, S, Obermair, A, Gebski, V, Armfield, N, Janda, M, Long-term quality of life outcomes of women treated for early-stage endometrial cancer., Int J Gynecol Cancer, 2021. 31 (4)(4): p. 530-536., https://pubmed.ncbi.nlm.nih.gov/33361459/
835. Rowlands, I. J., Lee, C., Beesley, V. L., Webb, P. M., Predictors of sexual well-being after endometrial cancer: results of a national self-report survey, Support Care Cancer, 2014. 22: p. 2715-23., https://www.ncbi.nlm.nih.gov/pubmed/24798754
836. Rowlands, I. J., Lee, C., Janda, M., Nagle, C. M., Obermair, A., Webb, P. M., Predicting positive and negative impacts of cancer among long-term endometrial cancer survivors, Psychooncology, 2012. 22: p. 1963-71., https://www.ncbi.nlm.nih.gov/pubmed/23239462
837. Nouri, K., Reinthaller, A., Fertilitätserhalt bei prämenopausalen Frauen mit Endometriumkarzinom im frühen, niedriggradigen Stadium, Speculum, 2015. 33: p. 12-16., https://www.kup.at/kup/pdf/12731.pdf
838. Hurria, A., Li, D., Hansen, K., Patil, S., Gupta, R., Nelson, C., et.al. Distress in older patients with cancer, J Clin Oncol, 2009. 27: p. 4346-51., https://www.ncbi.nlm.nih.gov/pubmed/19652074
839. Köhler, N, Götze, H, Mehnert, A, Psychische Belastung und psychosoziale Unterstützung älterer Krebspatienten, Der Onkologe, 2015. 21(6): p. 518-522., https://www.springermedizin.de/psychische-belastung-und-psychosoziale-unterstuetzung-aelterer-k/8665544
840. Kornblith, A. B., Powell, M., Regan, M. M., Bennett, S., Krasner, C., Moy, B., et.al. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer, Psychooncology, 2007. 16: p. 895-903., https://www.ncbi.nlm.nih.gov/pubmed/17245695
841. Rowlands, I. J., Janda, M., McKinnon, L., Webb, P. M., Beesley, V. L., Prevalence, predictors, and correlates of supportive care needs among women 3-5 years after a diagnosis of endometrial cancer, Support Care Cancer, 2014. 23: p. 1205-14., https://www.ncbi.nlm.nih.gov/pubmed/25304121
842. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Version 1.1, Januar 2014, AWMF-Registernummer: 032/051OL, 2014., http://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie/
843. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Version 1.0, September 2014, AWMF-Registernummer: 032/033OL, 2014., http://www.leitlinienprogramm-onkologie.de/leitlinien/zervixkarzinom/
844. Rowlands, I. J., Janda, M., McKinnon, L., Webb, P. M., Beesley, V. L., Prevalence, predictors, and correlates of supportive care needs among women 3-5 years after a diagnosis of endometrial cancer, Support Care Cancer, 2014. 23: p. 1205-14., https://www.ncbi.nlm.nih.gov/pubmed/25304121
845. de Rooij, BH, Ezendam, NPM, Vos, MC, Pijnenborg, JMA, Boll, D, Kruitwagen, RFPM, et.al. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY Care Trial: New insights for tailored delivery., Cancer, 2019. 125 (5)(5): p. 788-797., https://pubmed.ncbi.nlm.nih.gov/30500067/
846. Rowlands, I. J., Lee, C., Janda, M., Nagle, C. M., Obermair, A., Webb, P. M., Predicting positive and negative impacts of cancer among long-term endometrial cancer survivors, Psychooncology, 2012. 22: p. 1963-71., https://www.ncbi.nlm.nih.gov/pubmed/23239462
847. Geue, K., Sowa, E., Kuhnt, S., Körperliche Beschwerden und psychosoziale Folgen nach einer Zervixkarzinomerkrankung, Der Onkologe, 2016. 22: p. 780-784.
848. Weis, J, Giesler, J.M., Standards in der psychosozialen Versorgung von Krebspatienten, Der Onkologe, 2016. 22(3): p. 198-205., http://link.springer.com/article/10.1007/s00761-015-2938-9
849. Herschbach, P., Weis, J., Screeningverfahren in der PsychoonkologieDeutsche Krebsgesellschaft, 2010.
850. Beesley, V., Eakin, E., Steginga, S., Aitken, J., Dunn, J., Battistutta, D., Unmet needs of gynaecological cancer survivors: implications for developing community support services, Psychooncology, 2007. 17: p. 392-400., https://www.ncbi.nlm.nih.gov/pubmed/17680554
851. Chan, Y. M., Lee, P. W., Fong, D. Y., Fung, A. S., Wu, L. Y., Choi, A. Y., et.al. Effect of individual psychological intervention in Chinese women with gynecologic malignancy: a randomized controlled trial, J Clin Oncol, 2005. 23: p. 4913-24., https://www.ncbi.nlm.nih.gov/pubmed/15939927
852. Faller, H, Schuler, M, Richard, M, Heckl, U, Weis, J, Küffner, R, Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis., J Clin Oncol, 2013. 31 (6)(6): p. 782-93., https://pubmed.ncbi.nlm.nih.gov/23319686/
853. Manne, SL, Virtue, SM, Ozga, M, Kashy, D, Heckman, C, Kissane, D, et.al. A comparison of two psychological interventions for newly-diagnosed gynecological cancer patients., Gynecol Oncol, 2017. 144 (2)(2): p. 354-362., https://pubmed.ncbi.nlm.nih.gov/27887806/
854. Buchanan, A, Roddy, M, Badr, H, Patient-reported outcomes of non-pharmacological interventions for endometrial cancer survivors: a systematic review., J Cancer Surviv, 2021. 15 (4)(4): p. 526-535., https://pubmed.ncbi.nlm.nih.gov/33140266/
855. Gilbert, E., Ussher, J. M., Perz, J., Sexuality after gynaecological cancer: a review of the material, intrapsychic, and discursive aspects of treatment on women's sexual-wellbeing, Maturitas, 2011. 70: p. 42-57., https://www.ncbi.nlm.nih.gov/pubmed/15939927
856. Hasenburg A., Roxana Schwab R., Farthmann J., Sexualität nach gynäko-onkologischen ErkrankungenDe Gruyter, 2020.
857. Dadak, C, Sohlmann, S, Sexualität nach einer Krebserkrankung, Der Gynäkologe, 2014. 47(2): p. 99-103., https://www.springermedizin.de/sexualitaet-nach-einer-krebserkrankung/8105692
858. Faubion, SS, MacLaughlin, KL, Long, ME, Pruthi, S, Casey, PM, Surveillance and Care of the Gynecologic Cancer Survivor., J Womens Health (Larchmt), 2015. 24 (11)(11): p. 899-906., https://pubmed.ncbi.nlm.nih.gov/26208166/
859. White, ID, Sangha, A, Lucas, G, Wiseman, T, Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments., Gynecol Oncol, 2016. 143 (3)(3): p. 664-673., https://pubmed.ncbi.nlm.nih.gov/27671030/
860. Baser, RE, Li, Y, Carter, J, Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors., Cancer, 2012. 118 (18)(18): p. 4606-18., https://pubmed.ncbi.nlm.nih.gov/22359250/
861. Neijenhuijs, KI, Hooghiemstra, N, Holtmaat, K, Aaronson, NK, Groenvold, M, Holzner, B, et.al. The Female Sexual Function Index (FSFI)-A Systematic Review of Measurement Properties., J Sex Med, 2019. 16 (5)(5): p. 640-660., https://pubmed.ncbi.nlm.nih.gov/30956110/
862. M. M. Berner, L. Kriston, H.-P. Zahradnik , M. Härter, A. Rohde, Überprüfung der Gültigkeit und Zuverlässigkeit des deutschen Female Sexual Function Index (FSFI-d), Geburtshilfe Frauenheilkd, 2004. 64(3): p. 293-303.
863. S3-Leitlinie Mammakarzinom, Langversion 4.3, AWMF-Registernummer: 032 – 045OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
864. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 4.0, Dezember 2016, AWMF-Registernummer: 043/022OL, 2016., http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
865. Gilligan, T, Coyle, N, Frankel, RM, Berry, DL, Bohlke, K, Epstein, RM, et.al. Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline., J Clin Oncol, 2017. 35 (31)(31): p. 3618-3632., https://pubmed.ncbi.nlm.nih.gov/28892432/
866. Gysels, M, Higginson, IJ, Interactive technologies and videotapes for patient education in cancer care: systematic review and meta-analysis of randomised trials., Support Care Cancer, 2007. 15 (1)(1): p. 7-20., https://pubmed.ncbi.nlm.nih.gov/17024500/
867. Nilsen, ES, Myrhaug, HT, Johansen, M, Oliver, S, Oxman, AD, Methods of consumer involvement in developing healthcare policy and research, clinical practice guidelines and patient information material., Cochrane Database Syst Rev, 2006. (3)(3): p. CD004563., https://pubmed.ncbi.nlm.nih.gov/16856050/
868. Wofford, JL, Smith, ED, Miller, DP, The multimedia computer for office-based patient education: a systematic review., Patient Educ Couns, 2005. 59 (2)(2): p. 148-57., https://pubmed.ncbi.nlm.nih.gov/16257619/
869. Bundesgesundheitsblatt, 2013.
870. N, h, s, Effective Health Care: Informing, communicating and sharing decision with people who have cancerLatimer Trend & Company Ltd., 2000., https://www.ncbi.nlm.nih.gov/pubmed/11533427
871. Wright, E. B., Holcombe, C., Salmon, P., Doctors' communication of trust, care, and respect in breast cancer: qualitative study, BMJ, 2004. 328: p. 864., https://www.ncbi.nlm.nih.gov/pubmed/15054034
872. Jansen, S. J., Otten, W., Baas-Thijssen, M. C., van de Velde, C. J., Nortier, J. W., Stiggelbout, A. M., Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients, J Clin Oncol, 2005. 23: p. 6623-30., https://www.ncbi.nlm.nih.gov/pubmed/16170169
873. Katz, S. J., Lantz, P. M., Janz, N. K., Fagerlin, A., Schwartz, K., Liu, L., et.al. Patient involvement in surgery treatment decisions for breast cancer, J Clin Oncol, 2005. 23: p. 5526-33., https://www.ncbi.nlm.nih.gov/pubmed/16110013
874. Wagner, K., Koller, M., Keil, A., Trott, D., Engenhart-Cabillic, R., Pfab, R., et.al. [Radiotherapy in surgical and nonsurgical patients. Therapy expectations, quality of life and physician assessment], Chirurg, 1998. 69: p. 252-8., https://www.ncbi.nlm.nih.gov/pubmed/9576035
875. Weis, J., Giesler, J. M., Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence, Patient Educ Couns, 2008. 73: p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/18952394
876. Albert, U. S., Schulz, K. D., Alt, D., Beck, V., Doherty, J., Holsteg, K., et.al. [A guideline for guidelines--methodological report and use of the guideline women's information], Zentralbl Gynakol, 2004. 125: p. 484-93., https://www.ncbi.nlm.nih.gov/pubmed/14755359
877. Klemperer, D., Lang, B., Koch, K., Bastian, H., Brunsmann, F., M, Burkhardt, et.al. Die Gute Praxis Gesundheitsinformation, ZEFQ, 2010. 104: p. 66-68., https://www.ebm-netzwerk.de/pdf/publikationen/gpgi2.pdf
878. O'Connor, A. M., Fiset, V., DeGrasse, C., Graham, I. D., Evans, W., Stacey, D., et.al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications, J Natl Cancer Inst Monogr, 2000. p. 67-80., https://www.ncbi.nlm.nih.gov/pubmed/10854460
879. Dissemination, NHS Centre for Reviews and, Effective Health Care: Informing, communicating and sharing decisions with people who have cancerLatimer Trend & Company Ltd, 2000. 6:
880. Bundesministerium für Justiz, Patientenrechtegesetz, Gesetz zur Verbesserung der Rechte von Patientinnen und PatientenDeutscher Bundestag, 20. Februar 2013. Jahrgang 2013: p. 277-282., https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl113s0277.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl113s0277.pdf%27%5D__1489429188064
881. Cherny, NI, Radbruch, L, European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care., Palliat Med, 2009. 23 (7)(7): p. 581-93., https://pubmed.ncbi.nlm.nih.gov/19858355/
882. L, e, i, t, l, i, et.al. Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.0, 2015, AWMF-Registernummer: 128/001OL, 2015., https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/
883. G. J. Bauerschmitz, M. Hellriegel, G. Emons, Palliative Konzepte beim Endometrium‑, Zervix- und Vulvakarzinom, Der Gynäkologe, 2017. 12:
884. L, e, i, t, l, i, et.al. Komplementärmedizin in der Behandlung von onkologischen PatientInnen, Langversion, Registernummer: 032/055OL, 2021. Version 1.1:, https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/
885. Berger, AM, Abernethy, AP, Atkinson, A, Barsevick, AM, Breitbart, WS, Cella, D, et.al. NCCN Clinical Practice Guidelines Cancer-related fatigue., J Natl Compr Canc Netw, 2010. 8 (8)(8): p. 904-31., https://pubmed.ncbi.nlm.nih.gov/20870636/
886. Fabi, A, Bhargava, R, Fatigoni, S, Guglielmo, M, Horneber, M, Roila, F, et.al. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment., Ann Oncol, 2020. 31 (6)(6): p. 713-723., https://pubmed.ncbi.nlm.nih.gov/32173483/
887. Greer, J. A., Smith, A. L., Arya, L. A., Pelvic floor muscle training for urgency urinary incontinence in women: a systematic review, Int Urogynecol J, 2012. 23: p. 687-97., https://www.ncbi.nlm.nih.gov/pubmed/22246576
888. Hartmann, K. E., McPheeters, M. L., Biller, D. H., Ward, R. M., McKoy, J. N., Jerome, R. N., et.al. Treatment of overactive bladder in women, Evid Rep Technol Assess (Full Rep), 2009. p. 1-120, v., https://www.ncbi.nlm.nih.gov/pubmed/19947666
889. Berghmans, B., van Waalwijk van Doorn, E., Nieman, F., de Bie, R., van den Brandt, P., Van Kerrebroeck, P., Efficacy of physical therapeutic modalities in women with proven bladder overactivity, Eur Urol, 2002. 41: p. 581-7., https://www.ncbi.nlm.nih.gov/pubmed/12074773
890. Wang, A. C., Wang, Y. Y., Chen, M. C., Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder, Urology, 2004. 63: p. 61-6., https://www.ncbi.nlm.nih.gov/pubmed/14751349
891. Dumoulin, C., Hay-Smith, J., Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women, Cochrane Database Syst Rev, 2010. p. CD005654., https://www.ncbi.nlm.nih.gov/pubmed/24823491
892. Hay-Smith, E. J., Herderschee, R., Dumoulin, C., Herbison, G. P., Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women, Cochrane Database Syst Rev, 2011. p. CD009508., https://www.ncbi.nlm.nih.gov/pubmed/22161451
893. Imamura, M., Abrams, P., Bain, C., Buckley, B., Cardozo, L., Cody, J., et.al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence, Health Technol Assess, 2010. 14: p. 1-188, iii-iv., https://www.ncbi.nlm.nih.gov/pubmed/20738930
894. Choi, H., Palmer, M. H., Park, J., Meta-analysis of pelvic floor muscle training: randomized controlled trials in incontinent women, Nurs Res, 2007. 56: p. 226-34., https://www.ncbi.nlm.nih.gov/pubmed/17625461
895. Lo, Sing Kai, Naidu, Jaya, Cao, Yuelong, Additive Effect of Interferential Therapy Over Pelvic Floor Exercise Alone in the Treatment of Female Urinary Stress and Urge Incontinence: A Randomized Controlled Trial, Hong Kong Physiotherapy Journal, 2003. 21: p. 37-42., https://www.sciencedirect.com/science/article/pii/S1013702509700387
896. Patil, S. P., Nagrale, A. V., Ganvir, S. D., Additive effect of interferential therapy over pelvic floor exercises, International Journal of Therapy & Rehabilitation, 2010. 17: p. 596-602., https://www.magonlinelibrary.com/doi/abs/10.12968/ijtr.2010.17.11.79540
897. Hosker, G., Cody, J. D., Norton, C. C., Electrical stimulation for faecal incontinence in adults, Cochrane Database Syst Rev, 2007. p. CD001310., https://www.cochrane.org/CD001310/INCONT_electrical-stimulation-for-faecal-incontinence-in-adults
898. Norton, C., Cody, J. D., Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults, Cochrane Database Syst Rev, 2012. p. CD002111., https://www.ncbi.nlm.nih.gov/pubmed/22786479
899. Le Borgne, G., Mercier, M., Woronoff, A. S., Guizard, A. V., Abeilard, E., Caravati-Jouvenceaux, A., et.al. Quality of life in long-term cervical cancer survivors: a population-based study, Gynecol Oncol, 2013. 129: p. 222-8., https://www.ncbi.nlm.nih.gov/pubmed/23280088
900. Devoogdt, N., Christiaens, M. R., Geraerts, I., Truijen, S., Smeets, A., Leunen, K., et.al. Effect of manual lymph drainage in addition to guidelines and exercise therapy on arm lymphoedema related to breast cancer: randomised controlled trial, BMJ, 2011. 343: p. d5326., https://www.ncbi.nlm.nih.gov/pubmed/21885537
901. Hayes, S. C., Reul-Hirche, H., Turner, J., Exercise and secondary lymphedema: safety, potential benefits, and research issues, Med Sci Sports Exerc, 2009. 41: p. 483-9., https://www.ncbi.nlm.nih.gov/pubmed/19204604
902. Sagen, A., Karesen, R., Risberg, M. A., Physical activity for the affected limb and arm lymphedema after breast cancer surgery. A prospective, randomized controlled trial with two years follow-up, Acta Oncol, 2009. 48: p. 1102-10., https://www.ncbi.nlm.nih.gov/pubmed/19863217
903. Ahmed Omar, M. T., Abd-El-Gayed Ebid, A., El Morsy, A. M., Treatment of post-mastectomy lymphedema with laser therapy: double blind placebo control randomized study, J Surg Res, 2010. 165: p. 82-90., https://www.ncbi.nlm.nih.gov/pubmed/20538293
904. Kozanoglu, E., Basaran, S., Paydas, S., Sarpel, T., Efficacy of pneumatic compression and low-level laser therapy in the treatment of postmastectomy lymphoedema: a randomized controlled trial, Clin Rehabil, 2009. 23: p. 117-24., https://www.ncbi.nlm.nih.gov/pubmed/19164399
905. Tsai, H. J., Hung, H. C., Yang, J. L., Huang, C. S., Tsauo, J. Y., Could Kinesio tape replace the bandage in decongestive lymphatic therapy for breast-cancer-related lymphedema? A pilot study, Support Care Cancer, 2009. 17: p. 1353-60., https://www.ncbi.nlm.nih.gov/pubmed/19199105
906. Mohile, SG, Dale, W, Somerfield, MR, Schonberg, MA, Boyd, CM, Burhenn, PS, et.al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology., J Clin Oncol, 2018. 36 (22)(22): p. 2326-2347., https://pubmed.ncbi.nlm.nih.gov/29782209/
907. Decoster, L, Van Puyvelde, K, Mohile, S, Wedding, U, Basso, U, Colloca, G, et.al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†., Ann Oncol, 2015. 26 (2)(2): p. 288-300., https://pubmed.ncbi.nlm.nih.gov/24936581/
908. Nadaraja, S, Jørgensen, TL, Matzen, LE, Herrstedt, J, Impact of Age, Comorbidity, and FIGO Stage on Treatment Choice and Mortality in Older Danish Patients with Gynecological Cancer: A Retrospective Register-Based Cohort Study., Drugs Real World Outcomes, 2018. 5 (4)(4): p. 225-235., https://pubmed.ncbi.nlm.nih.gov/30460662/
909. Bourgin, C, Saidani, M, Poupon, C, Cauchois, A, Foucher, F, Leveque, J, et.al. Endometrial cancer in elderly women: Which disease, which surgical management? A systematic review of the literature., Eur J Surg Oncol, 2016. 42 (2)(2): p. 166-75., https://pubmed.ncbi.nlm.nih.gov/26647302/
910. Driver, JA, Viswanathan, AN, Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older., Gynecol Oncol, 2017. 145 (3)(3): p. 526-530., https://pubmed.ncbi.nlm.nih.gov/28359689/
911. Ahmed, A, Deng, W, Tew, W, Bender, D, Mannel, RS, Littell, RD, et.al. Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study., Gynecol Oncol, 2018. 150 (2)(2): p. 300-305., https://pubmed.ncbi.nlm.nih.gov/29807694/
912. Bauer, J, Denkinger, M , Freiberger, E., Frohnhofen, Geser, C, Goisser, S, Hofmann, W, et.al. S1-Leitlinie „Geriatrisches Assessment der Stufe 2, 2019., https://www.awmf.org/leitlinien/detail/ll/084-002.html
913. B, e, c, k, m, a, et.al. Gynäkologische Krebszentren – Kompetenzbündelung zur Qualitätsverbesserung, Frauenheilkunde up2date, 2009. 3: p. 71-74.
914. Wesselmann, S., Beckmann, M. W., Winter, A., The concept of the certification system of the German Cancer Society and its impact on gynecological cancer care, Arch Gynecol Obstet, 2013. 289: p. 7-12., https://www.ncbi.nlm.nih.gov/pubmed/24220845
915. Kowalski, C., Wesselmann, S., Ansmann, L., Kreienberg, R., Pfaff, H., Zertifizierte Brustkrebszentren aus Sicht der Zentrumsleitungen: Ergebnisse einer Schlüsselpersonenbefragung, Geburtsh Frauenheilk, 2012. 72: p. 235-242.
916. Huthmann, D., Seufferlein, T., Post, S., Benz, S., Stinner, B., Wesselmann, S., Zertifizierte Darmkrebszentren aus Sicht der Zentrumsleitungen: Ergebnisse einer Schlüsselpersonenbefragung, Gastroenterol, 2012. 50: p. 753-759.
917. Kowalski, C., Wesselmann, S., Ansmann, L., Kreienberg, R., Pfaff, H., Zertifizierte Brustkrebszentren aus Sicht der Patientinnen: Stärken und Verbesserungspotenziale, Geburtsh Frauenheilk, 2012. 71: p. 137-143.
918. Thiel, F. C., Scharl, A., Hildebrandt, T., Kotziabassis, E., Schrauder, M. G., Bani, M. R., et.al. Financing of certified centers: a willingness-to-pay analysis, Arch Gynecol Obstet, 2012. 287: p. 495-509., https://www.ncbi.nlm.nih.gov/pubmed/23080545
919. Lux, M. P., Fasching, P. A., Bani, M. R., Schrauder, M., Marketing von Brust- und Perinatalzentren – Sind Patientinnen mit dem Produkt „zertifiziertes Zentrum“ vertraut?, Geburtsh Frauenheilk, 2009. 69: p. 321-327.
920. Wesselmann, S., Winter, A., Ferencz, J., Seufferlein, T., Post, S., Documented quality of care in certified colorectal cancer centers in Germany: German Cancer Society benchmarking report for 2013, Int J Colorectal Dis, 2014. 29: p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/24584335
921. Beckmann, M. W., Adler, G., Albers, P., Bruns, J., Dreistufenmodell optimiert Behandlung unter Kostendeckung Wie die künftigen Strukturen der onkologischen Versorgung in Deutschland aussehen sollten, Dtsch Arztebl, 2007. 104: p. 3004-3009., https://www.aerzteblatt.de/archiv/57409/Onkologie-Dreistufenmodell-optimiert-Behandlung-unter-Kostendeckung-Wie-die-kuenftigen-Strukturen-der-onkologischen-Versorgung-in-Deutschland-aussehen-sollten
922. O, n, k, o, z, e, et.al. Kennzahlenauswertung 2020 - Jahresbericht der zertifizierten Gynäkologischen Krebszentren - Auditjahr 2019 / Kennzahlenjahr 2018, 2020., https://www.onkozert.de/wordpress/wp-content/uploads/2020/04/qualitaetsindikatoren_gynaekologische-krebserkrankungen_2020-A1_200402.pdf?v=44353574
923. Roland, P. Y., Kelly, F. J., Kulwicki, C. Y., Blitzer, P., Curcio, M., Orr, J. W., Jr., The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment, Gynecol Oncol, 2004. 93: p. 125-30., https://www.ncbi.nlm.nih.gov/pubmed/15047225
924. Macdonald, O. K., Sause, W. T., Lee, R. J., Dodson, M. K., Zempolich, K., Gaffney, D. K., Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium?, Gynecol Oncol, 2005. 99: p. 730-5., https://www.ncbi.nlm.nih.gov/pubmed/16139348
925. Chan, J. K., Sherman, A. E., Kapp, D. S., Zhang, R., Osann, K. E., Maxwell, L., et.al. Influence of gynecologic oncologists on the survival of patients with endometrial cancer, J Clin Oncol, 2011. 29: p. 832-8., https://www.ncbi.nlm.nih.gov/pubmed/21263082
926. Beckmann, M. W., et al., Der neue Schwerpunkt Gynäkologische Onkologie: nationale und internationale Chance?, Geburtsh Frauenheilk, 2006. 66: p. 123-127.
927. Ioka, A., Tsukuma, H., Ajiki, W., Oshima, A., Influence of hospital procedure volume on uterine cancer survival in Osaka, Japan, Cancer Sci, 2005. 96: p. 689-94., https://www.ncbi.nlm.nih.gov/pubmed/16232201
928. Diaz-Montes, T. P., Zahurak, M. L., Giuntoli, R. L., 2nd, Gardner, G. J., Bristow, R. E., Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortality, Gynecol Oncol, 2006. 103: p. 1043-7., https://www.ncbi.nlm.nih.gov/pubmed/16876234
929. Elit, L. M., O'Leary, E. M., Pond, G. R., Seow, H. Y., Impact of wait times on survival for women with uterine cancer, J Clin Oncol, 2013. 32: p. 27-33., https://www.ncbi.nlm.nih.gov/pubmed/24276779
930. Beckmann, M. W.,, Frauenarzt/-ärztin der Zukunft: müssen die Kliniken neu strukturiert werden?, Der Gynäkologe, 2010. 43: p. 748-756., https://www.springermedizin.de/frauenarzt-aerztin-der-zukunft-muessen-die-kliniken-neu-struktur/8104622
931. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft e.V., Stiftung Deutsche, Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V.), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm OnkologieLeitlinienprogramm Onkologie, 2017. 2017:, https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Methodik/QIEP_OL_2017_Version_2.1.pdf